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ABSTRACT 
The use of controlled release dosage forms has increased significantly in recent years as they result 
in increased patient compliance and higher therapeutic efficiency. This research focused on the 
development of a once daily dosage form that could be used for the treatment of hypertension. Both 
a separate sustained release dosage of metoprolol tartrate and a combination dosage form that 
included both an immediate release hydrochlorothiazide and a sustained release metoprolol 
component, were developed and evaluated. A matrix tablet, consisting of an ethylcellulose 
granulation of metoprolol tartrate compressed into a hydrophilic hydroxypropyl methylcellulose 
polymer matrix, effectively sustained metoprolol release over a 22-hour experimental period. A 
multiparticulate combination dosage form that consisted of six coated mini matrix tablets of 
metoprolol and a powder blend of hydrochlorothiazide packed into a gelatin capsule, displayed zero 
order release kinetics for metoprolol release over 22 hours (r2=0.9946). The release of 
hydrochlorothiazide was found to be comparable to that of a commercially available product tested. 
 
Differential Scanning Calorimetry was used to identify possible incompatibilities between MPTA 
and excipients initially, and long term stability testing was used to assess to behaviour of the dosage 
form. Dissolution testing of the dosage forms was performed using USP Apparatus III, which was 
found to be more discriminating between the batches assessed. Dissolution curves were evaluated 
for similarity and difference using f1 and f2 fit factors. Samples were analyzed using a high 
performance liquid chromatographic method that was developed and validated for the simultaneous 
determination of the compounds of interest.  
 
Various factors influencing drug release from the developed dosage forms were assessed and 
recommendations for further optimization of the formulation are made. Factors evaluated included 
 iii
the quantity of granulating fluid, matrix polymer content, drug load and process variables, including 
drying time and compression force. The influence of various coating levels on drug release was 
assessed and none of the levels assessed were found to adequately retarded drug release over a 22-
hour period. Combinations of tablets coated to different levels allowed for the successful 
development of a sustained release metoprolol component, which could be included into the 
combination dosage form. 
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STUDY OBJECTIVES 
 
Metoprolol is a beta-blocker that is commonly prescribed for the treatment of hypertension, angina 
pectoris and more recently for the treatment of congestive heart failure. Hydrochlorthiazide is a 
thiazide diuretic that is indicated as first line therapy for the treatment of hypertension in many 
countries, including South Africa, where it has been included in the Essential Drugs List. A 
combination of these drugs has been reported to be more beneficial than increased doses of either 
drug used alone. Metoprolol and hydrochlorothiazide exhibit a synergistic relationship, in which 
hydrochlorothiazide acts to decrease sodium and water retention caused by metoprolol, and the 
beta-blocker serves to counter-act the increased renin levels caused by the diuretic. This 
combination is therefore particularly advantageous in elderly or black patients that have low renin 
levels, and may therefore be particularly advantageous in a country such as South Africa where the 
majority of hypertensive patients fall into this category. Furthermore, a rapid decrease in blood 
pressure caused by an immediate release hydrochlorothiazide component followed by sustained 
release of metoprolol over a twenty-four period may be even more advantageous. A sustained 
release product of metoprolol only may also be advantageous for patients on beta-blocker 
monotherapy, and metoprolol sustained release products have been found to lower blood pressure 
more effectively than conventional dosage forms. 
 
The objectives of this study were therefore:  
1.  To develop and validate a suitable High Performance Liquid Chromatographic (HPLC)  
method for the simultaneous determination of both metoprolol and hydrochlorothiazide in 
aqueous solutions 
2. To develop a novel sustained release dosage form of metoprolol (100mg) that could be used 
as a stand-alone product or in a combination dosage form with hydrochlorothiazide 
(12.5mg). 
3.  To investigate the feasibility of using a matrix formulation developed in-house for 
sustaining the release of metoprolol tartrate over a 22-hour period. 
4. To evaluate the release of both drug components from the dosage form developed, using an 
appropriate dissolution method. 
5. To identify key aspects of the dosage form for further study.   
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 1 
CHAPTER ONE  
DRUG MONOGRAPHS 
 
1.1 METOPROLOL TARTRATE 
 
1.1.1 INTRODUCTION 
Metoprolol is a synthetic beta1-selective adrenoceptor antagonist [1,2]. The FDA approved 
metoprolol for the treatment of hypertension, in 1978 [3], and since then it has conventionally 
been used in hypertensives and in patients with ischaemic heart disease [4]. In recent years, 
however, the use of metoprolol has been extended to the treatment of stable angina and acute 
myocardial infarction. Metoprolol free base is highly lipophilic, therefore it is available either 
as succinate, fumarate or tartrate salts, which vary in solubility [1]. Only the tartrate salt will 
be discussed in further detail as this was selected for experimental work. 
 
1.1.2 PHYSICO-CHEMICAL PROPERTIES 
1.1.2.1 Description 
Metoprolol tartrate (MPTA) is a white, practically odourless crystalline powder [1,5]. 
Metoprolol tartrate is a salt consisting of a racemic mixture of optical isomers of the base and 
dextro-tartaric acid in a 2:1 ratio [1]. 
 
MPTA may be described by several chemical names, which include [1]: 
1. 2-propanol, 1-[4-(2-methoxyethyl) phenoxyl]-3-[(1-methylethyl) amino]-,  
(±)-, [R-(R*, R*)]-2,3-dihydroxybutanedioate (2:1) (salt) 
2.   (± )-1-(Isopropylamino)-3-[ - (2-methoxyethyl)- phenoxy]-2-propanol L-(+)-tartrate  
(2:1) (salt) 
3. 1-(isopropylamino)-3-[-(2-methoxyethyl)-phenoxy]-2-propanol (2:1) dextro-tartrate 
salt 
 2 
OCH2CHCH2NHCH(CH3)2
CH2CH2OCH3
OH
COOH
C OHH
C HHO
COOH
2
Metoprolol Tartaric Acid
 
 
 Figure 1.1: Structure of Metoprolol Tartrate [(C15H25NO3)2.C4H6O6] (MW = 684.82) 
 
1.1.2.2. Dissociation Constant and Distribution ratio 
MPTA has only one ionisable group, that is, a secondary amine. The dissociation constant 
(pKa) in water (ionic strength = 0.1) at 25°C has been reported by three separate sources to 
range between 8.9 –9.70 [1], however a pKa of 9.7 is quoted most often [6,7,8]. The pKa 
values for tartaric acid are 2.93 and 4.23 at 25°C [1]. In comparison to other -blockers, 
PHWRSUROROLVPRUHOLSRSKLOLFWKDQPRVWRWKHU -blockers, except for propranolol, which 
exhibits the largest degree of lipophilicity [4], as indicated by the permeability coefficient 
(Log Kp) in Table 1.1. Consequently, the route of elimination and potential for central 
QHUYRXVV\VWHP&16VLGHHIIHFWVGLIIHUIURPWKHPRUHK\GURSKLOLF -blocking agents [3], as 
will be discussed in §1.1.4.4. 
 
Table 1.1 Log Kp values for commonly used beta-blockers 
Compound Kp value 
Metoprolol 
Propranolol 
Atenolol 
Acebutolol 
Nadolol 
Timolol 
Pindolol 
2.15 
3.65 
0.23 
1.90 
0.70 
2.10 
1.75 
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1.1.2.3 Solubility and water absorption isotherm of metoprolol 
Metoprolol itself is highly insoluble in aqueous media [9]; however using different salt forms 
of the drug may increase the solubility. Of these, MPTA shows the greatest solubility in 
water. The approximate solubility of MPTA in several solvents at 25°C is listed in Table 1.2. 
MPTA is hygroscopic at humidities greater than 70% and is desorbed as the relative humidity 
decreases. The state of hydration and crystal form has been observed to be stable upon drying 
and re-analysis of MPTA [1]. 
 
Table 1.2 Solubility of MPTA in various solvents            
Solvent Solubility (mg/ml) Reference 
Water 
Methanol 
Chloroform 
Acetone 
Acetonitrile 
Hexane 
Ether 
> 1000 
> 500 
496 
1.1 
0.89 
0.001 
insoluble 
1,5,10 
1,10 
1,10 
1,10 
1,10 
1,10 
5,10 
 
1.1.2.4 Optical rotation 
MPTA contains three asymmetric carbon atoms; two of these are in the tartaric acid portion of  
the molecule, and one occurs at the 2-propanol position of the racemic base. The compound 
exhibits optical rotation in solution due to the optically active dextro-tartaric acid used in the 
preparation of the compound. The specific rotation for a typical sample of a 2% MPTA 
aqueous solution at 20°C, using the sodium D line, is +8.5°. The optical rotation range lies 
between +6.5° and +10.5°[1]. 
 
1.1.2.5 Ultraviolet absorption spectrum 
7KH89DEVRUSWLRQZDYHOHQJWKPD[LPD maxDQGPRODUDEVRUSWLYLWLHV RI037$LQ
various solvents are listed in Table 1.3. A typical UV absorption spectrum of metoprolol 
tartrate in 0.1M hydrochloric acid (HCl) is depicted in Figure 1.2. 
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Figure 1.2: UV absorption spectrum of MPTA in 0.1M HCl 
 
 
Table 1.3: Absorption maxima and molar absorptivities of MPTA  
                   
Solvent max (nm) 
 
x
 
10-3 
 
0.1N HCl 
221 
274 
281(shoulder) 
19.5 
2.83 
2.31 
 
Water 
223 
274 
280(sh) 
23.4 
3.60 
2.94 
 
0.01N NaOH 
223 
274 
280(sh) 
24.0 
3.66 
3.00 
 
Methanol 
223 
276 
282 
21.5 
3.11 
2.62 
 
Chloroform 
277 
283 
3.36 
2.86 
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1.1.2.6. Infrared spectra (IR) 
The infrared spectrum reveals (Figure 1.3) that the frequencies and functional group 
assignments of the major absorption bands, as listed in Table 1.4, are consistent with the 
structure of MPTA [1].  
 
 
Figure 1.3: IR spectrum for MPTA 
 
 
Table 1.4: Frequency and functional group assignment for MPTA                  
Wavenumber (cm) Assignment (s) 
3600-2300 
1580 
1580, 1515 
1250, 1015 
1180 
1100 
820 
NH2,  -OH, Aliphatic and aromatic CH 
Carboxylic acid salt 
Aromatic ring 
Aromatic ether 
Isopropyl group 
Aliphatic ether, Secondary alcohol 
1,4-disubstituted benzene 
 
1.1.2.7 Melting range 
MPTA melts over a 1-2° range between 120-123°C [1]. 
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1.1.3 STABILITY 
1.1.3.1.Solid state stability 
MPTA stored at room temperature and at 35°C for five years have been found to be both 
physically and chemically stable. No degradation is seen after storage at 50°C for 30 months, 
however a slight change in colour, from white to off-white, occurs. MPTA is found to retain 
its chemical and physical integrity upon drying [1]. 
 
1.1.3.2 Stability of solutions of MPTA 
Solutions of MPTA at pH 4, 7 and 9 stored at 60°C for 10 days show no chemical changes 
[1]. In another study of a prepared MPTA extemporaneous paediatric liquid, MPTA showed 
on 3% loss in potency when stored at 5°C and 25°C in the absence of light, for 60 days [8]. 
 
1.1.4 CLINICAL PHARMACOLOGY 
Metoprolol is a competitive 1-selective adrenergic antagonist, and therefore has been found 
to exhibit cardioselectivity. It acts as a partial agonist, as it is devoid of intrinsic 
V\PSDWKRPLPHWLFDFWLYLW\DQGWKHUHIRUHUHGXFHVH[HUFLVHKHDUWUDWHWRDJUHDWHUH[WHQWWKDQ -
blockers with intrinsic sympathomimetic activity. Metoprolol does not exhibit membrane-
VWDELOL]LQJDFWLYLWLHVDWWKHGRVDJHOHYHOVUHTXLUHGIRU -blockade [2,3,11,12]. The 
pharmacological properties of metoprolol compared with those of some other beta-blockers 
are listed in Table 1.5 [12] and it is evident that comparatively metoprolol is as potent as 
propranolol and atenolol.  
 
7DEOH&RPSDULVRQRIWKHSKDUPDFRORJLFDOSURSHUWLHVRIFHUWDLQ -blockers 
Drug Beta-blockade 
potency* 
Beta1-
selectivity 
Partial agonist 
activity 
Membrane stabilizing 
activity 
Acebutolol 
Atenolol 
Metoprolol 
Pindolol 
Propranolol 
0.3 
1 
1 
6 
1 
± 
+ 
+ 
0 
0 
+ 
0 
0 
+++ 
0 
 
+ 
0 
± 
+ 
++ 
 * Relative to propranolol, where 1 = equivalent potency 
0 Indicates no selectivity/activity 
± Indicates that selectivity/activity depends on the dose 
+, ++, +++ Indicates increasing levels of selectivity/activity 
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1.1.4.1. Mechanism of action     
0HWRSUROROLQVLPLODULW\WRRWKHU -antagonists competes with adrenergic neurotransmitters 
such as the catecholamines for binding at the sympathetic receptor sites. In low doses, 
PHWRSUROROVHOHFWLYHO\EORFNV 1-adrenergic receptors in the heart and vascular smooth 
PXVFOH7KH 1-receptor blockade results in a decrease in both resting and exercise heart rate 
and cardiac output, and thus a decrease in both systolic and diastolic blood pressure [3,5]. 
Inhibition of isoproterenol-induced tachycardia and reduction of reflex orthostatic tachycardia
 
also occurs [5]. At high
 
GRVHVLQH[FHVVRIPJSHUGD\037$ 2-adrenoreceptors are also 
inhibited  [3,5]. The pharmacodynamic effects of metoprolol have been categorized and 
include haemodynamic, electrophysiological, pulmonary, endocrine and metabolic effects. 
 
1.1.4.1.1 Haemodynamic, Electrophysiological and Pulmonary Effects 
Metoprolol results in a negative chronotropic effect on the heart; hence decreasing cardiac 
output and systolic blood pressure. In patients with mild to moderate hypertension, systolic 
blood pressure falls rapidly, however due to an increase in total peripheral resistance, diastolic 
pressure is maintained and a full anti-hypertensive effect may only be seen after several weeks 
of repetitive dosing. Patients with angina pectoris show a decrease in systemic arterial 
pressure and a mild reduction in contractility, resulting in a reduction in the myocardial 
oxygen demand. In myocardial ischaemia, the reduction in heart rate results in prolonged 
diastole which facilitates blood flow through poorly perfused regions of the myocardium [12]. 
The effect of metoprolol on human myocardial electrical activity results in a prolonged 
repolarisation time after 5 weeks of oral administration [12]. 
 
The -UHFHSWRUVLQWKHOXQJDUHSULPDULO\RIWKH 2W\SH>@WKHUHIRUHWKH 1-selectivity of 
metoprolol suggests that it would have fewer effects on lung function than the non-selective  
-blockers. However, this varies according to the type and status of pulmonary disease [4,12], 
DQGLQFUHDVHGDLUZD\UHVLVWDQFHFDXVHGE\ -blockers when used in asthmatics and patients 
with chronic obstructive pulmonary disease may lead to fatal bronchoconstriction [4]. 
 
1.1.4.1.2 Endocrine and Metabolic Effects 
Slight or no increase in plasma catecholamine has been reported with metoprolol treatment 
and plasma dopamine levels are unaffected after 4 weeks therapy, however such levels have 
been increased by 10-12 fold after 15 months of treatment [12].   
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Plasma renin activity in both healthy and hypertensive patients are decreased after short and 
long-term administration of metoprolol; the exercise induced increase in plasma renin activity 
is not consistently reduced [12]. Plasma renin levels are also important with respect to -
blocker treatment, where patients with low plasma renin levels are identified as poor 
UHVSRQGHUVWR -blockers. This group includes blacks and elderly patients, who respond better 
to diuretic and calcium antagonist therapy, whereas whites and young patients who have 
higher renin levels respond better to the drugs which act on the renin-angiotensin system, that 
LVWKH -blockers, angiotensin converting enzyme (ACE) inhibitors and angiotensin-II 
antagonists [14-17] 
 
Blood glucose regulation mechanisms are uQDIIHFWHGE\ -blockers and in moderately 
hypertensive patients with or without non-insulin dependent diabetes. The glucose response to 
glucagon challenge in patients on haemodialysis has also been reported to be unaffected by 
metoprolol [12]. In a study by Lager et al, it was found that neither the non-selective nor the 
FDUGLRVHOHFWLYH -blockers potentiated the effects of insulin on glucose-uptake in vitro, 
however propranolol results in an impaired rate of recovery of blood glucose levels in 
comparison to metoprolol  [18] 
 
Acute effects of metoprolol on lipid metabolism has shown a reduction in the uptake of free 
fatty acids by normal or occluded myocardium in dogs [14], however this effect was found to 
be less pronounced than with use of non-VHOHFWLYH -blockers [18]. Similar studies with rat 
and rabbit aorta have shown that metoprolol may have important effects against the formation 
of atherosclerotic tissue. In the long term, metoprolol has the tendency to elevate plasma 
triglyceride and very low-density lipoprotein triglyceride concentrations, hence elevating total 
serum cholesterol, whilst high-density cholesterol is decreased [14]. Although various studies 
have reported different results, there is as yet no evidence to support increased risk of 
ischaemic heart disease with prolonged metoprolol use [12]. 
 
1.1.4.1.4.3 Effects on Physical performance 
-blockers may also adversely affect the extent and quality of physical performance. 
However, metoprolol being a selective antagonist has fewer negative effects on performance 
than non-VHOHFWLYH -blockers. Heavy short-term exercise and prolonged exercise are both 
negatively affected to a larger extent by the non-selective beta-blockers, and anaerobic 
exercise may be affected by both the selective and non-seleFWLYH -blockers similarly  [12]. 
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1.1.4.2 Uses and indications 
Metoprolol has been used in the treatment of mild to moderate hypertension, and can be used 
alone or in combination with other antihypertensive agents [5]. Evidence from both primary 
and secondDU\SUHYHQWLRQWULDOVLQGLFDWHWKDWWKHXVHRIFDUGLRVHOHFWLYH -blockers such as 
metoprolol have a better preventive effect on total mortality, cardiovascular mortality and 
atherosclerotic complications than non-selective beta-blockers or diuretics alone [19,20]. 
Metoprolol has been found to be useful in this capacity due to its negative chronotropic 
effects, negative inotropic effects that decrease cardiac output, reduction of sympathetic 
outflow from the central nervous system and suppression of renin release from the kidneys. 
Thus, metoprolol affects blood pressure via multiple mechanisms that have been previously 
discussed in §1.5.1. Metoprolol is also used for the treatment of congestive heart failure 
(CHF), and has also been found to significantly decrease the morbidity and mortality 
associated with chronic CHF [21]. 
 
High efficiency and tolerability of metoprolol tartrate or metoprolol in combination with 
hydrochlorothiazide, in patients older than sixty-five years has been reported [12,22].  
Metoprolol in pregnant hypertensives reduces diastolic blood pressure slightly, but does not 
prevent the ocurrence of toxaemia in these patients [12]. In asthmatic patients the risk of 
bronchospasm is lower during acute and chronic metoprolol treatment as compared to the use 
of the non-VHOHFWLYH -blockers, however, it is probably safer to use other classes of 
antihypertensives such as the calcium channel blockers or the ACE inhibitors. Metoprolol has 
also been found to be safe and effective for use in diabetics for whom blood pressure was 
reduced but no significant changes in blood glucose or glucose excretion were noted [3,12]. 
 
Metoprolol has also been used in the management of chronic stable angina [3,11], where it 
reduces myocardial oxygen demand, and hence the frequency of anginal attacks and nitrate 
requirements, with a corresponding increase in exercise tolerance [3]. It may also be used in 
the prevention of myocardial infarction, atrial fibrillation, atrial flutter and for the 
symptomatic treatment of hypertrophic subaortic stenosis [3,11]. In the management of 
hereditary or familial essential tremor its use resulted in the reduction in tremor amplitude but 
not tremor frequency. The unlabeled uses of metoprolol include ventricular arrhythmias, atrial 
ectopy, migraine prophylaxis, aggressive behavior and essential and familial tremor [11]. 
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1.1.4.3. Contraindications and Precautions 
Metoprolol is contraindicated in sinus bradycardia, heart block greater than first degree, 
cardiogenic shock and overt cardiac failure. It should also not be used for myocardial 
infarction in patients with a heart rate of less than 45 beats per minute [5]. 
 
In the treatment of hypertension and angina patients who have congestive heart failure, ß-
blockers should be used with caution as myocardial contractility can be further depressed, 
precipitating more severe failure. Furthermore, metoprolol should not be used in patients on 
digitalis treatment as atrio-ventricular (AV) conduction is made slower by both these 
compounds [5]. Patients ZLWKRXWDKLVWRU\RIFDUGLDFIDLOXUHVKRXOGQRWXVH -blockers for 
prolonged periods as continual depression of the myocardium may ultimately lead to cardiac 
failure [5]. Furthermore, abrupt cessation of therapy could exacerbate angina pectoris and 
very rarely may lead to myocardial infarction. If chronically administered metoprolol needs to 
be discontinued, it should be gradually reduced over a 1-2 week period, and the patient 
carefully monitored during the titration period [5]. 
 
Although adrenergic selectLYH -blockers are preferred in patients with asthma or pulmonary 
FRQGLWLRQVLQZKLFKEURQFKRVSDVPFRXOGSXWWKHPDWULVNDOO -blockers should be used with 
FDXWLRQ>@6LQFH 1-selectivity is not absolute, the concomitant administration of a  
2-stimulating agent may be required, whilst using the lowest possible dose of metoprolol [5]. 
 
Metoprolol should also be used cautiously in patients with diabetes mellitus as it may mask 
V\PSWRPVRIK\SRJO\FDHPLD -blockers can also precipitate hypoglycaemia via inhibition of 
glycogenolysis, therefore should not be used in brittle diabetes but can be used cautiously in 
patients with stable diabetes [3,5]. When used in patients with hyperthyroidism or 
thyrotoxicosis, metoprolol can mask certain clinical signs such as tachycardia, and should 
therefore be used cautiously, and abrupt withdrawal of the drug in patients with 
hyperthyroidism can precipitate a thyroid storm [3,9]. The use of metoprolol before or during 
surgery is also controversial as the impaired ability of the heart to respond to reflex adrenergic 
stimuli may increase the risks of inotropic general anaesthetics and surgical procedures [3,5].  
 
Caution should be exercised in patients with severe hepatic disease as dosage adjustment, 
may be required due to decreased drug clearance [3]. Metoprolol is only relatively 
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contraindicated in Raynaud’s disease and peripheral vascular disease [23], and should be used 
FDXWLRXVO\LQSDWLHQWVZLWKGHSUHVVLRQ>@ -blockers may also exacerbate conditions such as 
psoriasis and may potentiate the symptoms of myasthenia gravis [5]. 
 
Metoprolol is classified by the FDA as a pregnancy category C drug and therefore should 
only be used in pregnant women if it is clearly indicated and consideration of the risks and 
benefits are essential before it is used. Metoprolol is also contraindicated in breast-feeding 
mothers as it is excreted into breast milk. Whilst studies in rats have revealed no evidence of 
impaired fertility or teratogenicity, there are no well-controlled studies in pregnant women 
[3], and therefore its use should be avoided if possible. 
 
7KHXVHRI -blockers in geriatrics may increase their risk to certain conditions such as 
hypoglycaemia due to decreased gastrointestinal, hepatic and renal functioning in these 
patients [25].  Safety and efficacy in children has not been established [3]. 
 
1.1.4.4 Adverse reactions 
The adverse reactions of metoprolol are usually mild and transient and usually occur at the 
onset of therapy, diminishing with prolonged therapy [3,5].  
 
Adverse central nervous system (CNS) effects include dizziness, fatigue and depression, and 
less commonly, CNS depression results in headaches, nightmares and insomnia [3,5]. 
Bronchospasm and dyspnoea may occur with doses greater that 400mg/day [3,5]. The most 
predominantly reported gastro-intestinal adverse effects include diarrhoea, nausea and 
vomiting, and flatulence has also been reported in about 1% of patients [3,5]. Hypersensitivity 
reactions such as pruritus, rash, exfoliative dermatitis and xenosis have been reported in about 
5 in 100 patients [5]. Musculo-skeletal pain, myalgias and tinnitus are less frequently 
reported. Sexual dysfunction, impotence and decreased libido are less frequent adverse effects 
with a less than 2% occurrence in patients [3]. 
 
Both hypoglycaemia and hyperglycaemia can occur on metoprolol therapy [3]. Congestive 
cardiac failure may occur but it is more likely in patients with pre-existing left ventricular 
dysfunction. Sinus bradycardia and hypotension may also occur however this can be easily 
reversed with intravenous atropine, if necessary [3]. 
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1.1.4.5 Drug interactions 
The anthypertensive effects of metoprolol are additive with other antihypertensive agents and 
therefore combinations may be used more effectively to reduce blood pressure [3]. The use of 
metoprolol should be avoided with catecholamine depleting drugs such as reserpine, 
guanethidine and rauwolfia alkaloids, as they may result in hypotension, marked bradycardia 
with resultant vertigo, syncope and postural hypotension [3,5]. When used with anti-
arrhythymics such as amiodarone, cardiac glycosides, diltiazem and verampamil it may result 
in complete atrio-ventricular block [3]. Care must be taken when clonidine therapy is stopped 
so as to avoid the possibility of rebound hypertension. The concurrent use of metoprolol with 
other sympathomimetic agents may result in antagonism of the desired therapeutic effects [3]. 
 
The effects of metoprolol may be enhanced or reduced with the concomittant use of certain 
drugs, which may affect bioavailiblity and hence, plasma levels of metoprolol. Metoprolol has 
been reported to interact with food and alcohol. Alcohol exacerbates drowsiness, dizziness, 
lightheadedness and blurred vision that may be caused by metoprolol, and should therefore be 
avoided [24]. 
 
1.1.5 PHARMACOKINETICS OF METOPROLOL 
1.1.5.1 Dosage and administration 
The dosage of metoprolol should be individualized when used for hypertension; however, the 
initial dosage for adults is usually 100mg, in single or divided doses. Metoprolol may be used 
alone or in combination with diuretics at the same dosages. The dosage may be increased 
weekly until the optimal blood pressure reduction is achieved [2,5]. The effective dosage 
range is 100-450mg per day [2,5,9,25]. Once daily dosing is effective and can reduce blood 
pressure throughout the day but the full effect may not be maintained at the end of the 24-
hour period therefore blood pressure should be carefully monitored initially. In elderly 
patients an initial daily dose of 25mg is recommended but may be increased up to 300mg per 
day [9]. In patients with hepatic disease a reduced dose may be necessary [9]. 
 
In the treatment of angina pectoris the usual dosage is 100mg daily in two divided doses but 
the dose may be increased at weekly intervals up to 400mg/day. If the drug is to be 
discontinued, it should be reduced over a period of 1-2 weeks [9]. When used for myocardial 
infarction, IV administration is required for the early treatment, thereafter 100mg twice daily 
is recommended as maintenance treatment for 1-2 years [5,9]. The usual dosage for children 
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is 1-5mg per kilogram per day, twice daily in divided doses. Dose adjustments should be 
performed every three days to optimize therapy [5].  
 
Oral dosage forms must be taken continuously and regularly with or immediately following 
meals and should not be discontinued without consulting a physician. Missed doses must not 
be taken with the following scheduled dose [9].  
 
1.1.5.2 Overdose 
Several cases of overdose with metoprolol have been reported. Symptoms of overdosing 
include hypotension, cardiac failure, bronchospasm and bradycardia. The oral LD50 in mice 
has been found to be 1158-2460 mg/kg, and is 3090-4670 mg/kg in rats [11]. There is as yet 
no specific antidote for the treatment of metoprolol overdose [11] therefore treatment should 
be symptomatic.  
 
1.1.5.3 Absorption         
The absorption of metoprolol is both rapid and complete and after administration about 95% 
of the drug is quickly and completely absorbed from the gastro-intestinal tract [3,5,27]. 
However, the oral bioavailability is low as only 40-50% of an oral dose reaches the systemic 
circulation as unchanged drug due to the effects of hepatic first-pass metabolism [25,28,29]. 
The onset of action for orally administered metoprolol is 20-30 minutes, and for IV 
administration is approximately 5 minutes [5]. Peak antihypertensive effects (tmax) are reached 
within 1.5-4 hours after administration and within 20 minutes after IV administration [3,5,27]. 
Peak serum concentrations have ranged from 0.035-0.125µg/ml after a 50mg dose and 0.046-
0.270µg/ml for a 100mg dose [30]. Following administration of extended release products, 
peak serum concentrations are approximately one third of those achieved with conventional 
release products, hence the peak concentration occurs about 7 hours after dosing [3]. Food 
increases the bioavailability of metoprolol, hence increasing absorption; therefore metoprolol 
doses should be taken at the same time each day [30]. Gastric motility may also have an 
impact on metoprolol absorption, and is especially important when sustained release products 
such as hydrophilic matrix tablets are administered, as it has been found that strong 
contractions may lead to crushing of the dosage form with subsequent increase in drug release 
[31]. It has also been found that the AUC during multiple dosing was increased, possibly due 
to decreased systemic clearance as a result of potential reduction in hepatic blood flow or due 
to decreased presystemic clearance as a result of saturation of the first-pass effect [32]. 
 14 
Certain drugs also affect the bioavailability of metoprolol and examples of which are listed in  
Table 1.6 [3,11]. 
 
Metoprolol pharmacokinetics are best described by a two-compartment model following IV 
administration of the drug and a one-compartment model after oral dosing [27,30]. 
 
Table 1.6: Some drugs that alter the bioavailability (F) of metoprolol 
Drugs which increase F Drugs which decrease F 
contraceptives 
flecainide 
mono-amine oxidase inhibitors 
hydralazine   
propafenone 
thyroid hormones                   
H2-antagonists                                                       
ciprofloxacin,    
calcium blockers, such as diltiazem,  
felodipine, nicardipine 
aluminium salts    
barbiturates    
calcium salts  
cholestyramine 
colestipol 
non-steroidal anti-inflammatories 
rifampin
salicyclates 
sulfinpyrazone 
 
1.1.5.4. Distribution 
The distribution of metoprolol is typical of a moderately lipophilic, basic drug [1]. Following 
absorption, metoprolol is rapidly and widely distributed to the peripheral tissue [27]. It 
crosses the blood brain and the placenta and can concentrate in breast milk [3,5]. Only a small 
fraction of the drug (about 12%) is bound to human serum albumin [1,3,5], however the 
hypotensive effects can last up to one month after discontinuation of the drug, possibly due to 
extensive tissue binding [3]. Due to minimal protein binding, metoprolol has a high apparent 
volume of distribution (Vd) of 5.6L/kg body weight [1,30]. The volume of distribution has 
been reported to be in the range of 1.2 to 10.4L/kg body weight [27,28], however the Vd has 
been reported to be much larger when drug is administered orally in comparison to IV 
administration [28]. 
 
1.1.5.5 Metabolism 
Metoprolol is extensively metabolized by the hepatic mono-oxygenase system in the liver 
[28]. The rate of drug metabolism is subject to genetic polymorphism [33] hence the extent of 
PHWDEROLVPRI -blockers ranges from very little to almost complete [27]. The rate of hepatic 
hydroxylation by the cytochrome P-450 isozyme system is determined by the genetic 
polymorph of the patient [3]. Hydroxylation generally occurs relatively rapidly, resulting in a 
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half-life (t½) of about 3-4 hours, but in slow hydroxylators the (t½) may be increased up to 7 
hours  [3]. Metoprolol has three major metabolites, the major hydroxylated metabolite being 
-hydroxy metoprolol [34,35], which exhibit no therapeutic effect [3,36].  
 
 
1.1.6.6 Elimination 
Elimination of orally administered metoprolol is mainly by biotransformation in the liver 
[1,7,30], and does not induce its own metabolism [1,30]. Approximately 3-10% of unchanged 
drug is recovered in the urine and the rest is excreted as metabolites via the kidney [36]. The 
three major metabolites, account for approximately 85% of the total urinary excretion. The 
excretion of these metabolites occurs primarily via glomerular filtration within 72 hours of 
administration [3]. 
 
 The elimination half-life (t½) of metoprolol is 3-4 hours but can range from 2.5 to 7.5 hours 
[1,5], where patients with a longer t½ value may be classified as poor metabolisers [28]. Half-
life is independent of the dose and duration of therapy, however, the duration of action of 
orally administered metoprolol is dose related [1,5]. This is demonstrated by the fact that a 
50% reduction of the maximum registered effect for single doses of 20mg, 50mg and 100mg 
occurs at 3.3, 5.0 and 6.4 hours, respectively [5,30]. This suggests that drug elimination from 
the plasma follows first-order kinetics, whilst the decline in response follows zero-order 
kinetics [30]. The systemic availability and t½ of metoprolol in patients with renal failure is 
not significantly different from normal subjects, therefore no reduction in dose is required in 
patients with chronic renal failure [5].  
 
IV doses of 5mg and 15mg yield a maximal reduction in exercise-induced heart rate of 
approximately 10% and 15%, respectively. The effect on exercise heart rate decreases linearly 
with time at the same rate for both oral and IV doses. There was no effect after 5 hours and 8 
hours for the 5mg and 15mg doses, respectively. Maximal beta-blocking effect after oral and 
IV administration is achieved with a ratio of the doses being about 2.5:1 [5].   
 
 
 
 
 
 16 
1.2: HYDROCHLOROTHIAZIDE 
1.2.1 INTRODUCTION 
Hydrochlorothiazide (HCTZ) is a widely used saluretic agent, which exhibits both diuretic 
and antihypertensive activity [37,38]. HCTZ belongs to the thiazide group of drug compounds 
It was which were discovered during research in sulfonamide chemistry [37]. It has been 
included into the South African Essential Drugs List for the treatment of hypertension and it 
is often used in combination with other antihypertensive agents such as beta-blockers [39]. 
 
1.2.2 PHYSICO-CHEMICAL PROPERTIES 
1.2.2.1 Description 
HCTZ appears as a white or practically white, practically odourless crystalline powder, which 
has a slightly bitter taste [37]. It has a moleculer weight of 297.73 [37,40]. 
 
HCTZ may be described by several chemical names, which include [37]: 
1. 6-chloro-3, 4-dihydro-7-sulfamoyl-2H-1, 2, 4-bezothiadiazine 1,1-dioxide  
2.  6-chloro-3, 4-dihydro-2H-1, 2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide 
3.  6-chloro-7-sulfamyl-3, 4-dihydro-1, 2, 4 - benzothiadiazine 1,1-dioxide 
            4.  2H-1, 2, 4-Benzothiadiazine-7-sulfonamide, 6-chloro-3, 4-dihydro-1, 1-dioxide 
    
   
OO
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Figure 1.4 Structure of Hydrochlorothiazide (C7H8ClN3O4S2)  MW = 297.73 
 
1.2.2.2 Dissociation Constant and Partition Coefficient 
The ionization constants (pKa) quoted in the literature range from 8.60-8.81 (Table 1.7), 
depending on the method by which the value was identified [37,41]. The apparent n-octanol: 
aqueous phase partition coefficients (P) are listed in Table 1.8. 
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Table 1.7: pKa values for HCTZ  
pKa-Value Method 
8.81 ± 0.05 Photometric titration 
8.6 Potentiometric titration 
8.7 Spectrophotometry 
 
 
Table 1.8: Partition coefficients for HCTZ  
Aqeous phase P 
0.1M HCl pH1.06 
0.1 M glycine buffer pH 3.0 
0.067M phosphate buffer pH 7.4 
1.94 
0.866 
0.855 
 
 
1.2.2.3 Solubility 
HCTZ is only very slightly soluble in water and therefore has the potential for poor 
gastrointestinal absorption [37,42]. It is soluble in aqueous solutions of organic bases, for 
example, n-butylamine, and inorganic bases such as sodium hydroxide. The solubility of 
HCTZ in aqueous solutions and certain commonly used inorganic solvents are listed in Table 
1.9A-B. The solubility of HCTZ increases upon the addition of non-ionic surface-active 
agents [37]. The surface tension of the saturated aqueous solutions at 23°C was found to be 
724µN.cm-1 [43]. 
 
1.2.2.4. Thermal Analysis 
The melting point of HCTZ has been reported to be 268°C [44], but may vary within a range 
of 263-275°C. The melting point is strongly dependent on the heating conditions and the 
effect responsible for this melting behavior is not clearly understood [37]. 
HCTZ is reported to contain < 0.1% volatile impurities up to a temperature of 280°C [37], 
and overall loss on drying at 105°C for one hour is not more than 0.5% of the weight of 
HCTZ [40]. Thermogravimetry results also indicate that decomposition of HCTZ starts at 
307°C [37]. 
 
1.2.2.5 Density and crystal structure 
HCTZ is a monolithic crystal system [37], with a density of 1.68 ± 0.01 g.cm-3 [37,43]. 
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Table 1.9A: Solubility of HCTZ in aqueous solvents 
Solvent Temp (°C) pH of solution Solubility (g/100ml) 
Water 
0.1M HCl 
0.067M phosphate buffer 
0.05M borate buffer 
1.0M ammonia 
0.1M NaOH 
Simulated gastric fluid pH 1.1 
simulated intestinal fluid 
37 
25 
25 
25 
25 
25 
37 
37 
7.2 
1.0 
7.4 
9.0 
11.6 
10.2 
1.1 
7.5 
108 x 10-3 
60.8 x 10-3 
61.6 x 10-3 
103 x 10-3 
2.2 
1.79 
108 x 10-3 
109 x 10-3 
 
Table 1.9B: Solubility of HCTZ in non-aqueous solvents  
Solvent Temp (°C) Solubility (g/100ml) 
acetone 
acetic acid 
acetonitrile 
ethylacetate 
chloroform 
ethanol(96%) 
methanol 
dichloromethane 
25 
25 
25 
25 
23 
23 
23 
23 
13.7 
0.15 
2.0 
0.59 
0.1 
1.3 - 1.4 
3.9 - 4.1 
< 0.02 
 
1.2.2.6 UV Absorption 
UV absorption data of HCTZ in various solvents are listed in Table 1.10 and a typical UV 
spectrum of HCTZ is shown in Figure 1.5 [37]. 
 
Table 1.10: UV Absorption data for HCTZ [35] 
Solvent PD[QP log  
ethanol 225 
269 
316 
4.576 
4.307 
3.505 
methanol 226 
271 
317 
4.513 
4.279 
3.471 
water 270 
315 
4.286 
3.495 
0.01N HCl 270 
315 
4.290 
3.500 
0.01N NaOH 272 
323 
4.193 
3.435 
 
1.2.2.7 Infrared Spectra 
The IR spectrum for HCTZ is shown in Figure 1.6. Assignments for the characteristic bands  
I ~~~-----------
" i 1 : . 1 ; ; .. :' SP,ctrulld~~-'---~ 
1.0 ++-±-+-+......;I:-.. -:--:~I.oT-+--7+ S.""I" 76-10' .. , ••••••••• 76 I 
I.
' II:! t· I' Holt'cular W(liI)ht: ZQ7.?5 
I ·,·.·: .. ! ····J,I .. ·! .': Sohl.'nl.:hthanol I 
0.8 
0.6 
I Conc;entr.lIl)n: 2".10""'ol./LiL. 
IT-+~~Lt!-I..,·.;.i-+!'091·· ", C.ll p.th: 1,00. ~ .. :., ,"; :':~r. 'J: :;'::J ~;!~~~~~!O~Ul :'lt~: 19.""11 1919 I ····_·I-·:...L-t·_-·_ ...... ·r· .. , I .! I ;. I : I'" "j' , I I ' . "I i ~:-:,.:; ~ . I ! . : . : : ! I ii' : ; I ! : : I : .. : :;: 
I. -I: -7". : ·t·-t"·Ii<-i-:~r~·-:-+-+I' T' +--+-+-+:-,::" 
. . .. ::.j! 1 ,., I I . 'I . .J' . ,. tt!. : ~'!1r!Ti-'i1:11tt rDf ! 
.....• ••.••••. : .f. ; ,.j 
... ,... j-- ............. .. 
; I 
. ~ ... i ..• ; 
• I 
0,4 .-t. 
0,2 
0,0 +t--+++-i--i--!-ot~~-l.-+-+-+-+-t:-1-+++-++1 
2S0 JOO lSO Wavelength (11m) 400 
Figure 1.5: UV scan ofHeTZ in ethanol 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
l-
SAMPLE 
ORIGIN 
76-10429} 
Deppel" 
SOLVENL "'"i· l • _ I SCAN • 51 
CONe. SLIT N 
CELt. PATH. OPERATOR P.B 
REFERENCE DATE 9.7.79 
.. PI! No 171·SOd 
Figure 1.6: Infrared spectrum ofHeTZ 
19 
.-~.-.. REMARKS 
£.14r .. /W5 
Prod.Stand. 16 
~ 
fIl 
::; 
~ 
 20 
in the spectrum are listed in Table 1.11, and are consistent with the structure [37]. 
 
Table 1.11: IR assignments for HCTZ 
Frequency cm-1 Assignments 
3380, 3280, 3180 
3080, 3020 
2960, 2900 
1600, 1525, 1460 
1335, 1320 
1165, 1155 
940, 900 
710, 675 
NH stretching 
aromatic CH stretching 
CH2 stretching 
C=C stretching 
SO2 asym. stretching 
SO2 sym. stretching 
S-N stretching + NH deformation 
ring deformations 
 
 
1.2.3 STABILITY 
1.2.3.1 Bulk stability and solid-solid interactions 
When stored at room temperature for five years, HCTZ shows no degradation. Heat affects it 
very slowly and treatment for 2 hours at 230°C results in slight discolouration but no change 
in physical properties [37]. In humid conditions, HCTZ reacts with excipients containing 
metal compounds, however, under normal manufacturing and storage conditions there are no 
indications of degradation of the drug when in contact with Aerosil® 2000, calcium stearate 
and talc [37]. 
  
1.2.3.2 Aqueous stability 
In aqueous solutions, HCTZ undergoes hydrolysis to give formaldehyde and 4-amino-6-
chloro-1,3-benzenedisulfonamide, via an equilibrium process [37,45,46]. This reaction is 
specific-acid and specific-base-catalyzed [47]. However, the equilibrium constant is 
independent of pH from 1.5 to 8.2 [46,47], and in this range the equilibrium favors HCTZ. In 
very alkaline solutions (pH > 12) or in the presence of reagents that react with formaldehyde, 
complete hydrolysis can occur [37,46,47]. The pH-Rate profile for the hydrolysis of HCTZ is 
shown in Figure 1.7. 
 
The slopes of the linear portions are -1.0 and +1.0 at the low and high pHs, respectively. This 
indicates first order dependence on both the hydrogen and hydroxide ions. The degradation 
rate constant (k) is representative of the pseudo-first order rate constant for the forward 
reaction. The intermediate portion is a bell-shaped curve. It has been established that this 
curve is a reflection of the kinetics of the reaction rather than the ionization constants of the 
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reactants. The portion of the profile from pH 7 to 11.5 probably results from the dissociation 
equilibra of HCTZ. The pKa values of HCTZ have been reported as 8.6 and 9.9. The 
decreasing degradation rate from pH 7 to 3 can be accounted for in terms of the degree of 
ionization of the substrate since there are no pKa values in this range, indicating an absence of 
the ionized species. This drop-off in rate may be due to a change in the rate-determining step 
of the reaction, and the occurrence of one or more intermediates resulting from the reaction, 
which is of two or more steps. The most common proposal is the formation of an imine 
intermediate, which results from ring opening of the HCTZ molecule [37,46,47]. 
 
 
 
 
Figure 1.7: pH-Rate profile for the hydrolysis of HCTZ 
 
1.2.3.3 Photolytic decomposition of HCTZ 
HCTZ decomposes upon irradiation with near-89OLJKW !QPLQERWKPHWKDQRODQG
aqueous solutions therefore these solutions should be protected from light [45,48].  
 
It is capable of acting as a skin photosensitizer by both free radical and excited single 
molecular oxygen mechanisms [49]. The chlorine substituent has been found to be 
photolabile, as seen from the photolytic pathway of HCTZ, as depicted in Figure 1.7 [45,48] 
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Figure 1.8: Photolytic pathway of HCTZ 
 
1.2.4 CLINICAL PHARMACOLOGY 
1.2.4.1. Mechanism of action 
HCTZ does not usually affect the normal blood pressure, but it does affect the distal renal 
tubular mechanism of electrolyte absorption. The diuretic effect is achieved by interfering 
with the transport of sodium ions across the distal renal tubes, hence increasing excretion of 
water and sodium and chloride in equal amounts [50]. Diuresis usually begins within two 
hours of an oral dose, peaks at about 4 hours and lasts for between 6-12 hours [51]. 
 
1.2.4.2 Uses and Indications 
HCTZ is indicated in the management of hypertension, either as the sole therapeutic agent or 
to enhance the effect of other antihypertensive agents. It is also indicated as adjunctive 
therapy in oedema associated with congestive heart failure, corticosteroid and oestrogen 
therapy and hepatic cirrhosis. It may also be useful in oedema due to various forms of renal 
dysfunction, such as chronic renal failure and acute glomerulonephritis. A short course of 
thiazides can also be used if a generalized oedema resulting from hypovolaemia occurs [51]. 
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Routine use of diuretics during pregnancy is not usually recommended; hence HCTZ should 
not be used unless it is essential to improve the well being of the patient. Thiazides are also 
indicated as treatment for oedema resulting from pathological causes during pregnancy [51]. 
 
1.2.4.3 Contraindications and Precautions 
HCTZ is contraindicated in patients with anuria and those who exhibit hypersensitivity to the 
drug and other sulfonamide derivatives. It should also be used with caution in patients with 
severe renal disease as thiazides may precipitate azotaemia, and in patients with impaired 
hepatic function or progressive liver disease. Sensitivity reactions may occur in patients with 
a history of allergy or bronchial asthma. HCTZ may also activate or exacerbate systemic 
lupus erythematosus. Thiazides may increase cholesterol and triglyceride levels [14,51].  
Hyperuricemia or acute gout may also be precipitated in susceptible patients as plasma urates 
are increased with HCTZ use [30,52]. 
 
Generally, patients on diuretic therapy should be monitored for evidence of fluid and 
electrolyte imbalance, namely, hyponatremia, hypokalaemia and hypochloremic alkalosis. 
Signs of such imbalance include dry mouth, drowsiness, muscle pain and fatigue, tachycardia, 
gastro-intestinal disturbances, weakness and restlessness. Hypokalaemia is more likely to 
occur with prolonged therapy, in patients with severe cirrhosis or where the patient does not 
have an adequate oral electrolyte intake. This may be avoided by using potassium-sparing 
diuretics or potassium supplements. Thiazides may also induce hypomagnesemia and 
hypercalcaemia [14,51].  
 
Caution should be exercised in diabetic patients and dosage adjustments of insulin or oral 
hypoglycemic agents may be required. Thiazide diuretics may also cause hyperglycaemia and 
the manifestation of latent diabetes mellitus [51]. 
 
Thiazides have been found to cross the placental barrier; hence there is a risk of neonatal 
jaundice and thrombocytopaenia. It is also excreted into breast milk, therefore either nursing 
or HCTZ have to be discontinued in such instances [51]. The safety and efficacy of HCTZ use 
in paediatrics has not yet been established [51].  
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1.2.4.4 Adverse reactions 
The most common adverse reaction experienced includes weakness, hypotension and various 
effects on the digestive system including pancreatitis, jaundice, diarrhoea, vomiting, 
constipation and gastric irritation [51]. Another commonly reported side effect is 
hypokalaemia, which in cases may be particularly dangerous as it may lead to cardiac 
complications [53]. Less common effects include haematological effects such as aplastic 
anaemia, agranulocytosis, hypersensitivity reactions such as anaphylactic reactions, 
respiratory distress, photosensitivity, fever and rash. Other effects include electrolyte 
imbalance, hyperglycaemia, glycosuria, hyperuricaemia, and muscle spasm, vertigo, 
dizziness, headache, renal failure and renal dysfunction. Alopecia, exfoliative dermatitis 
erythema multiformae, xanthopsia, transient blurred vision and impotence occur even less 
frequently [14]. More severe side effects may include the HCTZ-induced pulmonary oedema 
triggered by an autoimmune mechanism, in woman [54]. 
 
1.2.4.5 Drug Interactions 
The adverse effects caused by HCTZ may be potentiated by the simultaneous determination 
of certain drugs including alcohol, barbiturates, narcotics, corticosteroids and ACTH. Drugs 
such as cholestyramine and colestipol resins and the non-steroidal anti-inflammatory drugs 
decrease the absorption or the antihypertensive effect of HCTZ. When used with non-
depolarizing skeletal muscle relaxants, there may be a possible increased responsiveness to 
the muscle relaxant. Concurrent use of lithium and diuretics should be avoided because the 
renal clearance of lithium is decreased, and this may increase the risk of lithium toxicity [51]. 
 
1.2.5 PHARMACOKINETICS OF HYDROCHLOROTHIAZIDE 
1.2.5.1 Dosage and Administration 
As with most drugs, the dose of HCTZ used should be individualized according to patient 
response, and generally the smallest dose possible should be used, as the dose response curves 
of thiazide diuretics are flat, therefore increased dose does not correspond with a proportional 
increase in clinical effect [55]. 
 
To treat oedema in adults the usual dosage is 25-100mg daily in single or divided doses. In 
such patients intermittent therapy may be used, that is, on alternate or three to five days per 
week. This therapy reduces the risk of undesirable electrolyte imbalances. When used to treat 
hypertension, the initial adult dose is 25mg given daily as a single dose. Doses above 50mg 
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are associated with marked reductions in serum potassium and should be avoided. The usual 
paediatric dose is 0.5 to 1.0 mg /pound/day in two doses not exceeding 37.5mg per day. 
Infants under 6 months may require 1.5 mg/pound/day in two doses. Infants up to 2 years may 
be given 12.5-37.5 mg daily in two divided doses. Children over 12 years may be given 37.5-
100 mg per day, however, pediatrics with hypertension rarely benefit from doses exceeding 
50 mg/day [51]. 
 
1.2.7.2 Overdose 
The oral LD50 of HCTZ in the mouse and rat is greater than 10g/kg. The most common signs 
of overdosage are those associated with electrolyte depletion and dehydration resulting from 
excessive diuresis. In the event of overdosage, symptomatic and supportive measures should 
be used. Emesis should be induced and gastric lavage performed. Electrolyte imbalances and 
dehydration must also be corrected by established procedures [51]. 
 
1.2.5.3 Absorption 
After administration of IV and oral doses of HCTZ to human volunteers, 90-93% and 58-
63%, respectively, were excreted into the urine. The bioavailability of oral doses is in the 
range of 60-80% of the dose, however this is reduced in patients with congestive heart failure, 
renal and hepatic diseases and only about 40% of the dose is excreted. The existence of an 
absorption window of HCTZ in the gastrointestinal tract has been reported, as HCTZ is 
mainly absorbed in the duodenum and the first part of the jejenum, whilst absorption occurs 
in the stomach to a very small extent [54]. The onset of action is approximately 2 hours, with 
the peak plasma effect being achieved in about 4-6 hours. The AUC correlates linearly with 
the dose [37]. An AUC value of 1193.9ng.h/mL from a 25mg dose of HCTZ has been 
reported, where this value was significantly increased with co-administration of a calcium 
channel antagonist [50]. The duration of action for hydrochlorothiazide ranges between 6-12 
hours [37].  
 
HCTZ shows enhanced bioavailability when administered with food [43]. The bioavailability, 
however, remains unaffected by the concomitant administration of drugs such as metoprolol, 
sotalol or hydralazine. Redalieu et al studied the kinetics of HCTZ absorption in humans. The 
plasma level data was fitted to a two-compartment body model and tests for first-order and 
zero-order absorption were performed. It was concluded that the kinetics of HCTZ absorption 
is a zero-order process as opposed to the commonly implied first-order process [43,50]. It has 
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not yet been established why this is a zero-order process, however it has been suggested that 
the zero order process occurs either as a result of the concentration of drug at the site being 
constant or due to the presence of saturated carrier-mediated transport systems such as those 
involved in the gastro-intestinal absorption of riboflavine and thiamine [43]. Mal-absorption 
of HCTZ may occur in patients with congestive heart failure and after intestinal shunt surgery 
[37]. 
 
1.2.5.5 Metabolism 
HCTZ undergoes only minimal hepatic metabolism, but is eliminated rapidly by the kidney 
[56] 
 
1.2.5.5 Distribution 
The distribution pattern in rats obtained after a single oral dose of HCTZ (5mg) showed that 
the highest concentrations of HCTZ were in the liver (27.8µg/ml) and in the gastro-intestinal 
tract (36.0µg/ml) within an hour after dosing. At this time point the concentration in the 
plasma was found to be 1.53µg/ml. HCTZ does not bind significantly to serum protein and 
only a low degree of binding to bovine serum albumin was obtained with only one binding 
site class [37]. HCTZ displays a total protein binding of about 40% [57]. 
 
1.2.5.6 Elimination 
The percent of dose of HCTZ excreted unchanged in the urine is approximately 60% [57]. It 
is eliminated from the plasma in a biphasic manner with plasma half-lives of 5.6-14.8 hours. 
There is a correlation between urinary excretion and the dose administered. At oral doses of 
12.5, 25, 50 and 75mg, the urinary excretion was 8.5, 17.9, 33.4 and 48.9mg, respectively, the 
cumulative urinary recovery being 65-72% of the dose. Renal clearance was found to be 
independent of dose [37]. HCTZ has a renal clearance value of about 300-335mL/minute 
[50,57]. In patients with congestive heart failure high peak plasma concentrations are 
achieved and the terminal t1/2 in plasma is 8.9-28.9 hours, implying that urinary excretion of 
the intact drug may be reduced. A study has shown that an average urinary recovery of 40.7% 
was achieved for a person with congestive heart failure [37]. Patients after intestinal shunt 
surgery also show decreased urinary excretion with an average urinary recovery of 30.7% of 
the dose [37]. 
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1.3 RATIONALE FOR DOSAGE FORM DESIGN 
Metoprolol has a long been established as a relatively safe and effective antihypertensive 
DJHQWDQGFRQVHTXHQWO\LWKDVEHFRPHRQHRIWKHPRUHFRPPRQO\SUHVFULEHG -blocking 
agents. Furthermore, metoprolol has a relatively short half-life, is completely absorbed from 
the gastrointestinal tract and exhibits a degreHRI -blockade that corresponds well with 
plasma concentrations and this is particularly well suited to be formulated as a controlled 
release dosage form. A number of controlled release metoprolol formulations are currently 
available on the international market [58]. Such formulations include, Seloken® Durules, 
Betaloc® SA, Betaloc® Durules (Astra Cardiovascular), Lopressor® SR (Novartis) and Toprol 
XL®(Astra). Whilst a large number of these are matrix-based products, newer developments 
include the use of osmotic type systems and divisible tablets where pellets are embedded in an 
inert tablet mass. These dosage forms, which allow for once daily dosing of metoprolol, have 
increase in use substantially as they offer an opportunity for more convenient dosage 
regimens, and thus the potential for greater patient compliance. Furthermore, studies have 
shown that the use of controlled release, once daily formulations of metoprolol were equally 
or more effective than twice daily conventional metoprolol tablets [59,60].  
Both HCTZ and metoprolol have been found to be equally effective for the treatment of 
hypertension in certain populations [61], however in the black and elderly population, 
metoprolol does not result in effective blood pressure reduction due to lower renin levels in 
such patients. HCTZ has been found to be effective in such patients and therefore a 
combination of the two would be beneficial in such populations. 
 
A combination of both metoprolol and HCTZ has also been found to be more effective in 
reducing blood pressure than increasing doses of metoprolol used alone [62-69]. The two 
drugs exhibit a synergistic relationship with respect to lowering of blood pressure.  
 
Combination dosage forms of MPTA and HCTZ have therefore been developed, an example 
of which, is Selekomb® (100mg metoprolol, 12.5mg HCTZ). Combination dosage forms of 
these compounds are usually formulated to contain 100mg metoprolol and 12.5mg HCTZ 
[63,64]. These dosage forms deliver metoprolol at a controlled rate, and the HCTZ is 
immediately released [63,64], so that there is an initial immediate reduction in blood pressure, 
which is maintained throughout the day by sustained metoprolol release. A dosage form with 
these characteristics was selected as the target for development.  
 
 28 
Although, a number of products already are in existence on the global market, they are 
comparatively more expensive than immediate release or single drug dosage forms. This 
makes such products inaccessible to developing countries in both public and private sectors, 
hence the development of cheaper, yet effective generic products would allow for more 
widespread use of such products in the developing world. This would be particularly 
advantageous in a country such as South Africa, where the majority of hypertensives are 
either black or elderly patients.  
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CHAPTER TWO 
 
HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC ANALYSIS OF 
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE 
 
 
2.1 METHOD DEVELOPMENT 
 
2.1.1 INTRODUCTION 
The quantitative analysis of metoprolol in plasma has been accomplished using a variety of 
methods including electron-capture gas-liquid chromatography after derivatization [70,71], 
gas chromatography-mass spectroscopy [71], high performance liquid chromatography 
(HPLC) with ultraviolet (UV) detection [71,72], and reversed phase ion-pair HPLC with 
fluorescence detection [71]. Analytical methods for the determination of metoprolol in 
pharmaceutical preparations include HPLC with UV detection [73-75], non-suppressed ion 
chromatography [76], HPLC with spectroflourimetric detection [76] HPLC with UV 
spectrophotometry [70,77]. Analytical methods for the analysis of HCTZ include first 
derivative UV spectrophotometry [78], and HPLC [72,73,78-81]. Metoprolol and HCTZ in a 
multi-component dosage form have been simultaneously analyzed using HPLC with UV 
detection [73,74] and electron-capture gas-liquid chromatography [82]. 
 
HPLC with UV detection was selected as the preferred method of analysis for these 
components. This decision was based on the existing methods described in the literature and 
on availability of equipment in our laboratory. Furthermore, HPLC is a widely used technique 
that has proven to be efficient and in most cases a superior method for the analysis of ionic 
species [83]. A number of published HPLC methods for the determination of metoprolol and 
HCTZ, either alone or in combination in pharmaceutical dosage forms, are listed in Table 2.1. 
These existing methods were used as the starting point for the development of an HPLC 
method for the simultaneous determination of MPTA and HCTZ. 
 
2.1.2 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)             
Chromatography, in general, uses a range of techniques to separate a mixture of solutes by 
using a mobile phase, which pushes the mixture along an immobile, immiscible stationary 
phase, hence allowing solutes to separate out based on their different mobilities in that system 
[73,83,84]. Prior to the 1970’s there were few reliable chromatographic methods available for 
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use in the laboratory, however, during this period, pressure liquid chromatography was 
increasingly used. This method, however, did not offer consistent flow rates and HPLC was  
developed in the mid-1970s. HPLC technology has developed rapidly and since the 1980’s it 
has become a method commonly used for the separation of pharmaceutical and chemical 
compounds [86]. 
 
The HPLC method selected for an appropriate separation is dependent on the properties of the 
compound to be analyzed. These include liquid-liquid chromatography (LLC), liquid-solid 
chromatography (LSC), size exclusion chromatography, and normal or reversed-phase (RP) 
chromatography, ion exchange and affinity chromatography. Each of these operates on a 
different basis, whereas LLC and LSC operate on the basis of polarity, normal and RP 
chromatography operates on the basis of hydrophilicity and lipophilicity of compounds. Ion-
exchange chromatography is used for the separation of charged molecules and operates on the 
basis of selective exchange of the ions in the sample with counterions in the stationary phase 
[87], size-exclusion chromatography depends on the molecular size of compounds and 
affinity chromatography uses immobilized bio-chemicals that have a specific receptor for the 
compound of interest [86]. 
 
2.1.3 EXPERIMENTAL 
2.1.3.1 Reagents 
All chemicals used were at least of analytical reagent quality. Acetonitrile (HPLC grade, 
distilled in glass) was purchased from Burdick and Jackson (Michigan, USA). Sodium 
hydroxide pellets and ortho-phosphoric acid (85%, analytical grade) were obtained from BDH 
Chemicals (UK) and PAL Chemicals, respectively. Metoprolol tartrate was obtained from 
Genpharm (Toronto, Canada) and hydrochlorothiazide was purchased from Aspen-
Pharmacare (Port Elizabeth, SA). HPLC grade water was purified using a Milli-Ro®-15 Water 
Purification System (Millipore, Bedford,MA,USA), which consists of a Super-C® carbon 
cartridge, two Ion-X® ion-exchange cartridges and an Organex-Q® cartridge. The water was 
filtered through a 0.22µm Millipak® stack filter prior to use. 
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.         Table 2.1 HPLC Methods used for the analysis of Metoprolol Tartrate and Hydrochlorothiazide 
Compounds Stationary Phase Mobile Phase  (nm) 
Internal 
Standard 
Reference 
C-18 Methanol (550ml): Water (470ml) with 961mg pentane sulfonic acid, 82mg 
anhydrous sodium acetate and 0.57ml glacial acetic acid 254 
Oxprenolol    
HCl 
73 
MPTA 
C-18 30%v/v acetonitrile in monobasic potassium phosphate aqueous solution (pH 5) 274 Propranolol   HCl 
75 
MPTA & other  
-blockers 
non-suppressed ion 
chromatography 50mM nitric acid in aqueous solution of 4% v/v acetonitrile 270 
- 
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C-18 0.067M phosphate buffer (pH 3.0), with 0.2% triethylamine:  25%v/v acetonitrile 227 - 
88 
C-18 MeCN: H2O: acetic acid 10:88:2 v/v, 2.5% THF organic modifier 271 Hydroflu- 
methiazide 
79 
C-18 5%v/v MeOH in double distilled water  (pH adjusted to 4.5 with 0.1M acetic acid) 254 Sulfadiazine 
80 
Anion exchange 0.005Na2SO4 in pH 9.2 borate buffer: MeOH, 35:5  - 37 
Lichrosorb® SI60 n-hexane:2-propanol :chloroform: diethylamine, 77:18:5:0.01  - 37 
HCTZ 
C-18 0.1M monobasic sodium phosphate (adjusted to pH 3.0): MeCN, 9:1 254 - 73 
HCTZ + 
captopril Phenyl column RP 
Gradient elution using different concentrations of MeOH: phosphoric acid in water 
at various flow rates 210 - 
72 
HCTZ and 
amiloride C-18 Water:  MeOH 60:40 v/v pH3.2 280 Caffeine 
89 
C-18 0.02M monobasic K2PO4 aq.solution (pH5.9): MeCN, 30%/v/v 274 Propranolol HCl 
75 
C-18 0.02M monobasic K2PO4 aq.solution (pH5): MeCN, 30%/v/v. Diluted 4:1 with 
water 274 
Propranolol 
HCl 
75 HCTZ and 
MPTA 
Nucleosil® 5 SA 0.015M KMeSO3, 0.025M tetramethylammonium chloride,  50% MeCN 212 - 
74 
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2.1.3.2 Preparation of stock solutions 
The stock solutions were prepared as follows: 
Approximately 0.017g of HCTZ was accurately weighed and transferred into a 1L A-grade 
volumetric flask. This was dissolved in less than 10%v/v acetonitrile and 100mL of HPLC grade 
water was added. Approximately 0.130g of MPTA was accurately weighed and added to the 
volumetric flask. The solution was then made up to volume using HPLC grade water. Standards 
ranging in concentration from 0.28- JP/RI+&7=DQG- JP/RI037$ZHUH
prepared by serial dilution of the stock solution using A-grade glassware. 
 
2.1.3.3 Preparation of buffers 
Buffer solutions were prepared by pipetting the appropriate volumes of 85% phosphoric acid into 
an A-grade volumetric flask and making up to volume with HPLC grade water. The pH was then 
adjusted as required using sodium hydroxide pellets. The pH was measured using a Crison pH 
meter (Crison, LASEC, South Africa) 
 
2.1.3.4 HPLC system 
Two modular systems were used for the in-vitro analysis of the compounds of interest. System A 
was used in the initial stages of method development and analysis of the MPTA cores developed, 
whilst System B was used in the latter stages of formulation development. 
 
System A 
The modular HPLC system was comprised of a Waters Model 6000A solvent delivery system, 
with a Waters Intelligent Sample Processor (WISP) Model 710B autosampler (Waters Associates, 
Milford, USA), a Spectrochrom UV-100 UV detector (Linear instruments Corporation) and a 
Perkin Elmer 561 strip chart recorder (Hitachi, Japan). The separation was achieved on an Inertsil® 
(250 x 4.6mm i.d) 5µm column (MetaChem Technologies Inc, USA). 
 
System B 
The modular system differed from system A in that it consisted of a P100 pump (Thermo- 
Separation Products, USA) and a second WISP 710B autosampler. All other components were the 
same as used in System A. 
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2.1.3.5 Column selection 
Reversed-phase HPLC was identified as the preferred method for the analysis of the compounds of 
interest, as is evident from the methods described in Table 2.1. In contrast to normal phase 
chromatography, RP-chromatography uses a non-polar stationary phase and a polar mobile phase. 
The more hydrophobic the matrix, the greater the tendency of the analytical column to retain 
hydrophobic moieties whilst hydrophilic compounds elute more quickly, hence separation of 
compounds is achieved [86]. Normal phase HPLC is especially useful for highly non-polar 
compounds, such as the high molecular weight hydrocarbons, whereas polar compounds may be 
readily analyzed by RP-HPLC [90,91]. As MPTA is a polar weak base, either ion-suppression or 
ion pairing with RP-high performance liquid chromatographic methods have traditionally been 
used for its analysis, however newer methods that exclude the use of an ion-pairing agent, have 
since been developed [75].  
 
Column packings for HPLC may be either porous or superficially porous. Normally columns are 
usually packed with uniform porous silica particles either with spherical or irregular shape. 
Different chemical groups are bonded to the surface of the silica particles to produce the bonded 
phase. The most commonly used bonded phase consists of C-18 alkyl groups that are attached to 
the surface of the silica particles, and are called octadecasilane (ODS) bonded phases. C-8 and 
phenyl columns may also be used. The efficiency of a column can be improved by reduction of the 
particle size of the stationary phase material, hence, stationary phase particle sizes have becomes 
progressively smaller, and particles with 3, 5 and 10µm diameter have been used. Typical column 
lengths range between 10-25cm long and 4.6mm internal diameter and they are usually made of 
stainless steel [83]. The use of small bore/ microbore columns (2mm diameter or less) has also 
increased considerably. Microbore columns are advantageous as they are operated at slower flow 
rates than larger columns, therefore solvent consumption is reduced. Furthermore, the efficiency of 
the column is dependent on the velocity of the mobile phase and not column diameter, and smaller 
peak widths are achievable with these columns [83]. 
 
C-18 columns have been most frequently used for the analysis of MPTA. Consequently RP-HPLC 
with a C-18 column was chosen for the analysis of the compounds. An Inertsil ® 250 x 4.6mm-i.d 
column with 5µm-particle packing was used for initial work. This column offered adequate 
 34 
separation of compounds and resulted in well-resolved peaks, as will be discussed in latter 
sections, and it was therefore selected for use in this method of analysis. 
 
2.1.3.6 Mobile phase selection 
2.1.3.6.1 Factors influencing the choice of mobile phase 
The mobile phase or eluent not only moves the sample components through the chromatographic 
column but also interacts with the solute molecules and the stationary phase itself. The strength of 
these interactions determines the resolution obtained and hence the efficacy and efficiency of the 
separation, therefore the selection of an appropriate mobile phase is imperative [83,91]. The mobile 
phase selected must not alter the characteristics of, or be miscible with the stationary phase, and 
those that could be potentially detrimental to the life span of a column, should be avoided. For 
silica based RP columns mobile phases to be avoided are those with pH < 3 or > 9, as these may 
lead to hydrolysis of the bonded phase or dissolution of the silica [83,92]. The mobile phase must 
also be compatible with all analytical system components.  
 
Solutions for use in HPLC systems must be filtered to remove particulate matter that could 
interfere with the pumping action of the solvent delivery device or cause damage to the seals and 
valves, or collect on the top of the column causing irregular behavior and subsequent column 
blockages [83]. Solutions must also be degassed to remove dissolved or suspended air bubbles so 
that they do not collect in the pump or the detector cell and cause erratic behavior of the detector or 
an irregular pumping action. The viscosity of the mobile phase is also an important consideration 
and should not exceed 0.5cps [83] as high viscosity solvents reduce solvent diffusion coefficients, 
hence decreasing column efficiency [91].  
 
When UV detection is used, the solvents selected must exhibit very low absorbance at the 
operating wavelength; for example, if a wavelength of 254nm is selected, aromatic solvents cannot 
be used as all such solvents absorb UV light to some extent at this wavelength [91]. In general, 
however, wavelengths above 210nm can be used with limited interference but it is important that 
the UV cut-off values for all solvents to be used are considered. 
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The choice of a mobile phase for a specific analyte is critical and the greater the solubility of the 
analyte in the mobile phase, the shorter the resultant retention time (RT). Conversely, if the analyte 
displays limited solubility in the mobile phase, it is likely to partition readily onto the stationary 
phase, resulting in longer retention times. The retention times of weak acids and bases analyzed by 
RP-HPLC may also be altered by changing the pH of the mobile phase or by including suitable 
organic modifiers into predominantly aqueous phases [83]. Organic modifiers in predominantly 
aqueous mobile phases will alter the retention characteristics of the compounds to be analyzed. The 
choice and amount of the organic modifier required depends on the properties of both the analyte 
and the stationary phase [83,91]. 
 
Ion-pairing agents may also be added to the aqueous phase. When the solute is a non-absorbing 
ion, the inclusion of a UV absorbing agent of opposite charge results in a detector response. Ion 
pairs may also be used for the detection of samples of the same charge as the ion-pair and 
uncharged particles [93].   
 
2.1.3.6.2 Selection of a mobile phase for MPTA and HCTZ 
The selection of the mobile phase was based on methods published in the literature and on the USP 
methods for the individual analysis of MPTA and HCTZ. The USP methods for the individual 
drugs resulted in broad peaks with long retention times that was possibly a function of the column 
selected.  
 
A method described by Das Gupta et al was then considered in preference to the USP and other 
methods [75]. Monobasic potassium phosphate buffer (0.02M), pH 5.9 with acetonitrile (30%v/v) 
at a flow rate of 2.3 mL/minute was used, however due to differences in column length and 
diameter, the method was optimized for the analytical system used in our laboratory. 
 
The affects of buffer molarity and pH and the type and amount of organic modifier used, were 
assessed and considered in the selection of the mobile phase. For the assessment of the effect of 
these variables, compounds were detected at a wavelength of 274nm and 0.1 AUFS at 
1.0mL.minute [75]. 
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2.3.1.6.2.1 Buffer molarity 
An assessment of 0.01M-0.05M buffers showed that increasing the buffer molarity led to an 
increased RT. The 0.02M (Figure 2.1) buffer resulted in the shortest RT for both compounds, with 
2.2 minutes for MPTA and 4.6 minutes for HCTZ, respectively. The peaks of interest were sharp 
and well resolved and exhibited no tailing for all buffers assessed, except for the 0.03M buffer, 
which resulted in poorly separated peaks. The 0.02M buffer, which displayed both good resolution 
and short RT, was selected for further use. 
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Figure 2.1: The effect of buffer molarity on retention time of MPTA and HCTZ 
 
2.1.3.6.2.2 Buffer pH 
A change in buffer pH influenced both the RT and resolution of the compounds. pH values less 
than 2.5 resulted in well resolved peaks, however the MPTA peak eluted too close to the solvent 
front making quantitation difficult. The resolution and peak shapes were acceptable between the 
pH range of 2.5-5.0 and the RT in this region also did not vary significantly (Figure 2.2). The peaks 
that eluted from a mobile phase prepared using pH 5.0 buffer showed good resolution and shape 
but the absorbance was lower than at pH 2.5-3.65. A buffer that allowed for higher absorbance by 
the compounds is likely to be advantageous in allowing for the development of a more sensitive 
method. 
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A pH of 3.1 was selected as it exhibited similar retention and resolution characteristics to those 
observed for pH 2.5 with only a minimal increase in RT. pH 2.5 was not selected as buffers with a 
pH of less than 3.0 are known to cause damage to columns [92]. Furthermore, it has been reported 
that compounds with a pKa > 8 provide better peak shape at pH 3.0 [92], therefore the selection of 
pH 3.1 would have a short RT, good peak shape and would minimize damage to the column. 
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Figure 2.2: The effect of buffer pH on retention time of MPTA and HCTZ 
 
2.1.3.6.2.3 Organic modifier 
The initial organic modifier used was acetonitrile (MeCN). The ratio of aqueous phase: organic 
phase is of importance particularly with respect to RT and optimal proportions of acetonitrile were 
determined by assessing the impact of varying the organic content of the mobile phase. An increase 
of the organic modifier composition resulted in sharper, well-resolved peaks and decreased RT for 
both compounds, however, the inclusion of methanol resulted in broader peaks. Acetonitrile was 
selected as the organic modifier for use as good resolution and sharp peaks were obtained when it 
was included in the mobile phase. The proportion of acteonitrile: buffer selected as optimal was 
72:28 %v/v.
 
Furthermore, the possibility of an incompatibility, which may result between the 
organic modifier in the mobile phase and acetonitrile used in the preparation of HCTZ solutions, 
would be minimized. 
 
 
 38 
2.1.3.7 FLOW RATE SELECTION 
Mobile phases are usually pumped through the column at a rate or 1-5 cm3/min [83]. The flow 
rates used by Das Gupta et al were 2.3mL/min and 2.5mL/min, depending on the mobile phase 
being used [75]. Although this flow rate is within the acceptable range, it was thought that a slower 
flow would also be advantageous in terms if maximizing the life span of the pump, the column and 
would also be more economical. Consequently a flow rate of 1.0mL/min was selected for use in 
method development. 
 
 
Table 2.2 The effects of altering the organic modifier ratio and the addition of other 
organic modifiers on retention time, peak shape and resolution. 
 
RT (minutes) Mobile Phase* 
MPTA HCTZ 
Resolution Peak Shape 
buffer (pH 2.5):MeCN, 
50:50 
11.0  
 
3.0  
 
Compounds are well resolved  MPTA peak is broad with 
tailing. HCTZ peak is sharp 
buffer (pH 2.5):MeCN, 
90:10 
11.2  
 
9.0  
 
Peaks were well resolved Peaks were sharp, no tailing 
(broader than 70:30) 
buffer (pH 2.5):MeCN, 
80:20 
7.2  6.2  Peaks were well resolved Peaks were sharp, no tailing 
buffer (pH 2.5):MeCN, 
75:25 
4.4  5.5  Peaks were well resolved (possible 
degradant of HCTZ not resolved) 
Peaks were sharp, no tailing 
buffer (pH 3.1):MeCN,  
72:28 
3.2  4.5  Peaks were well resolved, separated 
from solvent front 
Peaks were sharp, no tailing 
buffer: MeCN:MeOH, 
70:15:15 
5.4  5.0  Not well resolved Sharp peaks, no tailing 
buffer: MeCN: H2O, 
70:15:15 
8.2  9.0  Well resolved peaks No tailing, peaks are 
broader  
*(0.02M PO4 buffer was used for all mobile phases tested) 
 
2.1.3.8 Detection 
2.1.3.8.1 Method of Detection 
Detectors based on UV or visible light absorption, refractive index, flame ionization, electrical 
conductivity and heat of adsorption have been used with HPLC systems [91]. Perusal of the 
literature revealed that commonly used methods of detection for HCTZ and MPTA include 
spectroflourimetric and UV detection, with UV detection being the more commonly used option. 
UV detectors measure the ability of the sample to absorb light and can be used at one or more 
wavelengths. Detectors that may be used include fixed wavelength detectors, variable wavelength 
detectors that measure at one wavelength but can detect over a wide range of wavelengths, and 
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diode array detectors, that measure a spectrum of wavelengths simultaneously [83,91]. UV 
detection with a variable wavelength detector was used in this case. 
 
'HWHFWLRQ:DYHOHQJWK  
7KH max for MPTA in water occurs at 223 and 274nm with a shoulder at 280nm (Table 1.3). 
+&7=H[KLELWVD max at 270 and 315nm in water (Table 1.10). To select a wavelength for the 
simultaneous detection of both compounds, the effect of varying wavelengths on the absorbance of 
the compounds was investigateG)LJXUH max values and wavelengths frequently reported in 
the literature for these compounds were assessed.    
 
Based on the results depicted in Figure 2.3, a wavelength of 227nm was chosen for the detection of 
MPTA and HCTZ. This wavelength was found to produce reproducible, well-resolved peaks and 
allowed for the detection of low concentrations of the drugs without the need to increase the 
sensitivity such that concentrations within the range of study would be off scale and require 
dilution prior to analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Peak height comparison obtained at different wavelengths for MPTA and HCTZ 
 
An attenuation (AUFS) of 0.05AUFS was selected as it offered adequate sensitivity for the 
detection of both compounds and early detection of degradation products. 
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2.1.4 CHROMATOGRAPHIC CONDITIONS SELECTED 
The optimal chromatographic conditions that were established are described below. 
 
Mobile Phase   0.02M phosphate buffer (pH 3.1): acetonitrile, 72:28 
Flow Rate   1.0mL/minute 
Detection Wavelength 227nm 
AUFS    0.05 
Injection volume   / 
Temperature   Ambient 
Retention Time  MPTA: 4.0 minutes 
    HCTZ: 5.2 minutes  
 
A typical chromatogram obtained for the two compounds is shown in Figure 2.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: A typical chromatogram of the separation of HCTZ (A), possible degradant (B) 
and MPTA (C) 
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2.1.5 STABILITY INDICATING ASSAY  
A stability-indicating assay is one in which the active drugs can be quantified in the presence of 
any of its degradation products; however, such an assay may not always be optimum, especially if 
the degradant increases from < 0.1% to 0.3% [94]. Both impurities and degradants must be 
detected and quantified by the developed method and minimum validation data must be provided 
as proof of efficacy of the method. The method selected was able to identify the presence of 
degradants however these were not quantified. The appearance of these degradants was merely 
used as an indication that new standard solutions were required and to identify the storage time for 
samples to be stored prior to analysis being completed.  
 
2.1.6 CONCLUSIONS 
The variables investigated indicate that buffer pH, molarity and organic modifiers all have a 
significant effect on peak shape and retention times of the compounds of interest. The choice of a 
suitable wavelength is also important, in terms of method precision, selectivity and sensitivity. The 
chromatographic conditions were optimized to yield well-resolved peaks with reasonable retention 
times.  
 
2.2 METHOD VALIDATION 
2.2.1 INTRODUCTION 
Validation is the process whereby the performance characteristics of an analytical method are 
established and the analytical method meets the requirements for its intended purpose [73,95,96]. 
A validation process is essential as it serves to ensure that the quality of analytical data generated is 
both reliable and accurate, and it is also capable of identifying potential problems with the method. 
Validation may not be able to rule out all the potential problems of a particular method, however 
the most common problems may be identified during the validation process. Such problems 
include column degeneration, changes in column behavior due to changes in the manufacturing 
process, and the co-elution of impurities, derived from the synthesis of the active, with the analyte 
of interest [96]. 
 
For pharmaceutical preparations, guidelines which form the framework for validation of analytical 
methods have been published in the United States Pharmacopoeia (USP), the FDA, regulatory 
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bodies in Europe and Canada and more recently a validation guideline has been published by the 
International Conference on Harmonization (ICH) [97]. Whilst these sources are in general 
agreement about the type of studies to be conducted and they provide definition of terms useful for 
carrying out the validation procedure, there is little agreement as to how these studies should be 
conducted [95,97] and few published strategies for determining validity of methods are available 
[98]. 
 
The validation parameters outlined by the various organizations vary slightly. The USP and ICH 
includes eight parameters for evaluation, namely, accuracy, precision (intermediate precision and 
repeatability/reproducibility), specificity, limit of detection (LOD) and limit of quantitation (LOQ), 
linearity and range. However, the ICH guidelines also include robustness and system suitability, 
and suggest that precision be assessed at three levels, namely repeatability, intermediate precision 
and reproducibility [73,99]. Most validation methods for HPLC analyses include some or all of the 
parameters described above [97, 100-102]. It is usually unnecessary to perform all the validation 
studies in the very early stages of drug development and many researchers focus on specificity, 
linearity, accuracy and precision studies. Other studies are performed when the drug reaches the 
efficacy stage of development and have a greater chance of becoming a marketed product [95]. The 
parameters described above are specific to the validation of a developed method, and forms a part 
of an overall validation process, which includes validation of hardware and software used and 
verification of system suitability and performance [99].   
 
2.2.2 SPECIFICITY 
Specificity is defined as the ability to measure the analyte in the presence of other components that 
may be expected in the sample matrix, accurately and specifically. This may include degradation 
products, impurities and placebo ingredients [73,95,99,103,104]. Specificity was assessed by 
comparing chromatograms obtained from analysis of a standard solution containing the analyte 
only with a sample mixture obtained by dissolving commercial tablets of MPTA and HCTZ in the 
dissolution medium. The resultant peaks were well resolved from the solvent front and each other 
and no interference was observed, indicating that the method is specific for HCTZ and MPTA. A 
possible hydrolysis product of HCTZ was also identified as a well-resolved peak, as shown in 
Figure 2.4.  
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2.2.3 LINEARITY 
A linearity study is used to verify that the sample solutions are in a concentration range where the 
analyte response is linearly proportional to concentration [73,95]. The linearity of the range of 
detectability is dependent on Beer’s Law, such that the absorbance of a solute is directly 
proportional to its concentration in the solution [105]. Linearity in this range is dependent on both 
the compound analyzed and the detector used [103].  
 
The ICH guidelines recommend that five concentrations spanning the concentration range to be 
studied are used [99], and it is necessary that a minimum of twenty assays be performed for 
statistical validity [106]. Linearity was assessed by repeated measurements (n=5) of seven 
concentration levels spanning the concentration range of 0.28- JP/IRU+&7=DQG-
 JP/IRU037$$FFHSWDELOLW\RIOLQHDULW\GDWDZDVMXGJHGE\H[DPLQLQJWKHFRUUHODWLRQ
coefficient (r2) on the regression line for the response versus concentration plot. An r2 value of 
>0.990 was considered to be sufficient to demonstrate linearity of the method. The calibration 
curve was linear over the concentration range studied, with r2 = 1.0 for both MPTA and HCTZ. 
The equations of the regression lines were y = 8.1111x + 0.9514 and y = 2.1078x + 1.6424 for 
HCTZ and MPTA, respectively. Typical calibration curves for HCTZ and MPTA are shown in 
Figure 2.5.  
 
 
 
y = 8.1106x + 0.9589
R2 = 1
0
25
50
75
100
125
150
0 2 4 6 8 10 12 14 16 18
Concentration (mcg/ml)
 
A
v
er
a
ge
 
Pe
a
k 
H
ei
gh
t (
m
m
)
HCTZ calibration data
Regression 
 44 
 
Figure 2.5: Typical calibration curves for MPTA and HCTZ 
 
2.2.4 PRECISION 
Precision is a measure of the closeness of data values to one other when a number of 
measurements are taken under the same analytical conditions. The ICH defines precision as 
having three components, namely: repeatability, intermediate precision and reproducibility 
[95,99]. Precision is usually expressed as the percentage relative standard deviation 
(%RSD) [73,95,99] and the tolerance for %RSD was set at ± 10% in our laboratory.  
 
2.2.4.1 Repeatability 
Repeatability refers to inter-assay precision and is expressed as the degree of variation arising from 
consecutive and non-consecutive injections run on the same day. It should be determined using a 
minimum of nine determinations covering the specified analytical range, for example three 
determinations at three concentration levels [99]. Consecutive measurements were obtained by 
repeated injections of the same concentration taken from different vials in succession. Interspersing 
vials of the same concentration with those of different concentrations was the method used to 
obtain non-consecutive measurements. Repeatability of this system was assessed by repeat 
PHDVXUHPHQWVQ RIFDOLEUDWLRQVROXWLRQVFRQWDLQLQJ JP/ JP/DQG JP/RI
037$DQG JP/ JP/DQG JP/RI+&7=UHVSHFWLYHO\6DPSOHVZHUHUXQLQ
both consecutive and non-consecutive sequence. Standard deviations and %RSD values obtained 
were < 6% (Figure 2.6), which was the limit set in our laboratory, indicating that the method 
displayed adequate repeatability 
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*A, B, C represent High, Middle and Low concentrations, respectively 
Figure 2.6: Precision data (repeatability) for the analytical method developed 
 
2.2.4.2 Intermediate Precision  
Intermediate precision is used to evaluate the reliability of the method in different environments 
other than that used for the development of the method, and depending on time and resources, the 
method may be tested on different days, using different analysts and instruments [103,107]. Inter-
day precision was determined using calibrators of the same concentrations as described in § 
2.3.4.1.Samples were run over a six-day period. Results (Table 2.3) show that all standard 
deviations values were within the acceptable range, resulting in %RSD values less than or equal to 
5% which is within the limits set in our laboratory.  
 
Table 2.3: Intermediate precision data for MPTA and HCTZ 
Concentration 
 JP/ 
Mean concentration 
GHWHUPLQHG JP/ 
Standard deviation Precision 
(%RSD) 
MPTA 
5.0 
50.04 
100.08 
4.59 
49.89 
98.96 
0.16 
0.82 
0.97 
3.40 
1.64 
0.98 
HCTZ 
0.74 
7.43 
14.86 
0.82 
7.26 
14.76 
0.32 
0.17 
0.32 
5.00 
2.37 
2.19 
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2.2.4.3 Reproducibility 
Reproducibility is used to express the precision of an analytical method when used in different 
laboratories, however this is not always possible, therefore tests for reproducibility are not 
normally expected if intermediate precision is accomplished [103], thus no tests were performed. 
 
2.2.5 Accuracy and bias 
Accuracy is a measure of the closeness between the true and measured values of a sample  
[73, 95,99,103]. A tolerance of 2% was set for % RSD for this parameter. This complies with the 
limits set by a number of pharmaceutical industries [108]. Bias assesses the influence of the analyst 
on the performance of the method. Accuracy and bias were evaluated by making repeat 
measurements of three samples of varying concentration. Accuracy studies for drug products are 
recommended to be performed at 80, 100 and 120% of the target concentration [95,103]. These 
targets may be specific to the apparatus used for the in vitro tests, where USP Apparatus II may 
result in larger concentrations from the same dose of drug than in USP Apparatus III. Both 
Apparatus II and III were used for dosage form assessment, thus accuracy studies were performed 
in triplicate on samples representative of high, medium and low concentrations. Measurements 
were performed in triplicate. The results are shown in Table 2.4 and shows that largest value 
obtained for % bias was 6.16%, indicating that no value obtained deviated by greater than 
approximately 6% of the stated value. % RSD values all complied with the 2% tolerance set, 
indicating that the method was accurate for the determination of both MPTA and HCTZ. 
 
Table 2.4 Percent error obtained during determination of blinded samples in accuracy 
testing 
 
Theoretical concentration 
 JP/ 
Mean concentration 
determined 
SD % RSD % Bias 
 METOPROLOL TARTRATE 
5.00 
50.04 
100.08 
4.71 
50.03 
98.97 
0.04 
0.26 
0.19 
0.19 
0.52 
0.83 
-6.16 
-0.02 
-1.12 
 HYDROCHLOROTHIAZIDE 
0.74 
7.43 
14.86 
0.70 
7.1 
14.44 
0.00 
0.12 
0.24 
0.00 
1.74 
1.63 
-5.71 
-4.65 
-2.41 
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2.2.6 RANGE  
The range of an analytical method is the interval between and including the upper and lower levels 
of the analyte that have been quantitated with the necessary accuracy, precision and linearity. The 
range was determined to be precise and linear over the 0.30- JP/UDQJHIRU+&7=DQGRYHU
a 2.25- JP/UDQJHIRU037$$OWKRXJKGLVVROXWLRQVWXGLHVZRXOGEHSHUIRUPHGLQERWK
USP Apparatus II and III, the concentration of the highest calibrator was determined as 120% of 
that obtained in Apparatus II. 
 
2.2.7 LOQ and LOD 
The LOQ is a measure of the level of analyte that can be measured with the required accuracy and 
precision, and LOD is the lowest analyte concentration that is detectable above the baseline noise 
of the system [73,95,99,103]. There are several methods for the determination of these parameters, 
the first of which suggests that the LOQ is the lowest concentration measurable resulting in a 
%RSD value of <10% upon multiple injections of the sample. The LOD would then be 30% for the 
concentration obtained for the LOQ [103]. The ICH recommends that LOQ and LOD are 
determined according to the Equations 2.1 and 2.2, only the calibration curve and replicate blank 
injections are considered in this case [109, 110].   
   
    /2' [ 6(quation 2.1 
    /24 [ 6(TXDWLRQ 
 
ZKHUH  QRLVHHVWLPDWHVWDQGDUGGHYLDWLRQRIWHQEODQNLQMHFWLRQV 
 S = slope of calibration curve determined in linearity studies 
 
The USP describes the LOQ as having a signal to noise ratio of 10:1, and the LOD as having a 
signal to noise ratio of 2:1 or 3:1. Although this concept is widely used, it must be noted that these 
values are likely to vary with changes in the detector, which may the include deterioration of the 
detector lamp on prolonged use [103]. 
 
The USP method was selected for the determination of the requisite validation parameters. Repeat 
measurements (n=6) of blank injections were used to establish the baseline noise. Repeat injections 
of decreasing sample concentrations (n=6) yieOGHG/2'YDOXHVRI JP/DQG JP/IRU
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+&7=DQG037$UHVSHFWLYHO\/24YDOXHVRI JP/56' IRU+&7=DQG
 JP/56' IRU037$ZHUHREWDLQHG$OWKRXJKWKH56'YDOXHVREWDLQHGZHUH
higher than for samples of higher concentration, all %RSD values were less than 7%.  
 
2.2.8 RUGGEDNESS 
This is expressed as the lack of influence of environmental and instrumental conditions on the 
analytical method. It is usually determined by analyzing samples under a variety of test conditions 
such as running the analysis on different days, with different analysts, and using different 
temperatures and reagents. Results from different day analysis have been described for 
intermediate precision and thus no further tests were conducted. 
 
2.2.9 ROBUSTNESS 
The robustness of an analytical method may be described as its capacity to remain unaffected by 
small but deliberate changes in the method parameters. This will provide an indication of its 
performance during normal use [73]. The effect of varying the organic modifier content was 
assessed in § 2.3.1.5.2. Tests for robustness were continued in the latter stages of development and 
are discussed in § 2.5.7. 
 
2.2.10 STABILITY OF ANALYTE 
MPTA and HCTZ are both known to be photolabile [1,45] and HCTZ undergoes hydrolysis in 
aqueous solutions. Consequently detection of possible degradants was thought to be advantageous, 
as this would allow for identification of acceptable storage periods for aqueous solutions of the 
compounds before they can be analyzed.  
 
Mixtures of MPTA and HCTZ (100µg/mL MPTA, 15µg/mL HCTZ) were prepared and stored 
under various conditions as described in Table 2.5. These were stored over a twelve-week period, 
with fresh calibration curves prepared on each day of analysis. Samples were stored to determine 
the effects of light and temperature on the stability of MPTA and HCTZ in solution.  
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Table 2.5: Conditions for the assessment of the stability of MPTA and HCTZ in aqueous 
solutions 
CONDITION ASSESSMENT POINTS 
Room Temperature (22°C), No foil cover 0, 6, 12, 24, 48 hours 
1, 2, 3, 4, 8, 12 weeks 
Room Temperature, Foil covered 
Refrigerator (8°C), No foil cover 
Refrigerator, Foil covered 
 
1,2,3,4,8,12 weeks 
 
Samples were initially analyzed over a 48-hour period in order to determine whether samples could 
be analyzed after storage for this period of time prior to analysis. Thereafter they were assessed 
weekly for a month, and then after two and three months of storage, as described. 
 
The statistical method developed by Timm et al was used to determine whether the resultant 
differences in concentrations constituted a relevant or significant change [111]. The method 
involves the calculation of the 90% confidence intervals for the difference between two data sets, 
where a change is considered significant if the confidence intervals for the difference between the 
two do, does not include zero change. However, a change may only be considered relevant if both 
the upper and lower limits of the confidence interval are either > 10% or < -10% [111]. This 
concept is graphically represented in Figure 2.7. 
 
The observed differences for the 48-hour assessment of samples stored at room temperature and at 
8°C showed neither significant nor relevant changes in MPTA concentration (Figures 2.8 and 2.9). 
This result was expected as MPTA was found to be stable in solution at 60°C for 10 days (§ 1.4.2). 
It was expected that MPTA solutions exposed to light would show a significant decrease in analyte 
concentration, due its instability upon exposure to light, however it was found that all solutions 
stored at room temperature over the three month period showed both significant and relevant 
increases in concentration. With the exception of the analysis of one of the samples stored at 8°C, 
changes in sample concentration were found to be significant and possibly relevant. Samples 
protected from light and stored at 8°C displayed less variability and resulted in less significant 
changes in comparison to uncovered samples and those stored at room temperature. Subsequently 
all samples were stored in foil covered glassware at 8°C if they were to be stored for longer than 48 
hours prior to analysis.  
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Figure 2.7: Determination of significant and relevant changes in response (Timm analysis) 
The bars represent confidence intervals for possible scenarios: 
A: The change us neither significant or relevant 
B: There is a significant, but not relevant increase in response 
C: There is a significant but not relevant decrease in response 
D: There is a significant and possibly relevant decrease in response 
E: There is a significant and possibly relevant increase in response 
F: There is a possibly relevant, but not significant decrease in response 
G: There is a possibly relevant, but not significant increase in response 
H: There is a significant and relevant decrease in response 
I: There is a significant and relevant increase in response 
With respect to HCTZ, a significant and relevant decrease in drug concentration occurred after two 
weeks storage at room temperature (Figures 2.10 and 2.11) and about 90% of the drug appeared to 
be degraded at the end of the three-month period. Comparatively, a change in drug concentration 
that was both significant and relevant occurred after four weeks storage at 8°C and this decrease 
did not exceed 20% of the original drug concentration. These results indicate that HCTZ undergoes 
rapid degradation, probably via a hydrolytic reaction, in solution and consequently samples must 
be analyzed with a 48-hour period, after which time drug solutions show both a significant and 
relevant decrease in concentration. Furthermore, samples stored in the refrigerator show 
significantly lower degradation rates than those stored at room temperature, over an extended 
period, however there appeared to be minimal difference in the decrease in drug concentrations of 
50 
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any of the samples over the first 48 hours. 
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Figure 2.8: 90% Confidence Intervals for differences in response for MPTA solutions stored 
at room temperature  
(A01-A04 and B01-B04 represents uncovered and covered solutions stored for 6,12,24,48 hours, 
respectively. A05-A10 and B05-B09 represents uncovered and covered solutions stored for 
1,2,3,4,8,12 weeks, respectively.) 
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Figure 2.9: 90% Confidence Intervals for differences in response for MPTA solutions stored 
at 8°C  
(C01-C03 and D01-D03 represents uncovered and covered solutions stored for 12,24,48 hours, 
respectively. C04-C09 and D04-D09 represents uncovered and covered solutions stored for 
1,2,3,3,8,12 weeks, respectively). 
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Figure 2.10: 90% Confidence Intervals for differences in response for HCTZ solutions stored 
at room temperature  
(A01-A04 and B01-B04 represents uncovered and covered solutions stored for 6,12,24,48 hours, 
respectively. 
A05-A10 and B05-B09 represents uncovered and covered solutions stored for 1,2,3,4,8,12 weeks, 
respectively.) 
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Figure 2.11: 90% Confidence Intervals for differences in response for HCTZ solutions stored 
at 8°C  
(C01-C03 and D01-D03 represents uncovered and covered solutions stored for 12,24,48 hours, 
respectively. 
C04-C09 and D04-D09 represents uncovered and covered solutions stored for 1,2,3,4,8,12 weeks, 
respectively.) 
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Over this extended period, a possible product from the hydrolysis of HCTZ was found to increase 
in peak height as HCTZ showed a corresponding decrease, as shown in Figures 2.12 and 2.13. This 
degradant occurred as a well-resolved peak that did not interfere with the other compounds being 
analyzed as shown in the chromatogram in Figure 2.4. Graphs were plotted using the ratios of drug 
and degradant with the internal standard for comparison as the degradants was not identified and 
therefore quantitative analysis was not feasible.  
 
It is likely that the degradant is 4-amino-6-chloro-m-benzene disulfonamide, which is one of the 
hydrolysis products of HCTZ. This reaction of HCTZ is first-order, however at constant pH the 
reaction kinetics are pseudo first-order (§1.2.3.2). The rate constants for the degradation of HCTZ 
under each of the conditions studied were calculated by linear regression of a semi-log plot of the 
ratio of drug/degradant to the IS versus time. These are depicted in Table 2.6. As expected the 
reaction rate was reduced significantly with a decrease in temperature, as was noted for samples 
stored in the refrigerator. 
 
Table 2.6: Calculated degradation rate constants for HCTZ 
 
 Rate constant (k) 
Room Temperature, No foil covering 
Room Temperature, Foil covered 
Refrigerator, No foil covering 
Refrigerator, Foil covered 
-0.0441 hr-1 
-0.0461 hr-1 
-0.0138 hr-1 
-0.0128 hr-1 
 
This study was conducted to determine whether the method was capable of detecting possible 
degradation products and to determine time limits for the storage of samples before analysis. In 
terms of storage conditions, it may be concluded that whilst MPTA may be stored for extended 
periods before analysis, HCTZ samples should be analyzed within 48 hours of collection. The 
method developed was also found to be capable of detecting possible degradants, although these 
were not identified. 
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Figure 2.12: Plot depicting HCTZ and degradant ratios with IS after storage at 8°C 
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Figure 2.13: Plot depicting HCTZ and degradant ratios with IS after storage at room 
temperature 
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2.3 METHOD RE-VALIDATION  
2.3.1 INTRODUCTION 
Revalidation of a method is usually necessary when changes to the chromatographic conditions are 
effected [106]. However, revalidation may be necessary when changes in instrumentation, analyst 
and the product are made [112]. Although no changes to the method were made, the system was 
changed to System B (§ 2.3.1.2). Furthermore, results obtained were observed to show greater 
deviations than were previously recorded. It was therefore deemed necessary to perform a re-
validation of the method. It was thought that this would also serve as a ruggedness test. Linearity, 
precision and accuracy were assessed.  
 
2.3.2 LINEARITY 
A calibration curve with the equation y = 2.1161x –0.2759 and a correlation coefficient of 0.9994 
for MPTA, and an equation y = 7.5041x –2.1586 and r2 = 0.9983 for HCTZ were obtained. It was 
concluded that linearity was maintained over the range studied. 
 
2.3.3 PRECISION 
2.3.3.1 Repeatability 
The data obtained for % RSD and standard deviations for both consecutive and non-consecutive 
samples of the same concentrations as listed in Table 2.7 are shown in Figure 2.14. The values 
obtained for both parameters far exceed the limits (6 % for RSD and 5.0 for SD) set for each 
parameter. Values for %RSD ranged from 2.54 –22.46. Poor repeatability was considered to be a 
possible function of varying samples volumes being injected. 
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A, B, C represent High, Middle and Low concentrations, respectively 
Figure 2.14: %RSD and Standard deviation values obtained from re-validation of the 
method 
 
 
2.3.3.2 Intermediate Precision 
Freshly prepared calibrators were run on six consecutive days to determine intermediate precision. 
Results are shown in Table 2.7. None of the values obtained for both % RSD and SD fell within 
the range of acceptable limits set, therefore the method was no longer considered to be precise. 
 
Table 2.7: %RSD and SD values of samples run over six days on system B 
Concentration 
 JP/ 
Mean Peak Height 
(mm) 
Standard 
deviation 
Precision 
(%RSD) 
MPTA 
5.0 
50.00 
100.00 
13.42 
115.03 
220.67 
2.87 
21.16 
18.91 
21.40 
18.40 
9.23 
HCTZ 
1.25 
6.25 
20.00 
9.92 
43.25 
177.33 
1.80 
8.59 
15.25 
18.16 
19.86 
11.04 
 
 
2.3.4 LOQ and LOD 
No evaluation of LOQ and LOD was performed. However it was noted that the sensitivity of the 
system had decreased therefore previously determined values would no longer be applicable. The 
most likely reason for the decrease in sensitivity was the ageing of the detector lamp.  
A 
B 
C 
C 
B 
A 
 57 
2.3.5 OUTCOMES 
It was concluded that the method could no longer be considered to be reliable; therefore changes 
were required in order to ensure that the method could still be used for the accurate and precise 
determination of the analytes of interest. The injector was presumed to be the most likely source of  
the inaccuracies and a decision was made to include an internal standard in the sample mixtures. 
The internal standard would be used to compensate for variable injections volumes, as the results 
would be independent of that specific variable. Furthermore, the decrease in the sensitivity of the 
system may require re-assessment of linearity over the range selected, LOQ and LOD values. 
 
2.3.6 INTERNAL STANDARD (IS) 
An internal standard is usually added to ensure accuracy of a method [94]. The IS chosen should be 
completely resolved from all other peaks and it should elute close to the solute to be quantified. 
Generally, it should also have similar chemical and physical properties to the analyte and should 
not be a degradation product of the analyte. An internal standard was not incorporated in the 
method initially, as it is stated that they should be avoided in stability indicating assays due to 
possible co-elution with unknown degradation products [94]. The method was not used specifically 
as a stability-indicating assay; however, the presence of the degradation product of HCTZ 
precluded the initial inclusion of an internal standard. 
 
2WKHU -blockers, such as propanolol HCL and oxprenolol HCL are commonly used as internal 
standards in HPLC either for MPTA only or MPTA in combination with HCTZ, as indicated in 
7DEOH2WKHU -blockers are considered as suitable candidates as they have similar chemical and 
physical properties. Although the use of propranolol HCL was commonly reported in literature 
(Table 2.1), retention time obtained with this candidate on this system was greater than
 
15 minutes. 
2WKHU -blockers were then tested and of these labetalol HCL was selected as the internal standard 
as it resulted in a RT of 8.0 minutes only. Furthermore, it displayed a sharp well-resolved peak and 
no interference with degradants or other analytes was observed.   
 
2.4 METHOD VALIDATION WITH AN INTERNAL STANDARD 
The addition of an internal standard does not require a complete re-validation, and some 
parameters including precision, accuracy, specificity and recovery need to be re-assessed [106]. 
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For this phase of the validation, all parameters excluding ruggedness were re-evaluated. Tests for 
robustness were also continued using the internal standard. 
 
2.4.1 SPECIFICITY 
Labetolol hydrochloride eluted after both MPTA and HCTZ, and the degradation product, 
therefore minimal interference was incurred by the inclusion of the internal standard. Peaks for all 
compounds were well resolved and no changes in RT were noted. A representative chromatogram 
of the compounds with IS is shown in Figure 2.15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15: A typical chromatogram of HCTZ (A), possible degradant (B), MPTA (C) and 
labetalol hydrochloride (D) 
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2.4.2 LOQ and LOD 
The LOQ and LOD were determined in the same manner as before, using six samples for each. 
The LOD was found to be 0.19µg/mL and 1.25µg/mL for HCTZ and MPTA, respectively. The 
LOQ was determined to be 1.22µg/mL (%RSD = 4.56) and 4.00µg/mL (% RSD = 5.20) for HCTZ 
and MPTA, respectively. Whereas the LOD values did not alter significantly, LOQ values were 
significantly changed, possibly as a function of a decrease in the sensitivity of the detector. 
 
2.4.3 RANGE 
The change in LOQ resulted in a subsequent alteration of the range over which the analytes could 
be accurately and precisely determined. The range over which adequate linearity was demonstrated 
was therefore 1.22 -17.00µg/mL for HCTZ and 4.00-30.20µg/mL for MPTA.  
 
2.4.4 LINEARITY 
The equations for calibration curves of the compounds were now representative of the 
concentration and the ratio of drug to internal standard. Representative equations were y = 
0.0296x-0.0209 for MPTA (r2 =0.9992) and y = 0.0113x-0.0098 for HCTZ (r2 =0.9997). The 
linearity of the method over the new range was comparable to that obtained during the method 
development stages, and showed a definite improvement over the results obtained in the method 
re-validation without the inclusion of the internal standard. Typical calibration curves are depicted 
in Figure 2.16. 
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Figure 2.16: Typical calibration curves for MPTA and HCTZ obtained using an internal 
standard 
 
2.4.5 PRECISION 
2.4.5.1 Repeatability 
Precision data was obtained at high, intermediate and low concentrations as described in § 2.2.4.1. 
The % RSD and standard deviation data are depicted in Figure 2.17. The % RSD values obtained 
all fell within the range of acceptable limits set (< 10%). The repeatability of the system was 
therefore improved with the inclusion of an internal standard, indicating that the earlier assumption 
that poor repeatability was a function of variable injection volume may be a probability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.17: % RSD and standard deviations of drug: IS ratio from validation with an IS  
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2.4.5.2 Intermediate Precision 
Intermediate precision was determined over a six-day period. The concentrations used are listed in 
Table 2.8, and although they differed slightly from those used for the previous validation studies, 
they are representative of the range that was considered. %RSD and standard deviation are listed in 
Table 2.8. Both parameters were significantly improved over data generated from method from the 
re-validation of the method without an IS, as all values obtained were with in the limits for 
acceptance set in our laboratory.   
 
Table 2.8: Intermediate Precision results from validation studies with an IS 
Concentration 
 JP/ 
Average Ratio  
Obtained 
Standard 
deviation 
Precision 
 (%RSD) 
MPTA 
4.0 
50.00 
100.00 
0.1064 
1.4441 
2.8197 
0.0058 
0.9649 
0.1364 
4.98 
4.19 
4.63 
HCTZ 
1.20 
7.60 
15.2 
0.1345 
0.8755 
1.6916 
0.0067 
0.0368 
0.0783 
5.44 
4.49 
4.84 
 
 
  2.4.6 ACCURACY 
Accuracy was determined using blinded samples of three concentrations (n=6), as was previously 
described (§2.2.5). The results (Table 2.9) revealed that the percent error was less than 5% for all 
samples analyzed, which compared favourably to the results obtained previously in § 2.2.4.2. 
 
Table 2.9: Percent error obtained during determination of blinded samples 
 
Theoretical 
FRQF JP/ 
Mean conc determined 
(µg/mL) 
SD % RSD % Bias 
METOPROLOL TARTRATE 
4.00 
50.40 
90.72 
3.94 
48.76 
90.41 
0.0028 
0.0724 
0.1152 
2.19 
5.17 
4.49 
-1.50 
-3.26 
-0.34 
HYDROCHLOROTHIAZIDE 
1.20 
7.50 
13.50 
1.15 
7.46 
13.68 
0.0034 
0.0429 
0.0665 
2.73 
5.08 
4.32 
-4.17 
-1.34 
0.48 
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2.4.7 ROBUSTNESS 
The compounds were dissolved in a range of buffers that would possibly be used as dissolution 
media for dissolution testing in USP Apparatus II and III. Results are shown in Table 2.10. Results 
are depicted for solutions containing 100.00µg/mL MPTA, 15.00µg/mL HCTZ and 50.00µg/mL 
labetalol HCL. The %RSD calculated for average ratios from the dissolution assessed are below 
5% for both compounds, indicating that the absorption is not significantly affected. The same set of 
calibration solutions may therefore be used for the analysis of all samples in dissolution studies. 
 
Table 2.10: Assessment of compound abosrbance in different dissolution media  
 
Dissolution Medium HCTZ MPTA 
 Average 
Ratio 
SD % RSD Average 
Ratio 
SD % 
RSD 
Water 
0.1M PO4 Buffer pH 1.6 
0.1M PO4 Buffer pH 3.4 
0.1M PO4 Buffer pH 4.7 
0.1M PO4 Buffer pH 6.8 
0.1M PO4 Buffer pH 7.2 
Mobile Phase 
1.48 
1.62 
1.50 
1.49 
1.52 
1.55 
1.52 
0.06 
0.04 
0.02 
0.13 
0.0054 
0.02 
0.03 
4.14 
2.56 
1.35 
8.60 
1.79 
1.22 
2.27 
2.63 
2.49 
2.60 
2.84 
2.73 
2.76 
2.64 
0.13 
0 
0.13 
0.09 
0.0059 
0.05 
0.07 
4.80 
0 
4.91 
3.25 
0.22 
1.88 
2.71 
Average for all media ± SD 
% RSD 
1.52 ± 0.05 
3.02 
2.67 ± 0.11 
4. 25 
 
 
2.5 CONCLUSIONS  
A linear, precise and accurate method has been developed for the simultaneous determination of 
MPTA and HCTZ over the range studied. The method is also suitable for the determination of drug 
release from both immediate and modified release dosage forms. 
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CHAPTER THREE 
FORMULATION, DEVELOPMENT AND ASSESSMENT OF A  
CONTROLLED RELEASE MPTA TABLET CORE 
 
3.1 CONTROLLED RELEASE SYSTEMS 
 
3.1.1 INTRODUCTION 
In contrast to conventional dosage forms, controlled release products have a dual functionality, that 
is to deliver the drug to that particular part of the body that it is needed, and to control the rate at 
which the drug is made available to its site of delivery [113]. There is often confusion surrounding 
the terms ‘controlled’ and ‘sustained’ release. The term ‘controlled release’ refers to a dosage 
form, which releases the drug in vitro by predicted physicochemical mechanisms that are believed 
to be operating in physiological in vitro test conditions [114]. As such, it describes the delivery of a 
drug specifically to the needs of a condition such that an optimal amount of drug, delivered at an 
optimal rate, is used to control the condition. Sustained drug delivery becomes necessary when the 
needs of the condition are such that drug release over a prolonged period is vital to therapeutic 
success [114]. 
 
Research into and clinical applications of controlled drug delivery have increased rapidly in the 
past few decades [114]. Such systems are considered advantageous as they can be used to ensure 
safety or enhance efficacy of drugs. The benefits are primarily achieved by better control of plasma 
drug levels and less frequent dosing. The decreased frequency of dosing also leads to increased 
patient compliance [115]. The use of controlled release dosage forms also leads to improved safety 
and minimization of side effects by reducing the fluctuations in blood plasma levels that are 
usually observed on frequent dosing of immediate release products [115]. In addition, there may 
also be economic advantages, despite the cost per dosage being greater than conventional dosage 
forms; the efficiency of the dosage regimen is improved in the long term [116]. 
 
3.1.2 ORAL CONTROLLED RELEASE SYSTEMS 
The interest in controlled drug delivery systems has not been limited to the oral route, however, 
this route of administration is by far the most popular as it allows for greater flexibility in dosage 
form design than for parenteral or transdermal routes of delivery [115]. The following discussion 
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will focus primarily on oral delivery systems, which may be broadly categorized as membrane, 
matrix or hybrid type systems [117]. 
 
3.1.2.1 Membrane systems 
A drug core surrounded by a rate controlling membrane characterizes such systems [117] and these 
may also be described as reservoir systems [114]. Membrane systems are generally non-
disintegrating technologies that release drug either by osmotic pumping or a solution diffusion 
mechanism [117]. Examples of commercial products that represent such systems include Adalat 
XL® (Bayer, SA) which is an osmotic pump system, and Erythrocin® (Abbott Laboratories, SA), 
which consists of coated beads in a rapidly disintegrating caplet. Membrane systems will be 
discussed in greater detail in Chapter Four. 
 
3.1.2.2 Matrix systems 
Matrix systems, in general consist of drug that is either dissolved or dispersed in a carrier matrix 
consisting of one or more polymers [114,117], and may include beads, pellets or tablets where the 
drug is uniformly dispersed or dissolved. Matrix systems have become increasingly utilized as they 
are relatively cheap to manufacture when compared to other types of controlled delivery systems. 
They are also easier to manufacture and they lack dose dumping potential of immediate release 
products [117]. 
 
3.1.2.3 Hybrid systems 
Such systems may also be referred to as sandwich systems, and are usually a combination of both 
matrix and membrane systems [114,117]. They combine a number of drug release mechanisms to 
achieve constant drug release and an example of a system in use is Theo-Dur® (Astra, SA).  
Theo-Dur® tablets are a multiple unit system that consists of coated beads embedded in a tablet 
matrix. These systems will be discussed in greater detail in Chapter Four. 
 
3.1.3 MATRIX SYSTEMS 
Matrix systems are prepared with an excess of uniformly dispersed drug occurring either as 
discrete crystals or as solid particles within the matrix system. A matrix system that contains only 
one rate-controlling polymer is referred to as a monolithic device.  
 
 65 
The choice of the matrix-forming polymer is critical and it should the proper ratio of ionisable 
groups and should exhibit gradual hydration and swelling, to allow for constant drug release 
throughout the gastro-intestinal tract [118]. Cellulose ethers have been increasingly used in matrix 
formulations in recent years [119]. Certain polymers such as glyceryl monostearate may be 
selected for use in matrix systems on the basis of their lipophilic character, where its lipophilic 
nature plays a greater role in retarding the release than do other factors such as the porosity and 
tortuosity of the matrix [120]. Polyvinylchloride, ethylcellulose, polyethylene and methacrylate 
polymers and copolymers have also been used as polymers for hydrophobic matrices [121].  
 
Ethylcellulose may be used as a matrix-forming agent in both direct compression and wet 
granulation formulations, however selection of the appropriate viscosity grade is essential [122]. 
Furthermore, interactions between drug to be delivered and polymer may lead to altered release 
mechanisms. Salicylic acid interacts advantageously with high viscosity chitosan to achieve a 
sustained release effect [123], whereas pseudoephedrine sulphate has been found to alter the 
hydration and erosion characteristics of HPMC in combination with PVP [124].  
 
Drug release from monolithic matrix systems may be controlled by the gelled matrix and the 
matrix-bulk medium interface [125]. The drug release from such systems is also in part dependent 
on the solubility of the drug in the matrix, however in a porous matrix, release depends primarily 
on the solubility of drug in the sink conditions within the particle pore network in addition to the 
tortuosity of that network [116]. Matrix formulations are seldom used for water-insoluble drugs 
due to difficulties in achieving one hundred percent drug release from these dosage forms [126]. 
Mehta et al found that for a highly water-soluble drug, the rate of release from matrix pellets with a 
higher drug loading was less than for lower levels of drug loading which may have resulted in 
differences in pore diameter within the matrix, and shape and surface area of the pellets [127]. 
The continual evolution of matrix technology had led to the development of innovative systems, 
which may utilize a combination of polymers to achieve the desired level of control over drug 
delivery. Such systems include the matrix forming polymers used in combination with channeling 
agents to achieve the required release rates [128] or systems where the drug is separated from the 
matrix by compression into a core that is surrounded by the matrix material [128]. Streubel et al 
described a multi-layered matrix tablets that may also be used to achieve bimodal drug release such 
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that rapid drug release occurs both initially to provide rapid onset of action and at a later time to 
compensate for poor absorption from the intestinal regions [129]. The inclusion of acidic 
excipients into a dosage form that contains a basic drug has also been reported to result in 
sustained release of the drug candidate [130]. It has also been reported that a hydrophilic polymer 
and an enteric polymer used in combination may be used to prevent the release of basic drugs in 
acidic media. In acidic media the enteric polymer contributes towards retarding drug release 
however in alkali media, the polymer dissolves, increasing the porosity of the dosage form, thereby 
increasing drug release from the dosage form [130]. Biodegradable matrices using lactide-
glycolide copolymers have also been used and release from such systems has been found to be 
coherent with the Higuchi model [131]. Pillay and Fassihi have also proposed that the inclusion of 
appropriate electrolytes into a matrix dosage form may be capable of sustaining the release of a 
highly water-soluble drug such as MPTA over an extended period in a pH-independent manner 
[132]. 
 
3.1.3.1 Mechanisms of drug release from matrix systems 
3.1.3.1.1 DIFFUSION CONTROL 
Drug release from polymers that do not absorb large amounts of water, for example, the 
polyamides and polyethylene is primarily controlled by Fickian diffusion. Control from hydrogel 
matrices that absorb water and simultaneously release the enclosed drug occurs via a different 
mechanism [133]. The dissolution medium has to penetrate into the matrix to dissolve the drug, 
which then diffuses through the matrix into the external medium. This is the primary mechanism of 
release for highly water-soluble drugs from these types of systems [117,134]. However, diffusion 
often occurs together with other mechanisms of release, including erosion, swelling or a 
dissolution-controlled mechanism [117]. In contrast, hydrophobic matrices exhibit counter-current 
diffusion as a primary mechanism of release [135]. Zero order release is not easily achieved in 
matrix systems, as the rate of drug release continually decreases with the increasing diffusional 
path length within the matrix [133,136,137]. In general release from matrix systems obeys square 
root of time dependent kinetics such that drug release continuously decreases with time at a rate 
that is proportional to the amount of drug remaining in the matrix at a specific time [113,133]. 
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Diffusion-controlled release is described by Fick’s Second Law (Equation 3.1). The simultaneous 
influx of solvent and efflux of drug from the polymeric dosage from must be taken into account in 
order for the relationship to hold [134]. 
 
&   = D 2 C                                  Equation 3.1 
W ;
2 
 
Where, 
 D = diffusion coefficient of the drug 
 C = drug concentration in the reservoir 
X = the perpendicular distance traveled by the drug 
 
The Higuchi model (Equation 3.2) best describes the square root of time dependent release kinetics 
usually exhibited by most matrix systems [117].  
 
     Q = [D (2A –Cs) Cs t] ½                          Equation 3.2 
 
Where, 
 Q = weight in grams of drug released per unit surface area 
 D = diffusion coefficient of drug in the matrix 
 A = concentration of the drug in the tablet (g/mL) 
 Cs = solubility of drug in the release medium 
 t = time 
 
In deriving Equation 3.2, Higuchi assumed that an excess solute was present in the matrix  
(A >>Cs) and that psuedo steady state is maintained during drug release. It was also assumed that 
perfect sink conditions were maintained and that the diffusion coefficient was constant throughout 
the test period. In addition drug particles should also be significantly smaller than those of the 
matrix material and no chemical or physical interactions should occur between the drug and the 
matrix material [138].  
 
This model was initially developed for non-eroding matrices and was later modified to describe 
release from eroding matrices, and therefore includes terms for porosity and tortuosity  
(Equation 3.3). 
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     Q = ['  (2A – &s) Cs t] ½      Equation 3.3 
       
 
 
Where, 
 SRURVRLW\RIWKHPDWUL[ZKLFKPD\EHDSSUR[LPDWHGE\FDOFXODWLQJWKHYROXPHRIGUXJ
(A) as a percentage of the matrix volume. 
 WRUWXRVLW\RIWKHPDWUL[ZKLFKUHIHUVWRWKHGHJUHHRIFRQYROXWLRQRIWKHFKDQQHOV 
D = diffusion coefficient of the drug in the fluid filled channels, which may be modified by 
KHQFHWKHHIIHFWLYHGLIIXVLRQFRHIILFLHQWLVH[SUHVVHGDV'  
For eroding matrices, the diffusion coefficient differs from Fick’s Law as it refers to 
diffusion through the fluid filled pores and not through the matrix. 
 
3.1.3.1.2 DISSOLUTION CONTROL 
Dissolution controlled release occurs mainly in the case of poorly water soluble drug particles 
within a matrix or in cases where a water soluble drug is present at a high drug loading [117]. In 
such cases drug dissolution becomes the rate-limiting step in drug release, in this instance where 
the depletion layer is small, the release profile will be linear over time.  
 
3.1.3.1.3 SWELLING AND EROSION CONTROL 
In general matrix systems commonly include a hydrophilic polymer and thus drug release may be 
controlled by both swelling and erosion dependent mechanisms [117]. Swelling is a complex 
process that is dependent on swelling inhomogeneity, polymer stress relaxation and solute 
diffusion which in turn is related to the structure and composition of the gelled matrix [125]. On 
contact with an aqueous medium, the polymer rapidly forms a viscous gel layer, as depicted by 
region A in Figure 3.1. At this stage there are two distinct fronts established around the matrix, 
namely, the penetrating swelling front and the erosion-dissolution front as depicted by the 
schematic diagram of a swelling hydrophilic matrix tablet in Figure 3.2. [117,125]. Swelling 
continues (region B in Figure 3.1), until the polymer concentration near the gel surface falls to 
below the ‘disentanglement’ concentration for the specific polymer. This is a region of 
synchronization (B) of both the swelling and erosion/dissolution fronts, and is characterized by a 
constant gel layer thickness. In this region almost constant rate of drug release occurs. In region C 
both erosion and dissolution occur and the gel layer recedes (Figure 3.2) becomes depleted.  
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Figure 3.1: Development of gel layer thickness in a matrix tablet over time 
 
                                                   Swelling front 
 
                                                                                               Dissolution/Erosion Front  
                    
         Gel Layer 
        Original surface  
  
Figure 3.2: Schematic showing the moving fronts during swelling and dissolution  
                   of a matrix tablet 
 
 
The release for certain drugs from a matrix system may be predominantly controlled by erosion of 
the matrix [139]. For example, it has been found that theophylline release from a cissus populnea 
polymer matrix is primarily erosion controlled [139]. Certain matrices may control drug release via 
polymeric degradation at a specified location in the body. Degradation may occur by breaking of 
cross-links, hydrolysis or ionization of polymer side chains or cleavage of the insoluble polymers 
into soluble monomers [113]. However, due to the possibility of bulk degradation and subsequent 
dose dumping degradation systems are not often used for controlled drug delivery. 
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3.1.3.1.4 NONUNIFORM DRUG DISTRIBUTION 
In systems in which drug load increases from the surface to the core of a matrix tablet, drug release 
is a function of its non-inform distribution within the dosage form, which compensates for the 
increasing diffusional resistance and decreasing area of the diffusion front. Drug release via this 
mechanism may approach zero-order and systems that have been based on this mechanism include 
pulsatile drug release systems and multi-layered tablets [117]. 
 
3.1.3.1.5 GEOMETRY AND AREA CHANGES 
Drug release for a particular drug may be optimized by changing the area and geometry of a 
dosage form. Changes in area and geometry compensate for the decreasing release rate displayed 
by most matrix systems and have been found to display linear release [117]. Ainaoui et al 
suggested that by calculation of the dimensions of dosage forms of different shapes, the required 
sustained release profile might be achieved [140].  
 
3.1.3.2 Hydroxypropyl methylcellulose (HPMC) as a matrix-forming agent 
HPMC has become one of the most commonly used polymers for matrix tablet formulations 
[117,141,142], as a result of its nontoxic nature, ease of handling and the elimination of 
uncomplicated methods of tablet fabrication [126].  
 
HPMC matrices exhibit a continuous increase in gel layer thickness during the synchronization 
phase of polymer swelling, however polymer erosion and dissolution occur simultaneously but at a 
significantly slower rate than the rate of swelling. Dissolution and erosion occur in all viscosity 
grades of HPMC but have a minimal impact on the rate of release of water-soluble drugs [117]. For 
water-soluble drugs release occurs predominantly by a swelling controlled diffusion process, as is 
the case for most other polymeric matrices whereas release of water insoluble drugs occurs via an 
erosion-dissolution controlled processes [117,143]. The release of high doses of water insoluble 
drugs may be both erosion and diffusion controlled [118]. This effect is enhanced by increasing the 
percentages of polymer in the dosage form and leads to the formation of a thicker gel layer [144]. 
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For certain drugs such as indomethacin which is water-insoluble, HPMC used in direct 
compression formulations, resulted in lower drug release than from a wet granulation of the same 
composition, suggesting the possibility that drug release from this particular dosage form is 
controlled by mechanisms other than erosion or diffusion [141].  
 
Drug diffusion through HPMC matrices may be influenced by various factors including swelling 
ratio, which refers to the amount of water contained within the hydrogel at equilibrium and specific 
pore size, which refers to the space available for drug transport through the matrix [145]. 
Characteristics of the drug candidate under investigation that are important include particle size 
and shape and the degree of ionization of the drug [145]. 
 
3.2 DOSAGE FORM DEVELOPMENT 
3.2.1 PROPOSED DESIGN 
Existing systems for the sustained release of metoprolol include matrix-based, OROS® and multi-
particulate systems. Although it has been reported that the matrix-based products are not ideal as 
they release almost the entire dose within 10 hours [141], matrix systems are still frequently used, 
as discussed in § 3.1.2.2, as they tend to be cheap and easy to manufacture.  
 
3.2.2 PRELIMINARY STUDIES 
A matrix formulation that was developed ‘in-house’ [146] was thought to be capable of retarding 
the release of highly water-soluble drugs, and was chosen as the basis for the development of a 
sustained release metoprolol tablet core. The tablet was manufactured by granulation with an 
ethylcellulose aqueous dispersion, and compression of the granules into a hydrophilic matrix tablet. 
HPMC was used as the matrix-forming polymer with dibasic calcium phosphate (DCP) and 
microcrystalline cellulose (MCC) included as additional excipients into the formulation. 
Magnesium stearate was added as a lubricant.  
 
Preformulation studies included screening for compatibility of MPTA with the chosen excipients 
and evaluation of the previously developed formulation using MPTA as the active. Differential 
Scanning Calorimetry (DSC) was used as a rapid method to determine potential incompatibilities.  
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3.2.2.1 DIFFERENTIAL SCANNING CALORIMETRY (DSC) 
3.2.2.1.1 Introduction 
The solid-state stability of a drug may be altered in the presence of excipients either directly in the 
form of a chemical interaction or indirectly as a result of adsorption of moisture or catalysis of a 
reaction [147,148]. Such information is usually obtained during preformulation studies and offers 
valuable information about potential physical or chemical incompatibilities between the active 
pharmaceutical ingredient and potential formulation excipients [149]. Techniques, which are 
commonly employed to detect incompatibilities between drug and excipients, include isothermal 
stress testing and thermal analysis using DSC or differential thermal analysis (DTA) [150]. 
 
DSC has a number of useful applications including the determination of drug purity, detection of 
polymorphic forms, melting and boiling point determination and the determination of glass 
transitions [151]. More recently its application has been extended to the determination of solid-
state interactions such as drug-excipient incompatibility in preformulation studies. Its applicability 
in this area has increased due to the relative speed and convenience of this method of analysis 
[147,152], which makes it particularly useful in early stages of drug testing or product 
development where time lines are critical. Furthermore, long-term storage and subsequent 
chromatographic analyses that are required for isothermal stress tests are eliminated [150,153]. 
DSC is also particularly advantageous when there is a limited availability of the drug, as only small 
samples (2-5mg) are required for this analytical technique [150,153,154]. It may also be used as a 
screening tool and as a complimentary technique to the proposed multivariate methods for the 
selection of excipients for a tablet formulation [155]. 
 
Although some industries routinely use DSC as a means of detecting possible incompatibilities 
between drug and excipients, this method remains controversial, as it is not considered to be fully 
reliable [154]. Therefore it should not replace long term stability testing and other tests should be 
performed in conjunction with DSC or DTA methods of analysis [147-150,154,156].   DSC has 
other pharmaceutical applications and may for example be used to characterize the effects of 
manufacturing processes such as powder grinding on drug release from a dosage from [157], and to 
identify the effects moisture on the drug release from microspheres [158]. 
 73 
DSC is a thermal analytical technique of thermal analysis that measures differences in energy 
inputs between a substance and a reference material as a function of temperature. The substance 
under investigation and the reference material are both subjected to a controlled temperature-
heating programme [156]. The appearance of, or shifts or disappearance of melting 
endotherms/exotherms, or variations in the enthalpy are indications of possible drug-excipient 
interactions [147]. Generally, a decrease in the melting peak area and heat of melting is an 
indication of a potential incompatibility. The greater the decrease in the melting point the more 
likely the potential for an interaction being the materials being heated. 
 
3.2.2.1.2 Experimental 
3.2.2.1.2.1 REAGENTS 
The excipients tested included DCP (Emompress®), MCC (Emcocel® 90M), magnesium stearate 
and HPMC (Methocel® K4M), which were utilized for the initial tablet batches. HCTZ was also 
included for screening. 
 
3.2.2.1.2.2 INSTRUMENTATION 
A Perkin-Elmer DSC-7 Differential Scanning Calorimeter (Norwalk, Conneticut, USA) was used 
for all thermogram scans. A Sartorius® 4305 microbalance was used for weighing of samples. 
 
3.2.2.1.3 METHOD 
Samples (2-5mg) were weighed into standard aluminum pans and covered with lids, and  
samples were heated in an atmosphere of nitrogen, at a constant heating rate of 10°C per minute. 
Thermograms of individual compounds, as well as, 1:1 mixtures of drug: excipient or drug:drug 
were used. The physical mixtures were prepared by grinding equal quantities of each component in 
a mortar and pestle. Physical mixtures (1:1) were used to maximize the likelihood of interaction 
and to avoid any endotherm masking phenomena resulting from higher ratios of either component 
[152]. Thermograms obtained from the individual compounds and of 1:1 mixtures were 
superimposed for comparison. 
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3.2.2.1.4 RESULTS AND DISCUSSION  
A trace of metoprolol tartrate heated alone is shown in Figure 3.3. The melting point temperature 
of metoprolol occurred at 120.33°C and was confirmed by values reported in the literature  
(§ 1.1.2.5). The tartrate salt resulted in a broad melting peak at 215.67°C that also corresponded 
with values reported in literature [159]. 
 
DSC scans of HPMC, MPTA 1:1 physical mixtures are shown in Figure 3.4. HPMC is a polymer 
therefore no endotherm was expected. Glass transitions of compounds such as polymers may lead 
to changes in the DSC curve rather than reveal a distinct peak [151]. The glass transition 
temperature of HPMC has been reported to lie between 170-180° C [159]. The trace for the 
mixture shows differences in the 190°C and 240°C region. This may possibly be attributed to the 
glass transition of the polymer. Browning of HPMC at 190-200°C and subsequent charring at 225-
230°C [159] may have also been contributors to the altered thermal activity observed.  
Typically a scan of a glassy polymer shows the glass, recrystallization and melting transitions as 
can be seen in the schematic in Figure 3.5 [151]. The scan does not show these events, however, 
the observed exotherms may correspond to recrystallization of the polymer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: A schematic DSC scan of a glassy polymer 
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Figure 3.3: DSC scan of metoprolol tartrate 
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Figure 3.4: DSC scans depicting the melting behaviour ofMPTA, HPMC and a 
mixture thereof 
Figure 3.6: DSC scans depicting the melting behaviour ofMPTA, DCP and a 
mixture thereof 
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Figure 3.7: DSC scans depicting the melting behaviour ofMPTA, MCC and a 
mixture thereof 
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a mixture thereof 
,,' 
I 
/" [ 
~ 
! " 1 
I 
MPTA MojO HCTZ AI.ONE VS 1:1 MIXTURE 
Figure 3.9: DSC scans depicting the melting behaviour ofMPTA, HCTZ and a 
mixture thereof 
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Figure 3.6 shows the DSC scans of DCP, MPTA and the mixture. DCP shows both considerable 
and complex endothermic activity, with potential interference with the MPTA curve. DCP is 
observed to decompose at temperatures below 100°C with a corresponding loss in water [159]. The 
scan of the mixture shows that although the metoprolol base peak is not displaced there is a 
definite change in the thermal behavior of DCP, with a disappearance of the peak at 192°C and 
displacement of the tartrate peak. This may indicate that although there is some form of interaction, 
the stability of metoprolol may remain unaffected. 
 
The scan of MPTA, MCC and the mixture (Figure 3.7) shows no significant displacements of the 
melting endotherm of the drug. MCC is depolymerized cellulose, which chars at 270°C and 
therefore no significant endothermal events were expected or observed [159].  
 
The DSC thermogram of magnesium stearate, MPTA and a mixture are shown in Figure 3.8. 
Magnesium stearate has a melting point of 88.5°C [159], and shows two broad melting endotherms 
in the 80-120°C region. Magnesium stearate consists of several fatty acids of varying chain length 
[151] and several pseudopolymorphs and hydrates of magnesium stearate have been characterized 
[150,151]. It is likely that the observed endotherms correspond to any of the pseudopolymorphs or 
hydrates of magnesium stearate. The scan of the mixture reveals a total disappearance of all 
endotherms, including that of MPTA. This is an indication of a definite interaction between MPTA 
and magnesium stearate, which is known to interact with a large number of acidic and alkaline 
substances. [159,160]. 
 
Thermograms of MPTA, HCTZ and the mixture are shown in Figure 3.9. A DSC scan of the 
mixture shows definite changes, however it is likely that the early melting of MPTA resulted in the 
release of water that subsequently led to the hydrolysis of HCTZ, resulting in the endothermal 
activity in the 220-280°C region. This may suggest that MPTA and HCTZ in combination dosage 
forms may be susceptible to interaction, especially under conditions of elevated temperature and 
humidity. 
 
 78 
3.2.2.1.5 CONCLUSIONS 
There were no potential interactions detected between MPTA and MCC and HPMC, however there 
are potential interactions between MPTA and HCTZ, DCP and magnesium stearate. Excipients that 
undergo thermal events at temperatures less than the melting point of the drug are more likely to 
result in incompatibilities, as seen with DCP and magnesium stearate. Whilst the detection of the 
interactions between each of the compounds provides valuable information, these conditions 
represent the worst case scenario and it is unlikely the dosage form would be subjected to the harsh 
conditions during normal manufacture and storage as those used for the purposes of DSC 
screening. Furthermore, DSC is unlikely to replace real time stability studies of each of the 
individual components or mixtures thereof. 
 
Therefore, although potential interactions were detected they did not seem to warrant exclusion of 
any of the compounds from the formulation. The interactions with magnesium stearate may result 
in softening of the dosage form, however as MPTA would mainly be incorporated into granules, 
the interaction between these agents would be minimized. Consequently all of the excipients 
originally considered for the formulation were used in the development of the core tablet.  
 
3.2.2.2 EVALUATION OF A MATRIX FORMULATION FOR THE SUSTAINED 
RELEASE OF MPTA  
The formulation, which was developed in-house for the sustained release of highly water-soluble 
drugs, is described in Table 3.1. MPTA was used in the formulation and drug release from the 
formulation was assessed over a 22-hour period, as described in § 4.5. 
 
Feasibility batches M0022005 and M011508 using MPTA as the model drug were manufactured to 
produce a dosage form with a 50 mg drug load. A significant retardation of drug release was 
observed as 50% drug was released in 4 hours when compared to an immediate release tablet 
(Lopressor®) from which all drug was released in less than 1 hour (Figure 3.10). All other relevant 
batch data are included in Appendix I.  
 
 
 
 79 
Table 3.1: Formula for matrix tablet core 
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Figure 3.10: Drug release profiles of feasibility batches (M002205 and M0110508) compared 
to an immediate release tablet (Lopressor®) (n=6) 
 
To obtain a minimum drug load of 100mg required for the envisaged sustained release MPTA 
dosage form, an increased tablet weight and size were required. The calculated theoretical weight 
was found to be greater than the capacity of the tooling available in our laboratory. Furthermore, 
Excipient Percent (w/w) 
Water-soluble drug (MPTA) 
HPMC 
MCC 
DCP 
Surelease®  
(g suspension/ g powder blend) 
15 
10 
40 
35 
± 0.18g 
 
Granules 67 
HPMC 
MCC 
DCP 
Magnesium stearate 
15 
7 
10 
1 
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tablets with a weight of greater than 800mg are often difficult for patients to swallow, and are 
recommended to be manufactured in an oblong shape so that they can be taken along the 
longitudinal axis to facilitate swallowing [161]. For our purposes a spherical concave or deep 
concave tablet was required to facilitate a coating procedure if required in the later stages of 
product development. The results from the preliminary batches indicated that the formulation was 
capable of retarding the release of the highly water-soluble MPTA over an extended period, and 
therefore further optimization of the formulation was considered feasible. 
 
 
3.2.3 OPTIMIZATION OF THE PROTOTYPE FORMULATION 
3.2.3.1 MATERIALS USED 
3.2.3.1.1 Drug Used 
Metoprolol tartrate (Genpharm, Canada) was used for initial studies. MPTA was later obtained 
from K.A.Malle Pharmaceuticals Ltd (India) and used for all further studies. 
 
3.2.3.1.2 Excipients 
3.2.3.1.2.1 Microcrystalline cellulose (MCC) 
MCC is a partially depolymerised cellulose which has been widely used as a pharmaceutical 
excipient [159,162,163]. A number of different MCC products including Emcocel® and Avicel® 
are currently available. Emcocel® 90M (Mendell, NY, USA) was used for all experimental 
formulations. Emcocel® 90M has similar properties to that of Avicel® PH 101 in terms of specific 
surface area, particle density, moisture content and flow and binding properties [164]. Different 
product grades may be used for specific applications [159]. MCC may be used as a binder or 
diluent in tablet formulations [165]. MCC powders exhibit large structural variations and it is this 
characteristic that has been thought to be responsible for its diverse and useful functional properties 
[163,166]. MCC is widely used due to properties that include good compaction, low friability and 
inherent lubricity [165]. Although it is most suited to direct compression formulations, MCC has 
been used in both wet and dry granulations [159,163,165] and in extrusion and spheronisation 
[162,167-170]. Due to its water absorbing capability MCC may also be used in a new moist 
granulation technique where the drying step is eliminated as excess water is absorbed by MCC 
[171]. Tablets that include MCC show good compaction with minimum compression force, and 
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due to plastic deformation [164], the bonds formed under pressure will remain intact even after 
pressure is released, hence resulting in dense tablets with minimal capping potential.  
 
3.2.3.1.2.2 Dibasic Calcium Phosphate (DCP) 
DCP is another commonly used diluent in tablet formulations due to its inherent flow properties 
and good compression characteristics, and is therefore commonly used in direct compression 
formulations. It is also non-hygroscopic at 20°C and at relative humidities up to 90% [159]. Unlike 
MCC, compaction takes place mainly by brittle fracture, that is, an applied stress initiates crack 
propagation rather than plastic deformation of the material [172]. The brittle fracture index can be 
determined as the stress concentration around a hole under the conditions of a tensile strength test, 
which is approximately three times the nominal applied stress, therefore the tensile strength in the 
presence of a hole should be one-third that of the strength without a hole [172]. The brittle fracture 
index may therefore be useful in assessing the potential for capping of a tablet formulation 
Emcompress® (Mendell, NY, USA) was used in all experimental formulations. 
 
3.2.3.1.2.3 Hydroxypropyl methylcellulose (HPMC) 
HPMC is a non-ionic long chained cellulose polymer. A number of HPMC products are available, 
such as Methocel® (Colorcon, Kent, UK) and Metolose® (Shin-Etsu) products. Such products are 
available in varying grades and with different nominal viscosities and as such may be selected for a 
particular purpose based on these specific properties [173-175]. HPMC with a lower nominal 
viscosity (4000cp) was used in the granules and that of a higher viscosity (100 000cp) was used in 
the tablet matrix. Methocel® K4M and K100M Premium grades were selected as they exhibit fast 
hydration rates which would lead to rapid gel formation, therefore providing optimal retardation of 
release of the highly water soluble drug from this formulation [175]. 
 
3.2.3.1.2.4 Granulating fluid 
Surelease® grade E-7-19010 (Colorcon, Kent, UK) was used as the granulating fluid. 
Surelease® is a complete pre-plasticised and stabilised aqueous polymeric dispersion of colloidal 
ethylcellulose [176]. It is mainly used in barrier coating but may be used as a granulation binder 
[176,177]. Ethylcellulose has also been used as hydrophobic polymer in matrix systems to retard 
drug release [122].  
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3.2.3.2 METHODS 
The process described below and illustrated in Figure 3.11 was used for manufacture of the tablets. 
All powders for granulation were individually weighed, screened through a 20-mesh sieve and then 
granulated in a Kenwood Major planetary mixer (Kenwood, UK) set on speed 1. Powders were 
blended for 1 minute prior to the addition of granulating fluid. The granulating fluid was added at a 
constant rate using a peristaltic pump (Masterflex Easyload, Cole-Palmer Instrument Company, IL, 
USA). The wet powder mass was then screened through a 10-mesh using an oscillating granulator 
(Erweka, Germany) at 50rpm. Granules were dried in an oven at 60°C for 12 hours, and then re-
screened. They were re-screened using a 20-mesh size on the oscillating granulator. Granulation 
was a single step procedure and no batches were re-worked. The dried granules were stored in an 
airtight container and blended with the accurately weighed and pre-screened matrix excipients in a 
cube blender for 20 minutes at 20 rpm prior to compression. Magnesium stearate was then added to 
the blend and the combination was mixed for a further 3 minutes at 20rpm. Tablets were 
compressed on a Manesty B3B rotary press using either 2 or 4 concave punches, to a target 
hardness of 13-17 kiloponds (kp).          
 
Drug release from the formulation was assessed after modifications to the proportions of 
excipients, the matrix polymer, drug load and the granulating fluid used in the formulation, were 
made. Drug release was assessed using dissolution testing as described in § 4.5. Physical 
characteristics of the tablets, including weight uniformity, hardness and friability were also 
assessed and are included in Appendix I for each batch, respectively. 
 
Content uniformity of representative batches was also assessed. Ten tablets from each batch were 
individually weighed and crushed separately using a mortar and pestle. The powder for each tablet 
was quantitatively transferred to a volumetric flask and made up to 100mL volume with methanol, 
and sonicated for ten minutes. An appropriate aliquot was removed with the aid of a swinney filter 
with 0.45µm filter paper, and subsequently diluted with HPLC grade water. Samples were 
analyzed using the validated HPLC method described in § 2.2.3. 
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Figure 3.11: Flow diagram of the Manufacturing Process  
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3.2.3.3 RESULTS AND DISCUSSION   
A brief summary of the batches manufactured, modifications made and the time taken to release 50 
and 100% of MPTA is included in Table 3.2.  
 
3.2.3.3.1 Effect of larger drug load in granules 
An increased percentage of drug in the granules (Batches M012208, M023009), which contained 
26.09% drug, with a corresponding decrease in percentages of granulation excipients, resulted in 
retarded drug release with 50% of drug being released in 3.5 hours and 100% in 14 hours (Table 
3.2, Figure 3.12). Drug release was found to be faster from these batches than from the batch 
originally manufactured (M011508). The similarity (f1) and difference factors (f2) were used to 
determine the similarity between two batches of tablets. These are discussed in greater detail in § 
4.3, however f1 values < 15 and f2 values > 50 indicate that there are no significant differences 
between the profiles compared. These values verified that there was no significant difference 
between the batches with increased drug load, however both batches are significantly different 
from the feasibility batch M011508, where f1=52.7, f2=29.7 values were obtained from 
comparison of M011508 to M023009. Although the differences in the release profile may have 
been a function of larger amount of granulating fluid, it is also likely that the amount of polymer 
(15%w/w) may have been insufficient to maintain sustained drug release over a 24-hour period. In 
addition it may be possible that as the amount of drug in the granules was increased greater 
amounts of drug were present at the granule surface and ultimately the tablet surface, resulting in 
more rapid dissolution from this formulation. It was found that increases in the amount of drug 
might be compensated for by increases in the amount of the HPMC K100M, the rate-controlling 
polymer used.   
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Table 3.2. Summary of formula modifications and time for 50% and 100% drug 
release from experimental batches 
 
 
Batch No. 
Modifications 50%  100%  
M0022005 None (USP Apparatus II) 4 hrs 14 hrs 
M001270502 +30&.0WR 5 hrs 22 hrs (80%) 
M011508 6XUHOHDVH® 8 hrs 22 hrs (70%) 
M012208 GUXJ JUDQXODWLRQH[FLSLHQWV 3.5 hrs 22 hrs 
M013009 
M011711 
As for M012208 
17 hour drying time 
3 hrs 
2.5 hrs 
22 hrs 
14 hrs 
M023009 GUXJ +30&.100M (20%) 3 hrs 22 hrs 
M010711 Drug (23%), HPMC K100M (18%) 2.8 hrs 22 hrs 
M011210 
M021711 
Drug (20%), HPMC K100M (20%) 
As for M011210 
6 hrs (53%) 
5 hrs 
22 hrs (83%) 
22 hrs (85%) 
M001080301 As for M011210, JUDQXODWLQJIOXLG 3 hrs 22 hrs 
M001080302 40% drug, RIJUDQXODWLRQ
excipients, 20% HPMC K100M 
3.2 hrs 22 hrs 
M001270501 As for M001080302 4.4 hrs 22 hrs (90%) 
M001270503 20% drug, 20% HPMC,  
0&& '&3 6XUHOHDVH
® 
 
4.5 hrs 22 hrs 
M001270504 As for M011210, 1 kg batch 3.5 hrs 22 hrs 
M00050601 As for M011210, small mesh size used 
in both screening steps 
5 hrs 22 hrs (90%) 
 
x All batches were assessed in USP Apparatus III unless otherwise indicated 
x  DUURZVLQGLFDWHLQFUHDVHVRUGHFUHDVHVLQWKHDPRXQWVRIH[FLSLHQWVRUGUXJXVHG 
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Figure 3.12: The effect of altered drug load on the MPTA release profiles from experimental 
formulations (n=6) 
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Figure 3.13: The effect of altering the amount of granulation fluid on MPTA  
release profiles (n=6) 
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3.2.3.3.2 The effect of Surelease® on the drug release profile 
Drug release from the original batches (M0022005, M011508) manufactured with the same 
formulation occurred at different rates, and this was thought to be a function of a higher amount of 
Surelease® used in the granulation of one of the batches. The amount of Surelease® added was 
found to have a significant effect on drug release characteristics. This may be expected as 
Surelease® contains the hydrophobic polymer, ethylcellulose which may also have a rate-
controlling effect on drug release. An assessment of six batches (Table 3.3) with varying amounts 
of Surelease® was found to exhibit different release profiles. Deviations in the amount of 
Surelease® that were greater than approximately 15% from a target amount of 0.21g/g of 
Surelease® added to the granules resulted in altered drug release profiles whereas batches that 
contained amounts of Surelease® that did not deviate by greater than 15% from the target amount 
resulted in similar release profiles (Table 3.1, Figure 3.13).  
 
Table 3.3: Surelease® composition of batches manufactured to assess the effect of granulating 
fluid on drug release rates 
 
 M011508 
(D) 
M01270502 
(E) 
M011210 
(F) 
M021711 
(G) 
M001080301 
(H) 
M00270504 
(I) 
Amount of Surelease® 
(g/g of powder) 
% Deviation from 
target amount 
0.36 
 
71.43 
0.18 
 
14.29 
0.19 
 
9.52 
0.21 
 
0.00 
0.16 
 
23.81 
0.14 
 
33.33 
 
 
 
 
Table 3.4: f1 and f2 for batches used to assess the impact of the amount of Surelease® added 
on drug release 
 f1 f2 
Batch G vs D 
Batch G vs E 
Batch G vs F 
Batch G vs H 
Batch G vs I 
18.3 
5.3 
2.1 
15.4 
15.8 
48.7 
73.2 
85.0 
48.5 
48.2 
 
Batches containing the higher amounts of Surelease® appeared to control the release of MPTA 
from the matrix more effectively than batches which contained less than 0.16g/g of Surelease®.  
This may indicate that increasing the amount of Surelease® added would possibly aid in achieving 
more controlled drug release from this formulation, however, increasing the amount of granulating 
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fluid to greater than 0.21grams/gram of powder blend resulted in an unworkable mass and granules 
obtained were spaghetti-like in nature. This was possibly due to over-granulation and the possible 
premature hydration and swelling of HPMC K4M incorporated into the granules, as a result of the 
excessive amounts of aqueous liquid from the granulation fluid. Klinger et al suggested that the 
controlled release effects exerted by Surelease® may be enhanced by the use of a double 
granulation procedure as it was found that the double granulation resulted in sustained release 
characteristics for three drugs namely, theophylline, chlorpheniramine maleate and acetaminophen 
[177].  
 
The amount of Surelease® added to each batch could not be standardized precisely as the 
granulations may be influenced somewhat by environmental conditions such as temperature and 
humidity. Manufacturing this formulation in an environmentally controlled room where all 
conditions can be optimized may eliminate these effects. It was found that a deviation of  >15% 
from the target value resulted in altered sustained release characteristics over a 22-hour period. 
Furthermore, the addition of larger amounts of granulating fluid would result in low batch yields, 
as a large amount of granules were lost on the screening mesh and as a result of large granule size.  
 
3.2.3.3.3 Effect of altering polymer content in the matrix 
The amount of polymer was then increased to compensate for the larger percentage of drug in the 
total formulation. The amount of polymer added was increased from 15 to 18 and then 20% of the 
total formulation (M011711, M010711, M021711, respectively) of the total formulation and the 
release profiles are depicted in Figure 3.14. It was found that increasing the content of Methocel® 
K100M added in the matrix even by a very small percentage of the total formulation resulted in 
significant retardation (f1, f2 in Table 3.5) of drug release. Although the f1 value obtained for a 
comparison of batches containing 15% and 18% polymer was <15, the f2 value was also < 50 
indicating that the profiles were significantly different. This was expected as increasing amount of 
polymer would lead to increased gel layer thickness and hence a more tortuous path for drug 
diffusion to occur, thus slowing down the release rate of drug from the tablets with 20% HPMC. 
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Table 3.5: f1 and f2 for batches used to compare the effect of varying polymer content  
 
Comparison f1 f2 
A vs B 
A vs C 
B vs C 
13.1 
39.7 
23.6 
41.4 
30.2 
42.6 
 
(A, B, C represent 15%, 18%, 20% respectively) 
 
The influence of polymer content on drug release is well documented [178], however drug release 
may also be affected by other polymer variables such as substitution type, viscosity and particle 
size [178], which were not evaluated. Furthermore, the ratio of drug: polymer is a critical 
consideration in the development of matrix systems, where increasing polymer content in relation 
to the drug load, results in decreased drug release [179]. The mechanisms of in-vitro drug release 
from this formulation are discussed in further detail in Chapter Four. 
 
3.2.3.3.4 Effect of increasing MCC content in granules 
The effect of increasing the content of MCC in the granules was assessed in batch M01270503 and 
compared to batch M011210. M01270503 resulted in slower initial release of the drug from the 
matrix, although f1 and f2 values (f1=15.4, f2=51.9) indicate that there was a significant difference 
between the release profiles. This may have been a result of increased binding capability due to the 
larger amount of MCC used in the wet granulation [165]. Furthermore, due to its hygroscopic 
nature, the larger amount of MCC may have resulted in greater swelling, which aided in retarding 
drug release to a greater extent in the early phases of the experiment. 
 
 MCC has also been found to have less brittle properties and to be more plastically deformable than 
other excipients such as lactose [180] and it was expected that this might have had an impact on the 
physical and compression properties of tablets, particularly with respect to hardness [180,181]. 
However, the average hardness for this batch of tablets was found to resemble values obtained for 
other batches (Appendix I), and this may have been due to the fact that only the MCC content in 
the granules was varied. This represents only a small percentage of the total formulation and 
therefore there was minimal impact on drug release from this formulation 
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Figure 3.14: The effect of altered polymer (HPMC K100M) content on the drug  
release profile (n=6) 
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Figure 3.15: The effect of granule drying time on MPTA release (n=6) 
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3.2.3.3.5 Effect of certain process variables 
It is important to evaluate the effects of both formulation and process variables on drug release 
rates from tablets. Therefore the effects of granule drying time and mesh sized used for granule 
screening and compression force (§ 3.2.3.3.6) were evaluated. 
 
3.2.3.3.5.1 Drying Time 
The duration that the granules were dried had an impact on drug release rate from the formulation. 
A drying time of 6 hours resulted in a faster rate of drug release than from batches in which 
granules were dried for 12 and 17 hours (Figure 3.15). A fit factor comparison of M011711 and 
M002208, which were dried for 6 and 12 hours, respectively, resulted in an f1=6.9 and  
f2=42.5, indicating that there is a significant difference between the release rate profiles of MPTA 
from these batches. 
 
As there appeared to be little difference between 12 and 17 hours drying time (f1=6.4, f2=65.5), 
granules for all batches were dried for 12 hours. The excess water present from incomplete drying 
in the case of 6 hours exposure, may have led to the formation of large pores within the tablet, 
hence facilitating water penetration into the dosage form [182], which may have resulted in a 
subsequent increased drug release rate. 
 
3.2.3.3.5.2 Mesh size for granule screening  
In order to assess the impact of granule size on drug release batch M00050601 was formulated to 
be similar to batch M011210. Batch M00050601 was screened through the 20-mesh both before 
and after drying, whereas granules for M011210 were screened through a 10mesh before drying, 
and the 20-mesh subsequent to drying. The release profile (Figure 3.16) was found to be unaffected 
(f1=7.5, f2=66.6) by the size of the granules to be incorporated in to the matrix formulation. 
 
3.2.3.3.6 Physical Evaluation of Tablets 
Tablet weight 
The weight of some batches manufactured was not adjusted to achieve the100mg dose exactly 
(690mg tablet weight), however as these were preliminary batches and data was to be presented as 
a percentage of drug released versus time, these batches were still tested. Variations between tablet 
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weights of individual batches were manufactured to be minimal where the % RSD values for 
weight variation for most batches was less than 5%. 
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Figure 3.16: The effect of screen mesh size on the drug release profile (n=6) 
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Figure 3.17: Comparison of the release profiles of tablets compressed to different target 
hardness values (n=6) 
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Tablet Hardness 
Tablet hardness was more variable than tablet weight and %RSD values were found to exceed 10% 
for most batches. This was more than likely due to inefficient die filling, which may have been a 
consequence of the small batch sizes compressed. Furthermore, an instrumented press was 
unavailable therefore only the compression force could be altered to achieve and maintain the 
desired tablet hardness within a specific range. As a result of the large deviations in tablet 
hardness, the effect of tablet hardness on drug release was assessed. The hardness of tablets from 
one batch (M01270504) was varied from 7.29 to 20.04kp, and the release profiles developed are 
depicted in Figure 3.17.  
                    
Theoretically, differences in hardness are an indication of differences in tablet density and 
porosity, and such differences may affect the initial penetration of dissolution media into a dosage 
form. In the case of matrix tablets, this may affect the rate of gel layer formation and subsequently, 
the rate of drug release from the dosage form [179]. In this formulation, it appeared that drug 
release was slower from tablets with a lower hardness (7.29kp and 10.55kp) as compared to tablets 
with hardness of 17.94 and 20.04kp. The release profiles for the harder tablets were almost super-
imposable, indicating those small differences in hardness had almost no impact on drug release. To 
assess whether the differences in hardness of tablets were significant, the f1 and f2 difference and 
similarity factors were used. It was found that none of the f1 and f2 values obtained fell out of the 
acceptance limits for similarity (Table 3.6), that is, none were > 15 or <50, indicating that the 
release profiles were not significantly different. This may indicate that the hardness of these tablets 
has a minimal impact on drug release from this formulation.  
 
 
Table 3.6: f1 and f2 Values for the comparison of the same batch with varying hardness  
 
 f1 f2 
A vs B 
A vs C 
A vs D 
B vs C 
B vs D 
C vs D 
9.1 
2.2 
8.0 
7.6 
9.1 
9.7 
60.2 
83.7 
61.5 
62.5 
60.2 
59.0 
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Content Uniformity 
Content uniformity data for batches assessed are included in Table 3.7. As the tablet weight was 
not maintained for earlier batches, the calculated theoretical amounts and the actual percentages 
determined are included in the table for comparison.  
 
Table 3.7: Content uniformity data from randomly selected batches  
 
Batch Theoretical   Actual  % RSD % Determined 
M011210  
M01270503  
M01270504 
M01270501 (200mg) 
M01270502 (50 mg) 
100.05 
93.72  
100.04  
197.54  
59.22  
96.45 ± 4.16 
85.96 ± 5.40 
98.30 ± 5.79 
178.34 ± 6.56 
55.43 ± 4.19 
4.46 
6.28 
5.89 
3.67 
5.67 
96.40 
91.72 
98.26 
90.28 
93.60 
(Actual and Theoretical amounts obtained are expressed in mg) 
 
As per the USP recommendations, a batch is passed for content uniformity if the amounts 
determined lie between 85-115% of the theoretical value, with a % RSD value <6% [73]. All of the 
batches assessed were analyzed and found to fall within the specifications, however the %RSD 
obtained for batch M01270503 was not below the 6% limit set in by the USP, indicating a failed 
batch. The content uniformity of batch M01270503 was found to be lower than for other batches 
containing 100mg of drug. This may have been a function of the altered percentages of DCP and 
MCC in the granules, and may indicate that powder flow might have been affected by altering the 
proportions of these excipients in the formulation. Flow rates of powders were not assessed in thses 
experiments. 
 
3.2.4 Conclusions 
Based on the evaluation of the batches described in § 3.2.3.3, the formulation selected for the tablet 
core is described in Table 3.8. Batches M011210, M021711 and M01270504 are replicates of this 
particular formulation. The formulation was found to be capable of sustaining the release of MPTA 
over a 22-hour period using USP Apparatus III. The results of physical testing reveal that the 
tablets were resilient and displayed good reproducibility on re-manufacturing. Drug release from 
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Batch M01270504 was significantly faster than the other batches of the same formulation, however 
this was more than likely due to a smaller quantity of Surelease® being used in the granules. This 
indicates that the amount of granulating fluid added is an important consideration, with deviations 
of greater than 15% from the optimized value resulting in significant changes in the drug release 
profile as discussed in § 3.2.3.3.2. Although the hardness of the formulation was kept within a 
target range, it was not found to have a significant impact on drug release from this formulation.  
 
Table 3.8: Formulation composition for a sustained release MPTA matrix tablet 
 
 
 
 
 
 
 
 
 
 
The matrix formulation listed in Table 3.8 was found to be capable of retarding the release of 
MPTA over a 22-hour period and may be used as a stand-alone once daily dosage form of MPTA. 
The formulation may also be considered for subsequent development of a combination dosage 
form containing both HCTZ and MPTA.  
 
 
 
 
 
 
 
 
 
Excipient Percent (w/w) 
Water-soluble drug (MPTA) 
HPMC 
MCC 
DCP 
Surelease® 
(g suspension/g powder blend) 
20 
10 
37.5 
32.5 
 
0.18-0.21 
Granules 62 
HPMC 
MCC 
DCP 
Magnesium stearate 
20 
7 
10 
1 
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CHAPTER FOUR 
THE IN VITRO RELEASE OF METOPROLOL TARTRATE  
FROM MATRIX TABLETS 
 
4.1 INTRODUCTION 
Dissolution testing is a valuable surrogate and tool for drug release rate characterization from a 
dosage form in vivo. Drug dissolution from a dosage form is one of the prerequisites for its 
absorption, bioavailability and ultimate efficacy in vivo [183]. It is used in the pharmaceutical 
industry during formulation development, stability testing and preclinical trials as a quality control 
tool. More specifically, it is used in the developmental stages to determine the best formulations 
for further development [184]. For a marketed product dissolution rate testing is widely used to 
assess batch to batch quality [183,185], provide control over the manufacturing process and quality 
assurance of a product [185], and such tests may also be used to assess whether further 
bioequivalence studies may be required after scale-up and post-approval changes (SUPAC) 
[185,186]. It has also become particularly valuable in the development of sustained-release 
products [183,186], where certain dissolution conditions may be chosen to simulate the passage of 
the dosage form in vivo, more closely, thereby allowing for better characterization of the behaviour 
of the dosage form in the GIT. The biopharmaceutical relevance of dissolution testing has 
increased in recent decades and its use in developing the biopharmaceutics classification (BCS) 
[187] and in establishing in vitro-in vivo correlations (IVIVC) is increasing for certain drug classes 
[187-189].  
 
4.2 THE BIOPHARMACEUTICS CLASSIFICATION SYSTEM (BCS) AND IN VITRO-IN 
VIVO CORRELATIONS (IVIVC) 
The BCS is based on the concept that two drug products that exhibit the same concentration profile 
along the GIT will have similar concentration profiles following oral administration [190]. It 
allows for estimation of the influences of dissolution, solubility and intestinal permeability on oral 
drug absorption from immediate release products [191]. The BCS has enabled the classification of 
drugs into four classes [190], which are listed in Table 4.1. Table 4.1 also includes some examples 
of drug candidates.  Of particular interest are the compounds of interest for this work, namely 
metoprolol and HCTZ, which are classified as Class I, and Class IV drugs, respectively. 
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Table 4.1: The Biopharmaceutics Classification System 
(Class I) 
 
High solubility, High permeability 
Eg. Metoprolol tartrate,  
Propranolol hydrochloride [190,192] 
(Class II) 
 
Poor solubility, High permeability 
Eg. Carbamazepine [190] 
(Class III) 
 
High solubility, Poor permeability 
Eg. Atenolol [190] 
 
(Class IV) 
 
Poor solubility, Poor permeability 
Eg. Hydrochlorothiazide [190] 
 
A draft guidance on biowaivers based on the BCS suggests that the documentation of 
bioequivalence by using dissolution studies may be appropriate for oral immediate release products 
which contain highly soluble and permeable drugs within a rapidly dissolving dosage form 
[185,190,193]. Consequently, the need for expensive and difficult analytical procedures that are 
required to analyze drugs in biological fluids following bioequivalence studies is eliminated. At 
present biowaivers, may only be granted for Class I immediate release products [193], whereas 
modified release must be assessed for in vivo bioequivalence and in vitro release characterized by 
dissolution testing [194]. However, the applicability of the BCS with respect to modified release 
systems is debatable and additional considerations of the product, including transit time, the non 
linearity of transport systems, the metabolic transformation process and the addition of certain 
adjuvants which may alter gastric transit, membrane transport or transformation variables are 
required [195].  
  
IVIVC aid in product development as it allows for a prediction of the plasma profile of a drug 
product without the need for a biostudy. In this case dissolution testing is used as a surrogate 
measure for predicting the in vivo behaviour of a particular product [196,197]. The establishment 
of an IVIVC is dependent on several factors and differs for the different drug classes described in 
Table 4.1 [187], where the design of an IVIVC increases in complexity for the less soluble or 
permeable (Class II, III and IV) drugs, and more especially for modified release products [196].  
 
 For modified release dosage forms, the in vitro test conditions must be selected to be 
representative of the in vivo conditions of the human gastro-intestinal tract, and are in general, 
more rigorous than for immediate release dosage forms. A weak dissolution test design may result 
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in a poor correlation with in vivo behaviour of the dosage form [197].  The implication is that a 
larger number of in vitro variables, including pH, agitation, physical stress and food effects must 
be evaluated to establish a predictive correlation with in vivo conditions [195].  
 
The validation of an IVIVC is also important as it allows for certain post-approval changes as 
described in the Scale-up and Post Approval Changes for Modified Release (SUPAC-MR) to be 
made, and may therefore justify biowaivers for such changes to be made [186,198]. The validation 
of a dissolution method, as described by Eddington et al allows for the identification of optimal 
dissolution conditions to be identified for a particular drug [199].  
 
4.3 COMPARISON OF DISSOLUTION PROFILES 
Dissolution testing therefore forms an integral part both product development and manufacture and 
throughout the shelf life of a product. Consequently, an effective and accurate means for the 
comparison of dissolution profiles is necessary. A number of methods to compare dissolution 
profiles are available and may be categorized either as model independent or model dependent 
approaches for comparison. Model independent approaches include the ratio test, pair-wise test 
procedures and analysis of variance (ANOVA) [200]. Some authors have described ANOVA 
analysis as a separate category [201]. Model dependent approaches may be based on any number 
of models including zero-order, first-order Hixson-Crowell, Higuchi, Weibull and others 
[200,202].    
 
Pair-wise test procedures include the difference factor (f1) [200,201], similarity factor (f2) 
[200,201] and two indices of Rescigno [200,201,203]. Pair-wise procedures are used for 
comparison of a pair of profiles and employ a 90% confidence interval approach [201].  
 
The f1 and f2 indices or fit factors, as they are more commonly referred may be calculated using 
Equations 4.1 and 4.2 [203]. f1 approximates the percentage error between two curves, and 
increases proportionally with increasing dissimilarity between curves. f2 on the other hand is a 
logarithmic transformation of the sum of the squared error and approaches zero as dissimilarity 
increases [202,204].  
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                                   n 
         f1 = { [  Rt –Tt]/ [5t]} x 100                                                                  Equation 4.1                         
                                 t=1 
 
 
                                                           n                  
 f2 = 50 log {[1 + 1/n  Zt (Rt – Tt)2] –0.5  x 100}              Equation 4.2 
                                                                       t=1 
 
 
Where, 
Rt and Tt = assay values of the reference and test at time t, respectively 
n = the number of pull points  
wt = an optional weight factor which can be used to give more weight to a value/s 
that are considered more important than others.  
 
f1 and f2 data must be generated from a minimum of 12 replicates [183,205] and a limit of one 
sampling time after 85% drug dissolution is recommended [205,206]. f2 may be calculated using 
mean data as calculations using both individual and mean data were not found to be statistically 
different [207], and dissolution measurements of two products must be made under exactly the 
same test conditions [205]. 
 
The similarity factor is more commonly quoted [201,208-210], as it is the simplest to use [205]. 
Furthermore the FDA recommends the similarity factor, for the comparison of dissolution profiles 
[205]. f1 values < 15 and f2 values > 50 are considered to be the limits for similarity between to 
curves, where f2 = 100 indicates that two profiles are identical and f2 =50 indicates that there is a 
10% difference at all measured time points [205]. Some have suggested that the acceptance criteria 
of 50-100  is too conservative [200], however this has not been altered to more liberal limits at 
present. Limitations of f2 include the disregard for the time and duration over which differences 
are found [211] and the failure to take into account differences in dissolutions between test and 
reference batches [206,212]. A new multivariate procedure for testing the similarity or equivalence 
between two dissolution profiles through Hotelling’s T2 statistic has recently been proposed, and 
has been found to eliminate some of the shortcomings of the f2 similarity factor [206]. 
 
Despite possible shortcomings of the f1 and f2 fit factors, these were chosen for comparison of 
dissolution profiles and were used either alone or in combination with certain model dependent 
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procedures, the Higuchi model in particular was considered. No extra weighting was given to any 
time for the analyses using f2 in this work 
 
4.4 SELECTION OF THE DISSOLUTION APPARATUS 
4.4.1 Factors affecting the choice of a dissolution apparatus 
The type of apparatus used mainly in dissolution testing of sustained release products includes the 
basket (USP Apparatus I) and the paddle (USP Apparatus II), however the reciprocating cylinder 
(USP Apparatus III) or the flow through cell (USP Apparatus IV) may also be used [179], and all 
four pieces of equipment are listed in the FDA Guidance for Industry: Oral extended release 
dosage forms, In Vivo Bioequivalence and In Vitro dissolution testing. [188,194].  
 
In terms of establishing an IVIVC for controlled release products, dissolution apparatus that allow 
for alteration of the dissolution medium with respect to pH, molarity, anions, cations, viscosity, 
buffers and surface-active agents, are becoming more valuable [188,213]. The Bio-Dis® (Apparatus 
III) is useful in the development of controlled release products, as it exposes the product to both 
mechanical and various physicochemical conditions that may influence drug release along the GIT 
[213]. The Bio-Dis® is also said to be advantageous because it is not subject to variability cause by 
air bubbles and minor modifications in the geometry of the dissolution vessel as the pump action of 
the reciprocating tube in which the dosage form is held, negates such effects [213]. Dissolution 
rates from Apparatus I and II, on the other hand have been reported to be altered by air bubbles and 
the geometry of the dissolution vessel [213]. Problems such as clogging of basket screens in 
Apparatus I, and ‘coning’ observed in Apparatus II are also eliminated in Apparatus III. ‘Coning’ 
is known to reduce dissolution rates significantly, resulting in variable data that is often dependent 
on the position of the dosage form in the dissolution vessel [213], as only the upper surface of the 
tablet is subject to erosion caused by the paddles whilst the bottom of the tablet is stuck to the 
vessel and remains unexposed to the hydrodynamic stress that is created in the dissolution vessel 
[213]. 
 
4.4.2 Selection of dissolution apparatus  
The selection of the dissolution apparatus for the assessment of a MPTA product or a combination 
product of MPTA and HCTZ was limited to a choice between Apparatus II and III, Apparatus III 
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was chosen for the advantages in the assessment of controlled release dosage forms as described 
above. Apparatus IV was not selected, as it is mainly applicable to poorly water-soluble drugs 
whereas Apparatus I is designed for dissolution testing of floating devices. The use of the basket 
may possibly alter release from a matrix tablet from which drug release is primarily controlled by 
three dimensional swelling of the polymer used in the dosage form.  
 
Comparative dissolution profiles of two batches tested using both Apparatus II and III (Figure 4.1) 
show that drug release from tablets assessed in Apparatus III was greater from both batches when 
compared to the release determined when Apparatus II was used.  
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Figure 4.1: Comparison of release profiles of two batches in Apparatus II and III (n=6) 
 
Furthermore, it was apparent that whilst both batches resulted in almost identical profiles over the 
first 12 hours of release in Apparatus II, as indicated by the overlapping error bars, whereas 
differences between the profiles were more apparent in Apparatus III. Calculated f1 and f2 values 
for the batches assessed in Apparatus II were 15.3 and 47.7, respectively and therefore indicated 
that the apparent differences in Apparatus III were significant. The hydrodynamics in these 
apparatus have been reported to be different. Madden et al found that of four hydrophilic matrix 
formulations assessed in Apparatus I-IV, only the release rate profiles in Apparatus III differed, 
indicating that the mechanism of drug release was possibly different. It was suggested that drug 
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release occurred by diffusion in the three apparatus that yielded similar profiles whereas erosion 
had a larger impact on drug release from the tablets assessed using Apparatus III [214].  
Furthermore, it was found that the hydrodynamics of the Apparatus II also affected release, whilst 
this was not the case for the other dissolution apparatus [214]. This suggests that the Bio-Dis® may 
be better able to simulate the GIT conditions, especially the conditions in the stomach, which is a 
‘grinding’ organ and may therefore contributes to greater initial erosion of a dosage form. 
 
Apparatus III, the Bio-Dis® (G.B.Caleva Ltd, Ascot, England) was therefore selected as the 
apparatus of choice for dissolution testing as it was found to be more discriminating between 
batches and it allowed for a close simulation of the passage of the dosage form in vivo. 
Furthermore, the technology developed could be designed to be more rigid with testing in USP 
Apparatus III. Apparatus II was used in preliminary and follow-up evaluation of some batches for 
comparative purposes.  
 
4.5 SELECTION OF THE DISSOLUTION TEST CONDITIONS 
4.5.1 Introduction 
The dissolution test may be affected by numerous variables such as the physico-chemical 
properties of the drug, the type of dosage form and other factors independent of the product itself. 
Drug properties that may influence the choice of dissolution conditions include particle size, 
solubility and ionization properties of the compound. Dosage form independent variables include 
the composition of the dissolution medium, agitation rates, pH, osmolarity and ionic strength of the 
dissolution medium and the surface area within the dissolution vessel [208,214,215]. The 
temperature of the dissolution medium is also an important consideration and is generally selected 
to simulate the in vivo conditions of 37°C [208]. The inclusion of additives such as surfactants to 
the dissolution medium may also affect the behaviour of the dosage form in these tests, thus the 
selection of dissolution conditions that allow for the establishment of a valid IVIVC are essential.  
 
4.5.2 Dissolution test conditions for USP Apparatus III 
The dissolution test conditions used in Apparatus III are described in Table 4.2. A 22-hour test 
period was selected, as this was the most suitable from the programme options available on the 
Bio-Dis®. The temperature was selected to simulate in vivo conditions and a volume of 185mL per 
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tube was selected based on the capacity of the tubes available in our laboratory. All calculations 
were performed on the assumption that 10mL of the sample was lost due to evaporation at the end 
of the 22-hour dissolution run. 
 
Table 4.2:  Dissolution conditions for Apparatus III 
Conditions Parameter 
pH Time 
Medium 
(0.1M phosphate buffers) 
1.6 
3.4 
4.7 
6.8 
7.2 
7.2 
1 
1 
4 
4 
4 
8 
Temperature 
Volume of medium 
Agitation 
37 ± 0.5°C 
185mL 
20 dips/min 
 
Buffers were prepared by making up 0.1M phosphoric acid solution using 5.82mL of 85% ortho-
phosphoric acid per litre of HPLC grade water. The pH was adjusted as required using sodium 
hydroxide pellets, as described in § 2.2.1.5.3 on mobile phase preparation. 
 
As part of the selection process certain variables, including the effects of buffer molarity and 
agitation rate were assessed to ascertain whether those conditions as described in Table 4.2 were 
indeed capable of discriminating between dosage forms without erroneously altering the drug 
release profiles.  
 
2.5.2.1 Effect of buffer molarity 
The effect of buffer molarity on drug release from this formulation was conducted using 0.05M, 
0.1M and 0.2M buffers. The similarity between the profiles was assessed using the f1 and f2 fit 
factors. Drug release was found to occur more rapidly in the 0.2M buffers than low molarity 
buffers, as depicted in Figure 4.2. The calculated f1 and f2 values as listed in Table 4.3 indicate 
that the profiles obtained for 0.05M and 0.1M buffers were similar whilst the release profile from 
drug dissolution testing in 0.2M buffers was significantly different from the 0.05M and 0.1M 
buffers. 
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Table 4.3: f1 and f2 comparison of buffer molarity 
Comparison f1 f2 
0.05M vs 0.1M 
0.05M vs 0.2M 
0.1M vs 0.2M 
3.1 
27 
30 
81 
38.3 
36.3 
 
It has been found that for two hydrophilic matrix tablet formulations containing a highly water 
soluble drug, a combination of a high ionic strength, resulting from increased buffer molarity, and 
a low pH resulted in significantly faster dissolution rates than at high pH [215]. This may explain 
the faster release rate from the tablets observed in 0.2M buffers, where it is likely that the 
combination of low pH in the first three rows of the Bio-Dis (pH < 5.0) and the increased molarity 
contributed to a greater drug release rate. No differences between 0.05M and 0.1M were found 
indicating that drug release may be unaffected by minor changes in buffer molarity. However 
increasing buffer molarity above a concentration of 0.1M may have implications for product 
dissolution testing.  
 
2.5.2.2 Effect of agitation rate 
Alteration of the paddle speed or agitation rate in Apparatus II and III respectively, will alter the 
hydrodynamics in the dissolution vessel, and may consequently impact on the dissolution 
behaviour of the drug. As Apparatus III was selected, the effect of altering the agitation rate using 
10, 20 and 30 dips/minute was examined. These agitation rates were selected, as 10-30dips/min is 
known to be representative of the physiological conditions in the GIT [213,214]. As shown in 
Figure 4.3, alteration of the agitation rate appeared to impact significantly on the drug release 
profiles, and the calculated f1 and f2 values (Table 4.4) reveal that none of the release profiles are 
similar.  
 
Table 4.4: f1 and f2 comparison of agitation rates 
Comparison f1 f2 
10 vs 20 dips/min 
10 vs 30 dips/min 
20 vs 30 dips/min 
17.9 
34.4 
67.3 
43.9 
28.7 
20.2 
 
It was expected that by increasing the agitation rate, drug dissolution rate would increase as a result  
of the more effective removal of the stagnant/unstirred layer of drug solution that surrounds drug  
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Figure 4.2: The effect of buffer molarity on the MPTA release profile (n=6) 
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Figure 4.3: The effect of agitation rate on the MPTA release profile (n=6) 
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particles, hence improving sink conditions. The increased effects from erosion of the dosage form 
may also be expected to contribute to a more rapid drug release rate. Furthermore, it has been 
reported that less energetic agitation rates may favour more homogenous gelation initially and 
subsequent slower erosion, leading to slower release rates [216]. Madden et al also reported that 
increasing agitation rate resulted in a corresponding increased dissolution rate and suggested that 
erosion is more than likely the predominant mechanism of release in Apparatus III [214]. It was 
found that although tablets assessed at 30dips/min showed the fastest release rate, the trend was not 
obeyed by those assessed at 10 and 20 dips/min.   
 
The choice of dissolution conditions for Apparatus III were therefore not altered as it was thought 
that tests using 0.1M buffers at an agitation rate of 20 dips/min were capable of adequately 
discriminating between batches without altering the hydrodynamics of the system and leading to 
false conclusions being drawn. 
 
4.5.3 Selection of dissolution test conditions for USP Apparatus II 
Apparatus II was used mainly for the assessment of immediate release products of both MPTA and 
HCTZ and for preliminary tests on the tablet core described in Chapter Three. Tests for immediate 
release products were conducted using the conditions depicted in Table 4.5.  
 
Table 4.5: Dissolution conditions for Apparatus II 
Medium 
Rotation speed 
Volume  
Temperature 
0.1M phosphate buffers pH 7.20 
100 rpm 
900mL 
37°C 
 
Dissolution testing of immediate release products of both drug compounds met the USP 
specifications when tested in 900mL of 0.1M buffer (pH 1.60), using a paddle speed of 100rpm.  
 
It has been reported that drug properties including its ionization at different pH’s does not alter the 
release characteristics of the drug from the product [217]. Sandberg et al [218] and Eddington et al 
[219] who both investigated metoprolol tartrate release from extended release formulations found 
that the rate of drug release was independent of the pH of the dissolution medium. Dissolution tests 
to determine whether this was also the case for MPTA release from the matrix formulation 
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developed, were therefore conducted. Tests were conducted in Apparatus II using 0.1M buffers of 
pH 1.60 and pH 7.20. Profiles for batches M001080301 and M011210 are depicted in Figure 4.4 
and it is evident that pH appears to have no effect on drug release from the matrix tablet 
formulation developed on our laboratories. Drug release from this dosage form is pH independent, 
which is a desirable characteristic in a controlled release dosage form in which drug release must 
be sustained throughout the passage of the dosage form in the GIT, viz pH 1.2- pH 7.2. 
 
4.6 MECHANISMS OF RELEASE FROM THE EXPERIMENTAL MATRIX 
FORMULATION  
Drug release from HPMC hydrogel matrices is mainly controlled by diffusion resulting in Fickian 
release that is characterized by square root of time dependent release rates. The drug release profile 
is characterized by a fast initial rate of drug release that is followed by a decreasing release rate 
over time [220,221]. A typical release profile is depicted in Figure 4.5. Diffusion in such systems is 
best described by the Higuchi model, as was discussed § 3.1.3.1.1. Polymers such as HPMC, which 
are initially dry glassy polymers that swell upon absorption of water resulting in a rubbery outer 
layer, as a consequence of rearrangement of the polymer chains [220], may also exhibit Fickian 
release kinetics that is dependent on polymer relaxation alone [221,222].  
 
When both diffusion and polymer relaxation processes are involved in drug release, the mechanism 
of release is altered and non-fickian or anomalous diffusion may occur.  In these cases, drug is 
released by a combination of both diffusion and swelling effects and this type of release is often 
also referred to as first order release, and a typical profile is shown in Figure 4.5 [221,222].   
 
Zero-order or Case II diffusion is also a type of non-Fickian diffusion, however the rate of drug 
release is constant over time, resulting in a linear profile, as shown in Figure 4.5. This type of 
release is controlled by a swelling mechanism only [220,221]. Super case II diffusion also exhibits 
constant release over time and in these instances release is dependent on both swelling and erosion 
of the polymer [223]. 
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Figure 4.4: Effect of pH of the dissolution medium in USP Apparatus II  
on MPTA release profile 
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Figure 4.5: Typical release profiles representative of different drug dissolution kinetics  
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Drug release through a matrix tablet may therefore be characterized mathematically using the 
Power Law equation (Equation 4.3). This equation, which may is often referred to as the 
Korsemeyer-Peppas equation, has become commonly used to predict the mechanism of diffusional 
release from matrix systems [202,220,221,225]. 
 
                             Mt  =  ktn                            Equation 4.3 
                   M 
Where, 
Mt/M    = the fraction of drug released at time t 
k = kinetic constant which incorporates structural and geometric characteristics of the 
controlled release device 
 n = diffusional exponent which is indicative of the drug release mechanism 
 
In the case of Fickian diffusion n = 0.5, whereas when n = 1.0 Case II or zero order transport is 
indicated. Values for n that fall between 0.5 and 1.0 are indicative of anomalous diffusion. The 
equation is also capable of predicting Super Case II diffusion when an n value greater than 1.0, is 
obtained [203,220,222-225]. However, this model is unable to explain release kinetics for n values 
less than 0.5 [225], and the equation can only be used to characterize 60% drug release from a 
dosage form as sample points where the drug concentration is > 60% are invalid and cannot be 
used in the calculation of the n value [223]. 
 
The use of the Higuchi equation in isolation, to characterize drug release from an HPMC matrix 
tablet may therefore not be capable of identifying the exact mechanism of drug release and 
therefore both the Higuchi model and the Power Law were used in an attempt to characterize drug 
release mechanisms from this formulation.  
 
The n values obtained for each of the batches assessed are listed in Table 4.6. Only batches 
M001270502 and M001270504 produced n values of 0.5, indicating that drug was released by 
Fickian diffusion controlled mechanism. The majority of the batches assessed resulted in 
calculated n values of between 0.5 and 1.0, indicating that anomalous diffusion was primarily 
responsible for drug release from these formulations. The Power Law could not characterize the 
mechanisms of release of batches M010711, M011210 and M021711, which resulted in n values of 
less than 0.5 being calculated.  
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With respect to batches M01270502 and M01270504, the square root time plots (Figure 4.6) 
indicate that drug release is linear with square root time, therefore drug release from these batches 
may be best described as Fickian diffusion controlled. Drug release is therefore controlled entirely 
the by diffusion of drug through the fluid filled pores on the polymer matrix. This was unexpected 
for batch M01270504 that differed from batch M011210 with respect to the amount of granulating 
fluid added. Only 0.14gram/gram of Surelease® was used in M01270504, in comparison to 
0.18gram/gram used in M011210. As was discussed in § 3.2.3.3.2, differences of greater than 15% 
from the target value resulted in an altered release profile and may imply that the larger amounts of 
Surelease® contribute to drug release control to a significant extent, thus altering the overall drug 
release mechanism from this dosage form. Due to the hydrophobic nature of the ethylcellulose 
polymer, penetration of fluid into the granules may have been hindered in batch M011210, hence 
delaying drug release. Drug release from batch M01270504 was controlled by the diffusion of drug 
through the fluid filled pores of the HPMC matrix only.  
 
Table 4.6: Calculated n values and correlation coefficients (r2) for square root time plots 
Batch n value  r2 for ¥WSORWV Time Period 
M001270502 
M0110508 
M012208 
M013009 
M011711 
M023009 
M010711 
M011210 
M021711 
M001080301 
M001080302 
M001270501 
M001270503 
M001270504 
M00050601 
0.50 
0.57 
0.57 
0.51 
0.57 
0.56 
0.29 
0.41 
0.43 
0.57 
0.53 
0.57 
0.67 
0.50 
0.62 
0.9964 
0.9908 
0.995 
0.9965 
0.9911 
0.9962  
0.9872  
0.9849 
0.9897 
0.9988 
0.9990 
0.9918 
0.9728 
0.9962 
0.8048 
0-10 hrs 
0-14 hrs 
0-14 hrs 
0-10 hrs 
0-10 hrs 
0-10 hrs 
0-14 hrs 
0-14 hrs 
0-14 hrs 
0-14 hrs 
0-14 hrs 
0-14 hrs 
0-22 hrs 
0-14 hrs 
0-14 hrs 
 
As was expected batch M01270502 displayed Fickian diffusion due to the larger percentage of 
HPMC used in comparison to the drug load, the primary result of greater percentages of HPMC 
was that a thicker gel layer through which the drug had to diffused was obtained. 
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Figure 4.6: Higuchi plots for batches M01270502 and M01270504 (n=6) 
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Figure 4.7: Higuchi plots for batches M101210, M011711 and M021711 (n=6) 
 
The majority of the batches displayed anomalous diffusion behaviour indicating that drug release 
was controlled by both diffusion and by the three dimensional swelling and relaxation of the 
polymer. Drug release may therefore be better described by first order release kinetics, which is 
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characterized by a rapid initial release that declines over time. The initial release in this case is 
slower than for a Fickian diffusion controlled release rate. 
 
Drug release from batches M011210, M010711 and M021711 could not be explained using the 
Power Law, as n values obtained were less than 0.5. Dissolution data was fitted to the Higuchi 
model (Figure 4.7) and although the correlation coefficients obtained were high, the data were not 
well fitted to the model. This may indicate that the drug release was controlled by mechanisms 
other than diffusion only, or it may be likely that these batches display a ‘burst’ effect [220], in 
which the drug is released from the tablet surface before the gel layer is formed.  This may have as 
a consequence of more drug being present on the tablet surface due to breaking of the more rigid 
granules during the compression stage of manufacture.  n values may be recalculated to exclude the 
initial times points over which rapid drug release occurs so as to obtain a new value which is more 
descriptive of the mechanism of drug release. The new values obtained were 0.50 for M011210 
and 0.40 for the two remaining batches. Whilst the value obtained for the former batch may 
substantiate the idea of a burst effect, this could not be conclusively verified. These batches 
contained between 0.19-0.24 g/g of Surelease® and therefore it may also have been likely that the 
larger amounts of Surelease® retarded drug release initially, such that the drug would have to 
diffuse through the hydrophobic granules prior to diffusion through the fluid filled pores of the 
matrix. The ultimate result of this combination is an altered overall mechanism of release.  
 
4.7 CONCLUSIONS 
It was evident that drug release from the batches assessed was affected by certain dissolution 
conditions including buffer molarity and agitation speed of the reciprocating cylinders. However 
the drug release from the dosage form appeared to be independent of pH, which is advantageous 
for an extended release dosage form. The mechanism of drug release from the dosage form varied 
depending on the alterations made to the batches, and it was more than likely that anomalous 
diffusion was the most common mechanism of release in most batches. The mechanism of drug 
release from the batch selected for further modification was not conclusively identified, however it 
is likely that the mechanism of release is predominantly first order, and is controlled both by the 
high viscosity HPMC used as the matrix-former and the Surelease® used as the granulating fluid. 
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CHAPTER FIVE 
STABILITY ASSESSMENT OF THE PROTOTYPE BATCH 
 
5.1 INTRODUCTION 
Stability testing of a drug substance or products is critical and as a result has become a mandatory 
procedure that is performed at various stages of development of a drug product [226-228]. It is of 
particular relevance in identifying any changes that may occur upon storage, and which may 
adversely affect the ultimate quality of the marketed product. Therefore stability testing is vital for 
obtaining information with respect to recommended storage conditions, shelf life and expiry date 
of a product [227-230]. With respect to controlled release dosage forms stability testing is 
necessary to identify a loss or alteration of sustained release characteristics that may lead to dose 
dumping and subsequent toxic or adverse effects following long term storage of these types of 
dosage forms. 
 
The stability of a pharmaceutical product may be affected by any number of factors including 
stability of the active compound(s), possible interactions between the active and excipients, the 
packaging or storage conditions, the length of time between manufacture and use of the product 
and environmental conditions experienced during transport, storage and handling [227,229]. The 
specific chemistry of the functional groups of a drug compound will determine the susceptibility of 
the compound to various degradation reactions. Degradation processes that drugs are primarily 
susceptible to include hydrolysis, oxidation, thermolabile reactions and degradation by light 
(photolysis). These processes are accelerated by environmental conditions that include, the 
presence of water and oxygen, heat and light [227,229,231]. This indicates that both chemical and 
physical stability of the dosage form must be assessed, as both affect the chemical stability of the 
active drug.  
 
According to the ICH Guidelines [226,228] on stability testing such tests should be conducted on a 
number of batches of the final product packaged in the containers and closures to be used in 
storage and distribution of the product. Recommended test storage conditions include isothermal 
and humidity conditions. Recommendations differ between countries, which have been divided 
into different climatic zones. South Africa falls in Zones I and II and therefore stability testing 
should be conducted under the conditions described in Table 5.1 [226-229, 232].  
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Table 5.1: Recommended conditions for stability testing in Zones I and II 
Recommended Conditions Test length References  
Temperature RH   
Long Term 
 
Intermediate 
 
Accelerated 
25 ± 2°C  
         
30 ± 2°C 
        
40 ± 2°C         
60 ± 5%RH 
 
60 ± 5% RH 
 
75 ± 5% RH 
1-5 years 
 
6 months reported, 
12 months study 
6 months 
226-229,232 
 
226,228,229 
 
226-229,232 
 
Accelerated stability testing at 40°C for a period of six months is generally used as an assurance of 
the stability of a product upon storage at recommended conditions. Six months at accelerated 
conditions is considered to be equivalent to 30 months at 25°C [233]. Results from accelerated 
stability studies are therefore used to assess potential long-term chemical effects, however they 
may not always be predictive of physical changes that also need to be assessed [234]. 
 
5.2 EXPERIMENTAL 
A stability study was performed on one of the experimental batches, to gain insight into the 
behavior of the dosage form under conditions of high humidity and temperature. This would 
provide information on the feasibility of the uncoated matrix as a once-daily sustained release 
dosage, and as a component in a combination dosage form of HCTZ and MPTA. Batch 
M001270504 was used for the study.  
 
The study was conducted using humidity chambers prepared in desiccators with saturated salt 
solutions to achieve the required relative humidity conditions. The chambers were prepared using 
sodium chloride and sodium nitrite, which are reported to produce a relative humidity of 75% at 
37°C to achieve humidity conditions required for accelerated stability. To achieve 60% RH 
required for long term and intermediate stability testing, sodium nitrite was selected as it is 
reported to produce a relative humidity of 66% at 20°C and 62% at 37°C [159]. The experiments 
were conducted using the recommended conditions for countries in Zones I and II, as indicated in 
Table 3.5, however, testing and was conducted for three months under all conditions. 
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The dessicator chambers were placed in ovens that were maintained at 30°C and 40°C. The 
assessment for long-term stability was conducted by storing the chamber in a dark cupboard in the 
laboratory that has a controlled temperature of 22°C. Tablets were placed in open glass jars and 
stored for the time periods described in Table 3.6. Although dosage forms should be tested in their 
final packaging, it was thought that these conditions would give a better indication of the ability of 
the dosage from to resist changes in humidity and temperature. Thermohygropens (Control 
Company, China) were used to monitor the temperature and humidity in each chamber, on a 
weekly basis. A plot depicting the temperature and humidity conditions for the period under 
investigation is shown in Figure 5.1. 
 
The temperature or percent relative humidity (RH) in all chambers did not deviate by greater than 
5% on any week that it was monitored. The temperature in the stability chamber designated to 
monitor ambient conditions was less than 25°C. The use of these humidity chambers was not 
optimum, however, samples were assessed for changes in stability under the storage conditions as 
described. The average of the actual conditions within each chamber are listed in Table 5.2.  
 
Table 5.2: Actual Temperature and Humidity Conditions 
Actual Conditions  
Temperature (°C) Humidity (%RH) 
Storage 
Period 
Long term (Ambient) 
Intermediate 
Accelerated 
19.14 ± 1.49 
29.97 ± 0.46  
40.28 ± 0.19 
77.29 ±1.27 
74.36 ±1.22 
86.93 ±1.90 
3 months 
3 months 
3 months 
  
The stability batches were also assessed in terms of its changes in weight, hardness, moisture 
content, friability and visual appearance. Visual assessment of colour and overall appearance of a 
dosage form may be an early indication of drug decomposition, as has been reported from 
assessment of eighteen ticlopidine products [233]. Stored tablets were also assessed for potency, 
after each storage period. The release of MPTA from the tablets was assessed using the dissolution 
method described in § 4.5 to determine whether changes in the sustained release characteristics of 
the dosage form occurred on long-term storage. These results were compared to those obtained 
from evaluation of the dosage form prior to storage.  
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Figure 5.1: Graphical representation of temperature and humidity recordings  
over 3 months 
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5.3 RESULTS  
5.3.1 PHYSICAL TESTS 
5.3.1.1 Visual Appearance 
In comparison to their appearance prior to storage, tablets stored at ambient and intermediate 
conditions displayed no obvious visual changes over the three-month period. However, in contrast 
those tablets stored at accelerated conditions showed differences after one month of storage. After 
one month, tablets appeared swollen and the surface appeared uneven and powdery and no changes 
in colour were observed. After two months, these changes were more pronounced and cracks were 
visible on all planes of the tablet, however tablets still retained their shape despite being difficult to 
handle. Tablets were also found to adhere to the jar walls and to each other. These effects were 
more pronounced after three months and at this stage a large amount of powder was found in the 
jar and the tablets were no longer completely intact. 
 
5.3.1.2 Tablet Hardness 
Tablet hardness was determined using an Erweka TBH 28 Hardness tester (Erweka-Apparatebau-
GMBH, Germany). Results of hardness testing are listed in Tables 5.3.1-5.3.3. A comparison with 
the hardness of tablets determined prior to storage, all tablets assessed showed a decreased 
hardness at all time-points of the study, as was expected. It was found that the hardness of tablets 
stored at intermediate conditions showed a smaller decrease in hardness than those stored at 
ambient conditions for all stability testing points. This may indicate that tablets stored at ambient 
conditions may have absorbed larger amounts of water, resulting in softer tablets. Tablets stored at 
accelerated conditions showed significant decreases in hardness after one month of storage such 
that tablets could not be handled without damaging them. The changes caused by high humidity 
and temperatures were considered to be unacceptable as such tablets could not be used easily by 
patient and may impact on the release rate profile of the drug formulation. 
  
Table 5.3.1: Hardness of tablets stored at ambient temperature (n=10)    
 Average Hardness ± SD % RSD 
Before storage 
1 month 
2 months 
3 months 
19.30 ± 1.17 kp 
13.81 ± 1.04 kp 
12.71 ± 0.54 kp 
11.99 ± 0.69 kp 
6.08 
7.51 
4.22 
5.77 
 
 118 
Table 5.3.2: Hardness of tablets from intermediate stability batch (n=10) 
 Average Hardness ± SD % RSD 
Before storage 
1 month 
2 months 
3 months 
19.30 ± 1.17 
15.98 ± 1.35 
15.66 ± 0.53 
15.78 ± 0.32 
6.08 
8.42 
3.35 
2.04 
 
 
Table 5.3.3: Hardness of tablets from accelerated stability batch (n=10) 
 Average Hardness ± SD % RSD 
Before storage 
1 month 
2 months 
19.30 ± 1.17 
3.17 ± 0.67 
1.70 ± 0.53 
6.08 
21.17 
19.78 
3 months Tablets too soft to handle 
 
5.3.1.3 Tablet Weight 
The weight of all stored tablets increased, as shown in Tables 5.4.1-5.4.3. Tablets stored under 
accelerated conditions showed the largest increases in weight whereas those stored at intermediate 
conditions showed comparatively smaller increases. These observations correspond with 
observations of hardness variations, and may also be an indication that the stored tablets absorbed 
more moisture that resulted in an increased tablet weight.  
  
Table 5.4.1: Weight of tablets stored at ambient conditions (n=10) 
 Average Weight ± SD % RSD 
Before storage 
1 month 
2 months 
3 months 
689.64 ± 10.88 mg 
708.20 ± 9.40 mg 
693.15 ± 22.51 mg 
710.67 ± 14.15 mg 
1.58 
1.33 
3.25 
1.99 
 
 
Table 5.4.2: Weight of tablets stored at intermediate conditions (n=10) 
 Average Weight ± 
SD 
% 
RSD 
Before storage 
1 month 
2 months 
3 months 
689.64 ± 10.88 mg 
699.46 ± 11.75 mg 
690.27 ± 4.53 mg 
699.79 ± 11.68 mg 
1.58 
1.68 
0.66 
1.67 
 119 
Table 5.4.3: Weight of tablets stored at accelerated conditions (n=10) 
 Average Weight ± SD % RSD 
Before storage 
1 month 
689.64 ± 10.88 mg 
721.34 12.99 mg 
1.58 
1.80 
2 months Could not be accurately weighed 
3 months Too soft to weigh 
 
 
5.3.1.4 Tablet Friability 
The test was conducted using an Erweka Friabilator (Erweka-Apparatebau-GMBH, Germany) at 
33 drops per minute for 3 minutes, and the results obtained are listed in Table 5.5. Tablets stored at 
intermediate conditions showed 0.15% loss after friability testing at all time points. At ambient 
temperature, the friability of tablets increased with increased exposure times, however, the percent 
weight lost during testing did not exceed 1%, as specified by the USP, and therefore the batch was 
still within specifications for this parameter. It was surprising that although tablets stored at 
accelerated conditions for a month showed a drastic decrease in hardness, only 0.57% of the tablet 
weight was lost after one month of storage. This was still within the acceptable limit and therefore 
is an indication that these tablets would possibly remain intact during transport and handling of the 
dosage form if exposed to these conditions.  
 
Table 5.5: Friability Data for stability samples 
Friability* (n=10)  
Ambient Intermediate Accelerated 
1 month 
2 months 
3 months 
0.15 
0.29 
0.28 
0.15 
0.15 
0.15 
0.57 
- 
- 
* Friability prior to storage was 0.15% 
 
5.3.1.5 Moisture Content 
The uptake of moisture was determined using the Karl Fischer procedure. Testing was performed 
using a Mettler DL 18 Karl Fischer Titrator. The Karl Fischer titration technique is commonly used 
to determine small amounts of water in a sample [105]. Tablets tested before storage had average 
moisture content of 2.59%. No limits for the moisture content of MPTA tablets were found in the 
literature however, a literature search revealed that the upper limit of moisture content for a multi-
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component nutritional supplement prepared by wet granulation was 3% [235]. Therefore this value 
was selected as a limit for moisture content of MPTA tablets that were tested prior to storage. as 
was expected, the water content in all tablets under all storage conditions assessed was increased. 
Tablets stored at intermediate conditions contained less moisture than those stored at a lower 
temperature. This correlates with the values obtained for hardness, weight and friability of these 
tablets. The average values for percent moisture content of all tablets are shown in Table 5.6. 
 
Table 5.6: Moisture Content (n=3) 
Moisture Content (%) ± SD *  
Ambient Intermediate Accelerated 
1 month 
2 months 
3 months 
5.49 ± 0.07 
5.83 ± 0.12 
5.91 ± 0.02 
4.03  ± 0.14 
5.49 ± 0.00 
4.37 ± 0.10 
6.48 ± 0.19 
6.37 ± 0.28 
6.79 ± 0.11 
* Average moisture content before storage was 2.59 ± 0.18 
 
5.3.1.6 Discussion and Conclusions 
The results from each of the physical tests performed indicate that tablets stored under each of the 
conditions assessed show a definite increase in moisture content. This was confirmed by 
corresponding increases in tablet weight and friability and a decrease in tablet hardness. Tablets 
stored at intermediate conditions absorbed less moisture than those stored at ambient and at 
accelerated conditions. Temperature and humidity both have an effect on the physical properties of 
a dosage form, and optimal conditions for both must be specified. The results also indicate that 
packaging for the tablets would be a critical consideration. 
 
The physical stability of the batch assessed is adversely affected by the absorption of moisture into 
the dosage form and it is likely that all other batches manufactured would behave in a similar 
manner. Mosquera et al [236] have found that increased moisture in HPMC tablets led to 
reductions in tablet hardness and an increase in tablet porosity and mean pore diameter, and this is 
probably likely for the batch assessed.  Swelling can be attributed to the diffusion of water from the 
interparticulate spaces into the HPMC molecules [236]. Mosquera et al also found that both HPMC 
K4M and K100M exhibited similar properties [236], indicating that the HPMC in both the granules 
and matrix may have contributed to an increased moisture content in the dosage form. This 
increase may have also been facilitated by the inclusion MCC, another hygroscopic excipient in the 
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dosage form. MCC is capable of holding large amounts of water within its internal structure 
without changes in volume, and increases in water lead to increased particle volume with the 
subsequent creation of voids [237], which may have further contributed to the resultant appearance 
and characteristics of the tablets. Furthermore, MPTA itself is hygroscopic and may alsolead to 
increased intake into the dosage form.  
 
As stability tests should be conducted on the dosage form in its final packaging, these tests 
represent extreme cases of each of the conditions assessed. These test allow for recommendations 
in terms of storage and packaging to be made. Due to the hygroscopic nature of the drug and 
certain excipients, the inclusion of a desiccant in the final packaging would be an essential 
requirement. Desiccants function to rapidly reduce humidity to a low level and to maintain this 
level during transport, storage and use of the dosage form [238]. An alternative may be the use of 
blister packaging that is designed to keep each dosage unit fresh until required for use [239]. This 
may be particularly beneficial as tablets stored under accelerated stability were observed to adhere 
to the jar and each other. The selection of such packaging would require further stability testing as 
certain packaging materials may interact with the dosage firm or may fail to protect the contents 
from environmental hazards [239]. It was found that humidity had a great impact on the integrity 
of the dosage form and therefore greater efforts should be made to minimize these effects, 
therefore suitable packaging and formulation compensation may be necessary. 
 
5.3.2 ASSAY OF TABLETS 
Content uniformity tests (n=6) were performed on the batch both prior to storage and after storage 
under each of the stipulated conditions, over one, two and three months. The amount of drug 
amount was compared to the reference samples using the Timm analysis [111] previously 
described in § 2.3.9. 
 
A significant change in drug potency is defined by the Medicines Control Council of South Africa, 
as being a loss of potency of greater than 5% from the initial assay value of the batch and in this 
event, it is recommended that further stability tests be conducted at intermediate conditions [240]. 
However, 90% of label claim is generally regarded as the lowest acceptable value for potency 
[227,231]. As depicted in Figure 5.2 only of the samples assessed showed significant and possibly 
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relevant decrease in the amount of drug determined, whereas all other samples showed neither 
significant nor relevant changes over the storage periods. This indicates that there was no loss in 
potency of MPTA after three months of storage at ambient and intermediate conditions, as none of 
the samples assessed showed changes of greater than 10%. However, due to the significant 
decrease in response for the three month accelerated stability sample, further testing at intermediate 
conditions should be conducted, possibly for 6-12 months, in accordance with recommendations by 
the Medicines Control Council of South Africa [240].  
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2 Ambient
3 Ambient
1 Intermediate
2 Intermediate
3 Intermediate
1 Accelerated
2 Accelerated
3 Accelerated
 
Figure 5.2: Timm analysis of stability samples 
 
5.3.3 DISSOLUTION STUDIES 
Dissolution studies were conducted as described in § 4.5. A dissolution study was conducted using 
six tablets of Batch M001270504 before storage and the release rate profile obtained was used as a 
reference for comparison for dissolution tests conducted on the stability samples. Profiles obtained 
for the stability samples are shown in Figures 5.3-5.5. 
 
The release profiles obtained for all batches assessed showed no significant differences in terms of 
shape, from the initial release profile. At ambient conditions, none of the release profiles appeared 
to be significantly different from each other (Figure 5.3), however, calculated f1 and f2 values 
(Table 5.7) for comparisons of each of the curves stored for one, two and three months, with the 
reference, indicate that whilst the curves are similar to each other after three months of storage, the 
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dissolution profile after three months was significantly different from the reference dissolution 
profile, where a greater rate of drug release was observed after three months storage, indicating a 
potential loss of rate controlling effects of the formulation.  
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Figure 5.3: Dissolution profiles of stability samples stored at ambient conditions (n=6) 
 
Table 5.7: f1 and f2 values for the comparison of dissolution profiles of stability batches 
 f1 f1 
1 AM vs 2 AM 
1 AM vs 3 AM 
2 AM vs 3 AM 
Reference vs 1AM 
Reference vs 2 AM 
Reference vs 3 AM 
1 IN vs 2 IN 
1 IN vs 3 IN 
2 IN vs 3 IN 
Reference vs 1 IN 
Reference vs 2 IN 
Reference vs 3 IN 
1 AC vs 2 AC 
1 AC vs 3 AC 
2 AC vs 3 AC 
Reference vs 1 AC 
Reference vs 2 AC 
Reference vs 3 AC 
6.2 
13.5 
7.4 
5.3 
10.4 
14.6 
9.8 
4.3 
13.6 
14.5 
5.2 
17.3 
22.1 
12.7 
20.8 
9.3 
10.5 
15.2 
63.9 
51.4 
62.4 
70.6 
53.7 
47.5 
54.9 
71.6 
50.0 
48.1 
67.5 
43.4 
43.1 
48.9 
42.9 
60 
55.1 
47.5 
(Where AM, IN and AC represent ambient, intermediate and accelerated conditions, respectively 
and 1,2,3, refers to the period of storage in months) 
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Figure 5.4: Dissolution profiles of stability samples stored at intermediate conditions (n=6) 
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Figure 5.5: Dissolution profiles of stability samples stored at accelerated conditions (n=6) 
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With respect to tablets stored at intermediate conditions, it was also found that the dissolution 
profiles for the tablets stored under these conditions were similar, however there was also a 
significant difference between the profile obtained after one and three months from the reference, 
as f1 was <15 and f2 was > 50 (Table 5.7).   
 
Following storage under accelerated conditions, all tablets showed a faster rate of drug release as is 
evident in Figure 5.5, however the calculated f2 values indicated that all profiles were significantly 
different from each other. Under these conditions it was noted that samples stored for two months 
released less drug than those stored for one and three months, and the calculated fit factor values 
indicate that whilst the release profiles for samples stored for one and three months were similar to 
each other, neither were found to be similar to the two month sample. Furthermore, samples stored 
for two months were similar to the reference samples, whereas those stored for three months 
exhibited significant differences (f1 and f2 in Table 5.7). These observations may have been a 
function of increased friability and decreased tablet hardness that may have resulted in loss of 
MPTA particles from the dosage form during handling of these samples. However, the variability 
observed for samples stored at intermediate conditions for one month and that observed for 
accelerated stability samples, may have also been a function of the inherent variability of sustained 
release dosage forms. 
 
5.4 CONCLUSIONS 
Evaluation of the physical properties of the tablets showed a trend of increasing friability and 
decreasing tablet hardness as the length of storage increased. Larger storage times also resulted in 
the absorption of larger amounts of moisture, which subsequently leads to softer tablets and it is 
likely that these effects may be exacerbated by the hygroscopic nature of the drug and other 
excipients as was discussed previously (§ 5.3.1.7). No loss in drug potency >10% was observed for 
any of the tablets tested after a three-month period under any of the storage conditions used in the 
stability assessment. 
 
Dissolution studies revealed that there was an increased rate of drug release with increased storage 
time and after three months storage under all conditions, there was a significant difference between 
the test and reference profiles, indicating a possible alteration of sustained release characteristics of 
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the dosage form. Although, varying the hardness of these tablets was not found to significantly 
alter the drug release profile under ambient conditions (§ 3.2.3.3.6.2), it is likely that a combination 
of decreased tablet hardness and subsequent increased porosity as a result of the increased moisture 
content of the dosage form under conditions of extreme temperature and humidity may have 
contributed to an alteration in the drug release profile. 
 
The observed softening of tablets due to the absorption of excess moisture may be problematic as 
handling of the dosage form would be difficult and the sustained release behaviour of the dosage 
form may be compromised. Therefore the final dosage form will require the inclusion of a 
dessicant in the packaged product. Subsequent manipulation of the formulation may also be 
required to prevent tablet softening and loss of sustained release characteristics over time, and 
therefore the addition of a coating may be necessary to minimize the potential environmental 
effects on the release rate controlling properties of the dosage form. 
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CHAPTER SIX 
THE DEVELOPMENT, FORMULATION AND ASSESSMENT OF THE 
 COMBINATION DOSAGE FORM OF MPTA AND HCTZ 
 
6.1 INTRODUCTION 
The use of controlled release systems for optimization of drug therapy has increased substantially 
in recent years. Consequently, methods to control release have become more diverse and efficient 
to meet the challenges of drug delivery. Whilst matrix systems are still the most commonly used, 
membrane and hybrid systems are also being increasingly used. This chapter focuses on such 
systems and the applicability of these technologies for the further development of the matrix 
MPTA tablet core previously discussed in Chapter Three.  
 
This chapter also focuses on the formulation of a combination dosage form of MPTA and HCTZ. 
Fixed-ratio combination products are only deemed acceptable when the combination has a proven 
advantage over the single compounds administered separately in terms of therapeutic effect, 
FRPSOLDQFHVDIHW\FKHPLFDOUHOHYDQFHDQGRYHUDOOFRVW>@7KHFRPELQDWLRQRID -blocker and 
a diuretic into a single dosage form, has several advantages which include convenience to both the 
patient and physician, simplified drug dosing regimen and improved patient compliance, reduction 
of adverse effects and potentiation of the anti-hypertensive effects of the two drugs used in 
combination [242]. As discussed in § 1.3, the combination of MPTA and HCTZ into a single 
dosage form is beneficial as the two drugs exhibit a synergistic or additive blood pressure lowering 
effect as it was found that a combination of the two lowered blood more effectively than increased 
doses of either drug individually [62-69,243]. Furthermore, a combination of these drugs is 
EHQHILFLDODVWKHGLXUHWLFDFWVWRGHFUHDVHWKHVRGLXPDQGZDWHUUHWHQWLRQFDXVHGE\WKH -blockers, 
ZKHUHDVWKH -blockers blunt the increase in plasma renin levels caused by the diuretic [243]. The 
increase in renin levels in especially advantageous in the South African context, as the majority of 
hypertensives are either black or elderly patients with low renin levels and are therefore poorly 
UHVSRQVLYHWRWUHDWPHQWZLWK -blockers, such as metoprolol, only.  
 
A dose of 100mg daily was selected for the metoprolol component of the combination dosage 
form, as the dose has been found to be effective in controlling blood pressure when used in a once 
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daily controlled release dosage form [59,60]. HCTZ exhibits dose-dependent blood pressure 
reduction that decreases with higher doses. A dose of 25 mg daily has been found to be as effective 
as higher doses, however, it has also been reported that lower doses of 6.25mg and 12.5mg daily 
were capable of achieving adequate blood pressure reduction without the adverse metabolic effects 
of HCTZ that may counteract the beneficial cardiovascular effects of the drug, as observed with 
higher doses [243]. Consequently, a dose of 12.5mg of HCTZ was selected for the combination 
dosage form to be developed. 
 
6.2 MEMBRANE SYSTEMS 
Membrane systems (§ 3.1.3) consist of a rigid membrane surrounding a drug-containing core, and 
drug release from these systems may be controlled either by solution diffusion, osmotic pumping 
or dissolution of the membrane itself.  
 
6.2.1 Solution diffusion 
This mechanism of drug release is characteristic to most systems where the drug core is surrounded 
by a rate-controlling membrane [117,138]. It is characterized by drug dissolution at one interface 
of the membrane and then diffusion down a concentration gradient into the external medium. 
Fick’s first law of diffusion, as described in Equation 6.1, describes diffusion through a membrane 
[117, 244] and the process of diffusion through the membrane is illustrated in Figure 6.1 [117,244]. 
 
J = -D  &    Equation 6.1 
               [ 
 
where, 
J = flux/ amount of drug moving through a unit cross-sectional area of membrane 
per unit time 
D = diffusion coefficient of the drug (incorporated partition coefficient between drug and 
membrane 
C = drug concentration in the reservoir (Ci) 
x = the perpendicular distance traveled /thickness of the membrane ( 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Figure 6.1: Schematic representation of drug diffusion through a membrane  
 
At steady state, Equation 6.1 can be integrated to Equation 6.2, which is the more common form of 
Fick’s first law when a water insoluble membrane is used to control release of a drug.  
               
          dM   =  ADK¨&                          Equation 6.2                 
           dt                
 
where,  
A = area 
D = diffusion coefficient 
K = partition coefficient of drug into the membrane 
 GLIIXVLRQSDWKOHQJWKPHPEUDQHWKLFNQHVV 
¨& FRQFHQWUDWLRQJUDGLHQWDFURVVWKHPHPEUDQH&L-Co) 
 
Zero order release kinetics are a characteristic of these systems, however a change in any of the 
variables shown in Equation 6.2 may result in non-zero order kinetics prevailing. 
                                                                                        
When a partially soluble membrane or a combination of water insoluble and soluble polymers are 
used, the water soluble components of the membrane dissolves, creating pores or channels through 
which drug can diffuse from the dosage form. Consequently, overall drug diffusion occurs through 
both the pores and the membrane itself [244]. The differences between drug diffusion through 
insoluble and partially soluble membranes is graphically depicted in Figure 6.2. 
Flux 
Drug Core 
Concentrated 
solution 
External medium 
Dilute solution 
Ci 
Co 
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Figure 6.2: Drug diffusion through an insoluble (A) and partially soluble (B) membrane 
 
6.2.2 Dissolution control 
Drug release may be dissolution controlled in systems where the drug is surrounded by a 
membrane, which is itself dissolved or eroded over time [244]. In this instance, drug release is 
dependent on the rate of membrane erosion and dissolution and a constant rate of erosion will 
result in zero order release kinetics. The rate of release may therefore be altered by increasing 
membrane thickness or by layering drug and coating as is the case for repeat action dosage forms 
[244,245]. 
 
6.2.3 Osmotic Pumping 
Osmotic systems may be one of two types. The first type is known as the elementary osmotic pump 
and is schematically represented in Figure 6.3.  
 
This technology consists of a semi-permeable membrane that surrounds a particle, tablet or drug 
solution that provides a constant reservoir volume [117,244]. An osmotic pressure difference is 
created between the inside and outside of the tablet, and the drug solution is ‘pumped’ out through 
an orifice in the membrane after water is taken in through the semi-permeable membrane [244]. 
The orifice is usually a laser-drilled hole. The core contains excess drug and/or an osmotic agent, 
and exhibits a declining release rate as the concentration of drug in the reservoir falls below 
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saturation [117], usually after about 60-80% of the drug has been released.  The osmotic pressure 
differential and the membrane regulate the osmotic water permeation, such that volume of drug 
solution delivered through the orifice is equivalent to water uptake of the membrane in a certain 
time interval. This is a simple system, which releases drug molecules by a zero-order mechanism 
irrespective of pH, however this elementary osmotic pump system is not well suited for water 
insoluble drugs [246,247].  
 
 
 
 
 
 
 
 
 
 
              Water entering the dosage form across a semi-permeable membrane 
 
 Drug solution leaving through a laser-generated orifice at a steady rate  
 
Figure 6.3: A schematic of an elementary osmotic pump system  
 
As the delivery rate of the drug from the osmotic pump depends largely on the solubility of the 
drug, the inclusion of water-insoluble drugs into an osmotic pump system may require co-
compression of the drug with excipients, such as swellable polymers, which can modulate the 
solubility of the drug within the core [248]. Multi-chamber osmotic pumps have also been 
developed for delivery of water-insoluble drugs over extended periods. The most commonly used 
of these is the push/pull design that consists of two compartments, one containing the drug and the 
other containing an osmotic agent in an expandable chamber [247,248].  In these systems, depicted 
in Figure 6.4, the upper compartment contains the drug and is connected to the outside 
environment via a delivery orifice. The polymeric osmotic agent is contained in the lower 
compartment has no direct contact with the outside environment. Upon contact with aqueous 
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media, both layers imbibe water, however the polymeric layer swells and pushes into the drug 
chamber and drug release through the orifice is effected [248,249]. 
 
 
 
 
 
   
  
 
 
 
 
 
 
      Water entering the dosage form across a semi-permeable membrane 
 
         Drug solution leaving through a laser-generated orifice at a steady rate 
  
 
Figure 6.4: A schematic of a push/pull osmotic system before and after water imbibition 
 
6.3 HYBRID SYSTEMS AND MULTIPLE-UNIT DOSAGE FORMS 
Hybrid systems are usually combinations of membrane and matrix systems and may occur either as 
single or multiple-unit dosage forms [117]. Drug release from these systems may therefore occur 
via a combination of mechanisms as described for matrix, membrane and perhaps even osmotic 
systems. 
 
Multiple-unit dosage forms 
These dosage forms are particularly advantageous as there is a lower risk of spontaneous drug 
release than from single units and there is a more reproducible dispersion of units throughout the 
GIT is prevalent, possibly lowering intra- and inter-subject variability [250]. Multi-unit systems 
typically comprise are typically comprised of microspheres in hard gelatin capsules, however 
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newer systems include microspheres within matrix tablets [251], matrix pellets [252] and coated 
pellets [245], and coated pellets incorporated into divisible tablets [253]. 
 
6.4 TABLET COATING FOR CONTROLLED RELEASE DOSAGE FORM 
PRODUCTION  
 
6.4.1 Introduction 
The process of tablet and pellet coating has become increasingly utilized for a variety of purposes 
including protection of active ingredients from environmental factors, taste masking and as 
functional coats [254-257].  A coat may also impart resistance to abrasion and may be used to 
promote easy identification of a product [254]. Functional coats are of particular interest as these 
may be used to impart enteric or controlled release properties to a dosage form. Enteric coating is 
used to prevent drug release in the acidic environment of the stomach in order for release to occur 
once the dosage form has passed into the small intestine in which the pH is alkaline [254,255].  
 
Three types of coating processes are commonly used for tablet dosage forms. The use of sugar 
coating, which is a panning technique, has decreased substantially and as a result, film coating has 
become increasingly used [254,256]. Compression coating may be utilized for highly water-
sensitive drugs or to separate materials where chemical incompatibilities are likely to occur [254].  
 
6.4.2 Film Coating 
The coating technique of choice when considering the application of a coat to controlled release 
dosage forms is film coating. The obvious advantages include simplicity and automation of the 
process, as a single manipulation in the coating process is required as opposed to conventional 
sugar coating techniques. Furthermore, the possibility of moisture exclusion in the case of water-
sensitive drugs and the ability to exhibit distinctive markings, are other distinct advantages of film 
coating. A number of polymeric materials have been developed and are available for application to 
dosage forms to achieve membrane control of drug release [255,256]. More recently, film coating 
materials have been used for application to granules, pellets and powders that are then incorporated 
into capsules, suspensions or tablets as a multiparticulate or hybrid system for controlling release 
of the active pharmaceutical ingredient [257]. Film coating materials have been used in the 
preparation and manufacture of osmotic systems, as described in § 6.2.1.3. Drug release from 
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membrane systems occurs via diffusion across the membrane, where the drug may diffuse through 
the membrane itself or through pores created in the membrane as depicted in Figure 6.2. 
 
6.4.2.1 Film coating polymers  
A number of synthetic polymeric materials, including cellulose derivatives, are now available for 
film coating [254,257]. These are selected on the basis of their low toxicity, solubility 
characteristics in-vivo, and their ability to form non-tacky mechanically strong coats that are 
resistant heat, light and moisture [254,257]. These types of polymers used for enteric coats include 
cellulose acetate phthalate and the polymethacrylates [254,257]. The Eudragits® [258,259], in 
particular methacrylic acid copolymers [260,261] and cellulose ester derivatives such as cellulose 
acetate phthalate [262] may also be used for their enteric functionality. 
 
Polymeric materials that are used for controlled release dosage forms include the cellulosics such 
as HPMC [263] and ethylcellulose [263,264] and the acrylics such as the Eudragits® [263]. Water-
soluble polymers however, are generally not well suited for controlling drug release [265]. The 
most predominantly used for controlled release coatings therefore include ethylcellulose or the 
polymethacrylates [265]. These polymers may be used individually or in combination with other 
polymers [258,266] with or without plasticisers [254]. As the use of organic solvents has decreased 
for environmental and safety reasons, consequently, latex or pseudolatex technologies have been 
developed and allow for such polymers to be dispersed in aqueous vehicles [267,268]. Psuedolatex 
products which are available include Aquacoat®, Surelease® and the Eudragits® [263,264]. 
 
6.4.2.2 Film coating plasticisers 
The use of plasticisers to modify the physical properties of the film-forming polymers 
[254,257,269], such as reduction of the minimum film formation temperature to below the coating 
temperature [267], is well known. Film properties such as permeability, solubility, workability and 
flexibility may be optimized [254,257,269, 270]. The choice of plasticiser is dependent on the 
polymer used and on the desired drug release profile. Commonly used plasticisers include the 
polyols, PEG’s, fixed oils such as oleic acid and organic esters such as triethyl citrate (TEC), 
acetyltriethyl citrate and dibutyl sebacate (DBS) [270]. Plasticisers are generally required for 
pseudolatex deformation to improve film coalesence, where an increase in plasticiser content 
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results in a decreased drug release in most cases [271]. 
 
6.4.2.3 The Coating Process and Apparatus  
The coating process is characterized by formation of droplets of the coating solution, which then 
come into contact with the core to be coated. The droplets spread along the surface of the core and 
coalescence of the droplets then occurs. The drying conditions must then allow for solvent 
evaporation, leaving a thin film of polymer around the core [254,272]. The coating layer is not 
applied in a single step but requires the dosage form to pass through the coating zone several times 
for a complete film to form.  
 
Film coating may be carried out in a coating pan or in a fluidized bed system [254,257], the 
fluidized system being the preferred technique for coating of small units. The principle of the 
fluidized bed system is that tablets are suspended in an upward stream of air that is moving at a 
rate that is great enough to set the tablets in motion so that they are not in contact with one another 
[257]. The coating solution is introduced onto the tablets by means of a spray atomizer located at 
the base of the coating chamber, and cores are then carried away from the spray area and dried by 
the fluidized air [257].  
 
Various types of fluidized bed systems may be used. These may exhibit incipient or smooth 
fluidization, bubbling, slugging or spouting fluidization. The fundamental difference between these 
systems is the difference in airflow in each region of the bed. Incipient fluidization refers to that 
point at which the bed just becomes fluidized and the system cannot be utilized in this state of 
fluidization. Bubbling fluidization beds provide random mixing of particles and efficient rates of 
evaporation and may be used to achieve good quality films. The spouting bed in which the air 
forms a single opening, through which particles flow and then fall out of, is more commonly used 
and is the bed-type used in the Wurster coating process [272].   
 
Coating or granulation solutions may be introduced by one of three inserts, which may be selected 
based on the cores that are to be coated. Each of these differs in terms of the ultimate spray patterns 
achieved. In top spray systems, the nozzle for spraying of coating/granulating solutions is located 
at the top of the chamber. This is the method of choice for wet or spray granulation [273], however 
it is not suited for sustained release coatings as the droplet distance traveled cannot be controlled 
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due to random fluidization pattern [272]. However, this method may also be used for hot-melt 
coating with PEG’s or waxes [274].  
 
Nozzles may also be fixed tangentially within the bed. This insert is comprised of two nozzles that 
may be used to perform different operations such that one nozzle may be used to spray the powder 
into the chamber and the other to deliver the coating/granulation liquid. A tangential insert may be 
used for coating, granulation, pellet formation and drug loading onto non-pareil beads [272]. 
However, the use of such an insert may be undesirable in the coating process due to the potential 
for strong mechanical forces, which may cause damage and abrasion to the coated cores [273]. 
 
The Wurster or bottom spray process is applicable to beads, pellet, particle and powder coating 
[272], and more recently for processes such as thermosensitive microcapsule preparation [275]. In 
addition small tablet cores can be coated. The components of the Wurster system are illustrated in 
a schematic diagram, Figure 6.5. The system is comprised of a coating chamber inside which is a 
partition (Wurster column), which has a diameter that is approximately half the diameter of the 
base of the chamber. The spray nozzle is located at the bottom of the chamber and is surrounded by 
a nozzle surround, which keeps the particles from entering this region, as it is here that droplet 
density is the highest and contact at this region may lead to uneven film formation or excessive 
particle deposition at certain points close to the spray nozzle. An air distribution plate and a fine 
screen are located at the bottom of the Wurster insert [272]. There is a region of high volume and 
air velocity below the column, which causes the particle to move upwards through the spray zone. 
As the particles enter a region of lower velocity outside the column, they fall back to the bottom of 
the column and are simultaneously dried. Particles may then re-enter the spray zone and the 
process is repeated [272,276]. 
 
The Wurster process is considered advantageous as both small and large particles can be uniformly 
coated [276], more rapid drying rates are achieved and accurate fluid pumping and efficient 
methods for heating large volumes of air are achieved [277]. A Strea-1 fluid bed drier with a 
wurster insert was used for coating tablets in our laboratory. 
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Figure 6.5: Schematic of a Wurster coating apparatus 
 
6.4.2.4 Variables affecting the coating process 
In terms of controlled release dosage forms, film coating must produce a uniform and coherent film 
that is stable on storage [278]. It is therefore of vital importance that the coating process is 
optimized to ensure the integrity of the films that are produced. The coating process may be 
affected by a number of variables, which may be categorized into process, and product variables. 
With respect to the product, substrate particle size, shape, porosity, density and friability are 
important considerations [272]. 
 
Certain process variables that must be considered are discussed in further detail below. The volume 
of the fluidization air affects the velocity and fluidization pattern of all particles within the coating 
chamber and must therefore be consistent between different batches that are coated [272]. Poor 
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fluidization of the tablet bed results in poor movement of the cores through the spray zone and 
therefore inconsistent and a non-uniform coat thickness may result [278]. Therefore, the 
configuration of the air distribution plate is one of the critical process considerations. 
 
The polymer and the type of coating solution used can also influence the fluidization air 
temperature, and therefore selection of the appropriate fluidization air temperatures must be 
selected upon consideration of these factors. For aqueous-based coating systems, a low temperature 
may result in fluctuating drying capacity with seasonal changes  [272]. The air temperature affects 
the drying capacity of the system and consequently impacts on the drying time [269]. Although the 
fluidization air temperature can be manipulated, temperature of the product bed and exhaust air 
must also be monitored. Differences in substrate and film expansion and contraction during the 
heating and cooling phases of the coating process may result in internal stresses within the film, 
which may lead to cracking, edge splitting and peeling [279]. The selection of a column of 
appropriate height in relation to the air distribution plate must be considered as must the distance 
between the plate and the column [280]. The selection of appropriate column height and air 
distribution plate affects particle fluidization [273]. 
 
Excessive spray rates may result in conditions such as film picking [263,278], which may also be a 
function of under-drying. Conversely rapid drying may result in an orange-peel effect in which the 
resultant coat has a rough appearance [263]. The spray rate must be selected based on 
consideration of the tackiness of the coat being applied, the speed at which particles travel through 
the coating zone and the capacity of air to remove the carrier solvent being used [272].  
 
The viscosity of the coating solution must be a considered as solutions with a very high viscosity 
may result in a large droplet size resulting in low surface area for evaporation leading to poor film 
formation, whilst low viscosity solutions will have the opposite effect [281]. In contrast, coating 
solutions containing high levels of HPMC as the fixing agent can lead to agglomeration of droplets 
due to increased viscosity of the coating solution [282]. 
 
Humidity may affect drying of both aqueous and organic coating systems. In cases where low 
temperature and high humidity are used for aqueous-based systems, lower spray rates may be 
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required [272], whereas for organic systems increases in humidity may decrease air temperature 
resulting in condensation of the solvent on the substrate surface [272], which results in poor film 
formation. 
 
6.5 DESIGN OF A COMBINATION DOSAGE FORM 
6.5.1. PROPSED DESIGN 
The matrix tablet core developed for MPTA (Table 3.8) was found to be capable of retarding drug 
release over an extended period, however the large initial release observed in the first two hours 
would probably lead to 100% drug release in less than 24 hours. Furthermore, HCTZ could not be 
incorporated directly into the formulation, as the polymeric matrix would retard its release. The 
option of dispersing the HCTZ in a water-soluble coating, which would rapidly dissolve to release 
drug, was excluded due to the rapid hydrolysis of HCTZ in aqueous solution. A multi-unit hybrid 
formulation that would involve the compression of the matrix formulation into mini-tablets was 
considered. To achieve zero-order release the mini-tablets could be coated to varying levels to, and 
subsequently incorporated into a capsule. HCTZ could then be included as a single mini-tablet or 
loose powder into the capsule, an approach that would minimize potential incompatibility 
problems between the two drug components, as identified in § 3.2.2.1. 
 
6.5.2 COMPRESSION AND ASSESSMENT OF MINI-TABLETS 
6.5.2.1 Materials and Methods 
The mini-tablets were manufactured as per the method described in § 3.2.3.2, utilizing the 
formulation described in Table 3.8. Granules were screened through the smaller mesh size both 
prior to and after drying. The tablets were compressed on a Manesty F3 single punch press, using a 
3mm die and biconcave punches. The tablets were compressed to a target hardness of 7-8kp and 
weight of 120mg such that each tablet would be equivalent to approximately 16.67mg MPTA. 
Therefore six tablets could be included into a capsule to achieve 100mg overall MPTA load and 
this would represent one dosage unit.  
 
6.5.2.2 Evaluation of Mini-tablets 
The mini-tablets resembled the larger tablets in appearance. Batch manufacturing records for these 
tablets are included in Appendix II. The resultant hardness ranged from 6.80 –8.50kp for all 
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batches manufactured. Friability was less than 1% for all batches, indicating the suitability of the 
tablets for a coating procedure. Highly friable tablets were not desirable due to the abrasive nature 
of the coating procedure in a fluidized bed system. Weight variation was also found to be minimal. 
Ten dosage units, which consisted of six mini-tablets per unit, from batches M00110601M and 
M00020901M were assessed for uniformity of content using the method described in § 3.2.3.2. 
Batch M00020901M contained 98.35mg of drug per dosage unit and therefore the batch was 
accepted for uniformity of content as the amount of drug determined represented 105% of the 
theoretical amount. Batch M00110601 contained 90.54% of the theoretical amount, however it was 
used for further work and the cumulative percentages of drug released were calculated according to 
average values obtained from content uniformity tests. Release profiles for three batches of mini-
tablets that were manufactured using the same formulation, are shown in Figure 6.6. The profiles 
are characterized by rapid initial release such that almost the entire amount of drug was released 
within 6 hours and f1 and f2 values (Table 6.1) indicate that all batches were similar to each other 
with respect to their release characteristics.  
 
Table 6.1: f1 and f2 comparison between batches of mini-tablets 
Comparison f1 f2 
M00200910M vs M00110601M 
M00110601M vs M00050601M 
M00200910M vs M00050601M 
9.8 
7.9 
13.1 
55.4 
62.0 
50.6 
 
When compared to the release profiles for larger tablets (Figure 6.7) which were manufactured 
using the same powder blend as for the mini-tablets, release from the mini-tablets was significantly 
more rapid, and the difference between the release profile was significant, yielding f1 and f2 values 
(Table 6.2) which were not within the limits for acceptance of similarity between batches. Initial 
release from the uncoated mini-tablets was much greater than from the larger tablet cores, and 
approximately 65% of the drug was released within the first two hours of dissolution from the 
small tablets, which were not contained within a gelatin capsule. The increase in release rate may 
be a function of the larger surface area available for drug release. Murakami et al also reported that 
an increase in the surface area available for drug dissolution resulted in increased release of 
theophylline from matrix tablets, where surface area had the largest effect on drug dissolution 
when compared to the effects of tablet weight and drug loading [283]. 
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Figure 6.6: Release profiles of three batches of mini-tablets manufactured using  
the same formula (n=6) 
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Figure 6.7: Release profiles of large matrix tablets and mini-tablets enclosed in a capsule and 
without a capsule (n=6) 
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Table 6.2: f1 and f2 comparisons of large tablets and mini-tablets with/without a capsule 
Comparison f1 f2 
Large tablets vs mini-tabs (no capsule) 
Mini-tabs (capsule) vs mini-tabs (no capsule) 
Large tablets vs mini-tabs (capsule) 
20.81 
16.7 
12.6 
37.5 
45.2 
52.1 
 
Tablets were also enclosed in a size 00 capsule and in comparison to the profiles obtained for 
tablets tested without a capsule, drug release rate was decreased (Figure 6.7). f1 and f2 values 
(Table 6.2) indicate that there was no difference between the mini-tablets which were filled into a 
gelatin capsule and the larger matrix tablets. The capsule therefore had a significant retarding 
effect on the release from the mini-tablets. The capsule shell might have acted to prevent the initial 
removal of drug from the tablet surface before the formation of the gel layer. It may also be likely 
that upon dissolving, the gelatin acted to bind the small tablets together, as depicted in Figure 6.8 
C, resulting in a surface area that was smaller than for the tablets without the capsule, but that was 
comparable to the surface area of the larger tablet cores.  
 
The mechanism of release from the mini-tablets occurred by anomalous or first order diffusion, as 
indicated by the calculated n values of 0.73 and 0.55 for batches M00200910M and M00050601M, 
respectively. The n value for batch M00110601M could not be calculated as greater than 70% drug 
was released within 2 hours. This corresponded with the release from most batches of the large 
tablets assessed. It was interesting to note that the n value obtained for drug release from tablets 
included in a capsule was 0.42, which was closer to the value obtained for the final formulation of 
the large tablets selected. This indicates that there is also an initial rapid release portion followed 
by a slower release component after a certain time point. This pattern was also observed for 
metoclopramide release from a matrix tablet in which case the release was characterized by a 
biexponential model in which both the rapid initial phase and the slow phase were separately 
accounted for [225]. 
 
It was thought that the difference in the spatial arrangement of tablets within the dissolution vessel 
may have had an impact on the drug release profile, thus the release profiles resulting from the 
dissolution of tablets with different configurations, as depicted if Figure 6.8, were compared. It was 
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thought that the configuration of the tablets would alter the surface area of the dosage form 
available for drug release to occur, however the release of MPTA from the tablets tested in USP 
Apparatus II using 0.1M buffer with a pH of 7.2 was found to be similar as can be seen from the 
overlapping error bars at all points. Therefore, it was concluded that the orientation of tablets in 
this dissolution vessels did not have a significant impact on drug release rates. The orientation of 
tablets in USP Apparatus III could not be isolated as a result of the manner in which dissolution 
testing is conducted. However, in most cases tablets adopted the shape depicted in Figure 6.8C. 
However the small standard deviations and the close similarity obtained from six tablets in 
Apparatus II (Figure 6.9) may indicate that the orientation of the tablets also has minimal impact 
on drug release in this dissolution apparatus. 
 
 
 
 
 
 
 
 
 
 
Figure 6.8: Schematic representation of the orientation of mini-tablets in dissolution testing 
apparatus 
 
6.5.2.3 Conclusions 
The inclusion of six tablets with smaller diameter led to increased drug release especially during 
the first two hours of dissolution rate testing. The rate of release was considered to be too rapid for 
the production of a once-daily dosage form of HCTZ and MPTA and consequently a coating was 
considered necessary to further decrease the initial release of MPTA and to ensure that the release 
of the drug is sustained over the desired period. It has been reported that low tablet friability is 
more a prerequisite for coating than high tablet hardness [263]. Therefore the batches of tablets 
manufactured on the single punch press could be used in a coating process, as the friability was 
low for all batches.  
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Figure 6.9: The Effect of tablet orientation on drug release in Apparatus II (n=6) 
 
 
6.5.3 COATING OF MINI-TABLETS 
6.5.3.1 Materials and Methods 
To further retard the release of MPTA, a hydrophobic coating material was selected. Ethylcellulose 
and polymethacrylates are routinely used for sustained release film coating of tablets and 
ethylcellulose is particularly suited for use in oral dosage forms as it is odourless, tasteless and it 
possesses physical and chemical properties that make it ideal for film coating [263].  
 
Ethylcellulose was selected for the coating experiments and was used in the form of Surelease® 
grade E-7-19010 (Colorcon, Kent, UK). Surelease® is an aqueous dispersion of ethylcellulose 
which consists of approximately 25%w/v ethylcellulose dispersed in ammoniated water, oleic acid, 
and dibutyl sebacate (a plasticiser). Large amounts of plasticiser are generally required for 
ethylcellulose coating suspensions to enhance film formation and flexibility of the films [263]. No 
pigments or opacifiers were included, as they are known to influence film permeability and 
behaviour [263]. Surelease® was diluted to approximately 15%w/v solids with distilled water prior 
to use to facilitate spraying and droplet coalescence. An additional amount of plasticiser was added 
to the coating solution as 10%w/w of the solids component. Triethyl citrate (TEC) (Morflex, North 
Carolina, USA) was selected, as it has been reported to result in good film formation and resulted 
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in further retardation of release of psuedoephedrine sulfate which is also highly water-soluble, in 
comparison to drug release from films that did not contain plasticiser [284]. 
 
The coating was performed using an Aeromatic Strea-1 fluidised bed drier (Aeromatic AG, 
Switzerland) fitted with a Wurster insert 150mm in length. A peristaltic pump (MaterflexL/S, 
Cole-Palmer instruments, Illinois, USA) was used to deliver the coating suspension, and the 
coating parameters are summarized in Table 6.3.  
 
Initially the tablets were coated to varying levels and drug release from 6 dosage units was 
assessed at each of these levels. Tablets coated to different levels were then assessed in different 
combinations in order to achieve the desired release profile. 
 
Table 6.3: Coating Parameters 
Parameter  
Inlet air temperature 
Outlet air temperature 
Product bed temperature 
Atomizing air pressure 
Spray rate 
Drying temperature 
Drying time 
46-48°C 
40°C 
43-45°C 
20 psi 
1.25-1.30g/min 
42°C 
15 minutes 
 
 
6.5.3.2 Results and Discussions 
Dissolution studies were performed in USP Apparatus III on 6 dosage units. Batches 
M00110601M and M0020901M were coated to varying levels using 100g of tablets for each 
coating experiment. In the initial stages the tablets were coated to actual weight gains of 4.8%, 
6.8% and 10.4% and all three coating levels appeared to further retard drug release (Figure 6.10).  
 
The 4.83% coat displayed sustained drug release characteristics for approximately 10 hours after 
which point no further drug release occurred possibly as result 100% drug release from the dosage 
form. The coating was observed to split along the tablet edges, indicating that tablet swelling due 
to the HPMC in the matrix occurred predominantly in the axial direction. This may have also been 
a function of the coating process, which resulted in coats that may have been thinner at the tablet 
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edges than on the surface. Drug release occurred by Case II or zero order transport (n=1.0), which 
indicates that drug release was dependent on polymer relaxation and swelling characteristics. This 
may have been a function of the hydrophobic polymer used in the coating such that drug release 
was permitted only after relaxation and swelling of this polymer subsequent to the wetting of the 
coat.  
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Figure 6.10: MPTA release profiles from tablets coated to 4.83, 6.84 and 10.40% weight gain, 
respectively (n=6). 
 
 
Tablets coated to 6.84% resulted in an S-shaped dissolution profile, which was characterized by a 
lag of approximately two hours followed by rapid release up to 14-16 hours and a subsequent 
plateau. This coating level demonstrated a greater ability to control drug release over an extended 
period than the tablets coated to 4.83%. Drug was released by a Case II diffusion mechanism  
(n=1.0). 
 
Tablets coated to 10.4% released approximately 55% of the drug within the 22-hour dissolution 
period. Although a small percentage of drug was released before 14 hours, this was taken to be 
representative of a lag phase, and the initial release may have been due to MPTA particles lost 
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from the tablet surface during coating and which may have subsequently been incorporated into the 
coat. This initial release may also have been a function of imperfect coalescence of the coat or the 
presence of cracks or holes, which may have resulted in increased drug release. A scanning 
electron micrograph (SEM) showing a coat that split along the tablet surface reveals that apart 
from imperfections in the coat, coat splitting may have also contributed to greater initial release is 
shown in Figure 6.11.  
 
 
Figure 6.11: SEM of a coat split along the surface of a tablet after dissolution 
 
 
 
Figure 6.12: SEM of a membrane after dissolution testing, showing pores created 
in the membrane 
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Drug release occurred by a zero-order mechanism where n=1.31 indicating Super Case II transport. 
The resultant correlation coefficient (r2) 1.0 from a plot of drug release against time verified a zero-
order release mechanism. Drug release from all coated tablets, however, was characterized by the 
formation of pores within the coat throughout which the drug could diffuse into the dissolution 
medium. These pores are clearly visible in the membrane on the tablet surface, photographed 
following the dissolution test (Figure 6.12) 
 
In order to optimize drug release additional coating levels of 3.10%, 6.97%, 6.93% and 9.13% 
weight gain, respectively (Figure 6.13) were assessed in Apparatus III. As expected tablets coated 
to 3.10% showed faster release than tablets coated to all other levels, which was a function of the 
lower coating, hence allowing for the passage of more drug through the membrane. Furthermore, 
the more rapid swelling of the matrix, in tablets with a lower coating may have contributed to 
faster splitting of the coat, as was observed for all tablets coated to a low level, causing drug to be 
released both by diffusion across the membrane and through the matrix itself.  
 
The n values that were calculated using the Korsemeyer-Peppas equation (Table 6.4) indicate that 
drug was released from the coated tablets mainly by super case II transport and is therefore 
characterized by a zero-order mechanism, however the 9.13% coat resulted in drug release 
characterized primarily by Fickian diffusion. 
 
Table 6.4: Calculated n values for tablets coated to different levels 
Coating Level (% weight gain) n 
3.12  
6.93 
6.97 
9.13 
1.13 
1.94 
1.63 
0.50 
 
It was interesting to note that small increases in the applied coat had a significant retarding effect 
on drug release, as was observed with tablets coated to 6.84%, 6.93% and 6.97%, respectively. 
Tablets coated to 6.84% released almost 30% drug within 6 hours, whereas those coated to the 
higher levels showed little or no drug release. Tablets coated to 6.93% displayed a similar release 
profile to that of the 6.84% coat although a smaller amount of drug was released at all sample 
points in the dissolution test, whereas the 6.97% coat retarded drug release such that only about 
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60% drug was released within 22 hours. This indicates that the coating process is required to be 
highly efficient and accurate to achieve reproducible results, as minimal changes in the coating 
levels may have a significant impact on the resultant drug release profile.  
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Figure 6.13: Comparison of release profiles of mini-tablets coated to 3.10, 6.84, 6.93, 6.97 and 
9.13% weight gains, respectively and uncoated mini-tablets (n=6) 
 
The coating process in this system was found to be highly inefficient, as can be seen from the 
SEMs in Figures 6.14 and 6.15. Figure 6.14 shows areas where the coating solution agglomerated 
to form regions where the coat thickness will be greater, as well as tears or holes within the coat. 
Figure 6.15 clearly shows that the deposition of the coating solution was non-uniform resulting in 
areas where no coat was applied whilst the coating solution was concentrated in certain areas.   
 
A similar conclusion was made upon assessment of tablets coated to 9.13% and10.40% actual 
weight gain, where assessment of randomly chosen tablets yielded a lower rate of release from 
tablets with lower coating levels, such that tablets coated to 9.13% released 34% in 22 hours 
whereas tablets coated to 10.40% released an average of 56% in the same test period. Dissolution 
test results for tablets coated to both 9.13% and 10.42% weight gain had a characteristic non-or-
slow release profile in the early stages of the experiment, which may be representative of a lag 
phase. The drug release was further characterized by zero-order release after 14 hours had elapsed. 
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Figure 6.14: SEM of a coat showing agglomeration of the coating solution droplets 
 
 
 
 
 
 
Figure 6.15: SEM showing a non-uniform coat with holes and areas where over-spaying 
occurred 
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None of the coating levels assessed retarded drug release over the 24 hour period desired, therefore 
drug release rates from combinations of tablets coated to varying levels were also evaluated in 
order to achieve a zero-order release profile for MPTA over a 22 hour period. 
 
6.5.4 COMBINATIONS OF COATED MINI-TABLETS OF MPTA 
Six tablets coated to different levels were incorporated into a capsule to make up the sustained 
release MPTA portion of the dosage form. The capsules were manually filled with the desired 
combination of tablets. The various combinations that were tested are listed in Table 6.5. 
 
Table 6.5: List of combinations tested 
 
Combination  Number of tablets used per coating level (%weight gain) 
 Uncoated 3.10 4.83 6.84 6.93 6.97 9.13 10.42 
C1   2 2    2 
C2 2   2    2 
C3 1  1 2    2 
C4 1 1  2    2 
C5 1  1 3    1 
C6    3    3 
C7   2    2 2 
C8   2 2   2  
C9 2  1 1   2  
C10 1  1 2   2  
C11   2 1 3    
C12   2 2 2    
C13 1   2  3   
C14   2   4   
 
 
Combinations of the 4.83%, 6.84% and 10.40% coated tablets were initially assessed, and selection 
of the combinations were based on the profiles obtained for the coated tablets run individually. For 
example, it was thought that the 10-14 hour lag for the 10.40% tablets would be compensated for 
by tablets with a lower coating level and from which 100% of the drug would be released within 14 
hours. 
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In contrast to uncoated mini-tablets, the release profiles for the combinations displayed definite 
sustained release characteristics. Profiles for C1-C5 are shown in Figure 6.16.  
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Figure 6.16: Release profiles of combinations C1-C5 in Apparatus III (n=6) 
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Figure 6.17: Release profiles of combinations C6-C8 compared to the profile of C1 (n=6) 
 
 153 
The release from C1 was considered to be too rapid as 50% of the drug was released in 
approximately 4 hours. Combinations C2-C4 showed a more sustained release initially, however 
no drug was released between 10-14 hours after the start of the dissolution test. 
 
The release profile from combination C5 was more acceptable however, drug release did not occur 
via a zero order release mechanism. Furthermore, the profile was not comparable to the prototype 
batch for the large tablets cores (M011210) as indicated by the fit factor values listed in Table 6.6. 
Therefore this combination was not selected for further development, as it was hoped that a 
combination could be produced to release 50% and 100% drug within 8-12 and 24 hours, 
respectively.  
 
The release from combinations C6-C8 are depicted in Figure 6.17 and showed greater sustained 
release behaviour when compared to the previous combinations. However approximately 70% of 
the drug was released within 22 hours for each of these combinations. This indicated that although 
these combinations did not exhibit the desired release characteristics, the potential for further 
modification such that 100% drug was released within 22 hours, was feasible. 
The release from combinations C9 and C10 (Figure 6.18) were found to be similar to batch 
M011210 (Table 6.6), and were considered for incorporation into the final combination product. 
 
Table 6.6 Fit factors for the comparison of combinations C5, C9 and C10 with M011210 
Comparison f1 f2 
M011210 vs C5 
M011210 vs C9 
M101210 vs C10 
35.0 
7.9 
11.6 
33.7 
64.3 
54.0 
 
Resultant release profiles from combinations C11-C13 are depicted in Figure 6.19. In this 
combination tablets coated to 10.40% weight gain were replaced with tablets coated to either 
6.93% or 6.97%. This resulted in release profiles in which 50% MPTA was released between 6-7 
hours and almost all drug was released in 22 hours for combinations C11 and C12. Zero order 
release was observed for all these combinations and the correlation coefficients are included in 
Table 6.7. Zero order kinetics were not followed after 14 hours which may have a function of 
either too rapid initial release or slow, incomplete release from tablets with higher coating levels. 
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Figure 6.18: Comparison of drug release profiles of combinations C9 and C10 with 
combination C1 and the large matrix tablets (Batch M011210) (n=6) 
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Figure 6.19: Drug release profiles of combinations C11-C13 (n=6) 
 
Table 6.7: Correlation coefficients (r2) for drug release from combinations C11-C14 
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Combination r2 value Linearity Time period 
C11 
C12 
C13 
C14 
0.9919 
0.9846 
0.9978 
0.9946 
Time 
Time 
Time 
Time 
1-14 hrs 
0-14 hrs 
0-10 hrs 
0-22 hrs 
 
 
The release profiles for combination C14 is depicted in Figure 6.20 and showed zero order kinetics 
throughout the 22-hour test period, as was indicated by the correlation coefficient following linear 
regression analysis of the release profile. This combination was therefore chosen for the final 
product. In comparison to the uncoated mini-tablets and the larger matrix tablet, the rapid initial 
release observed with the uncoated tablets was reduced by the addition of a film coating. 
Furthermore, 85% drug was released in 22 hours, which would possibly allow for the remaining 
drug to be released within a 24-hour period.  
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Figure 6.20: Comparison of release profiles of combination C14, large matrix tablets (Batch 
M011210) and uncoated mini-tablets (Batch M00200901M) (n=6 for all batches) 
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6.5.5 INCLUSION OF THE IMMEDIATE RELEASE HCTZ COMPONENT 
Initially, the inclusion of HCTZ as a loose powder was considered. This method would be easier 
and would save time and resources, as the number of manipulations during the manufacturing 
process would be reduced, however the complexity of filling both tablets and a powder may be 
problematic for large-scale production. 
 
6.5.5.1. Materials and Method 
MCC was selected as the diluent for the powder blend as it would serve to enhance the flow 
properties of the mixture. The mixture was blended in a cube blender for 20 minutes at 20 rpm. 
Magnesium stearate was then incorporated as 0.5% of the mixture and the mixture was blended for 
a further 3 minutes. HCTZ and MCC were added in a ratio of 1:7 so that 100mg of this blend 
would include 12.5mg HCTZ, which is the desired dose. The release of HCTZ was assessed over a 
two-hour period in both USP Apparatus II and III. The powder blend was accurately weighed into 
a gelatin capsule containing the desired combination of 6 mini-tablets (C14). 
 
6.5.5.2 Results and Discussion 
HCTZ release in both Apparatus II and III was found to be within USP specified limits for an 
immediate release product and the profiles obtained are depicted in Figure 6.21. The USP states 
that not less than 60% of the dose label claim must be released within 60 minutes [73], however 
85-100% HCTZ was released within the first hour from all samples tested. This release was 
comparable with that observed for a commercial immediate release product tested in Apparatus II, 
as indicated by the overlapping error bars.  
 
Consequently, HCTZ inclusion into the dosage form was performed using this method. Herman et 
al found that a mixture of HCTZ and MCC for use in a sustained release pellet formulation 
resulted in slower release of HCTZ [285], however no sustained release effect was observed with 
the powder blend used. This may be a result of incorporation of the mixture as a loose powder in 
the dosage form as compared to the pellet formulation which undergoes a number of processes 
including granulation, extrusion and spheronisation, and more than likely resulted in a greater 
interaction and possible binding of the HCTZ, thus prolonging release. 
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Figure 6.21: Release profiles of HCTZ in from capsule in Apparatus II and II compared to 
an immediate release HCTZ product (n=6) 
 
 
6.6. CONCLUSIONS 
The combination dosage form developed consisted of six mini-tablets that were coated to two 
different coating levels (viz two tablets were coated to 4.83% and four tablets to 6.97%), and an 
immediate release HCTZ component that was included into the capsule as a powder blend. MPTA 
release from the dosage form was retarded a 22-hour period, whereas almost 100% of the HCTZ 
was released within the first hour (Figure 6.22).  
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Figure 6.22: Release profile of HCTZ and MPTA from the combination dosage form (n=6) 
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The release from the coated tablets occurred mainly via a zero order mechanism, as was expected 
for these coated tablets, suggesting that the application of a film coat resulted in an alteration of the 
mechanism of drug release from first order that was observed with the majority of the large matrix 
tablets and the uncoated mini-tablets, to a zero-order mechanism. This combination product would 
be useful for once daily dosing of MPTA and HCTZ. 
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CHAPTER SEVEN 
CONCLUSIONS 
 
In this study two sustained release dosage forms were developed for the treatment of chronic 
hypertension. A hydrophilic matrix system was used to produce a modified release MPTA tablet 
that could be used as a once daily dosage form, particularly for patients on long-WHUP -blocker 
therapy. The second dosage formed consisted of an immediate release HCTZ component, delivered 
in the form of a powder blend of the drug and MCC, and a sustained release MPTA component 
which was formulated as six mini matrix tablets coated to different levels, which were 
subsequently incorporated into a size 00 gelatin capsule. The combination dosage form would be 
particularly beneficial for hypertensive patients who are unresponsive to monotherapy. 
 
Dissolution testing of both the separate MPTA and combination dosage forms was performed in 
USP Apparatus III, which was found to be more discriminating than USP Apparatus II, and which 
was used as it is able to simulate the passage of the dosage form in-vivo, more closely. Samples 
were analyzed using a validated HPLC method that is described in Chapter Two.  
 
Modification of a sustained release matrix tablet formulation that was developed to sustain the 
release of psuedoephedrine sulfate [146], resulted in the effective retardation of MPTA release 
over the over a 22-hour dissolution test period. This matrix formulation was also successfully 
manipulated to produce mini-tablets, which were subsequently coated to appropriate levels to 
achieve zero order release of MPTA over an extended period. HCTZ was successfully incorporated 
into the capsule as a powder blend such that approximately 100% of this drug was released within 
the first hour of dissolution testing.  
 
The rate and mechanisms of drug release were found to be altered by formulation variables that 
include the amount of Surelease® added in the granulation process, drug load in the dosage form 
and the amount of HPMC included in the matrix. This indicated that drug release was not 
controlled entirely by the matrix composition itself, but via a combination of effects exerted by the 
hydrophobic ethylcellulose polymer in the granulation fluid and the hydrophilic HPMC polymer 
contained in the matrix.  
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Preformulation studies using DSC as a tool for identifying potential incompatibilities between the 
drug (MPTA) and tableting excipients, revealed that the potential for interaction of MPTA with 
magnesium stearate and dibasic calcium phosphate, existed and may subsequently result in issues 
with the stability of the dosage form on long term storage. Stability testing conducted over a three-
month period at ambient, intermediate and accelerated conditions indicated that drug release from 
the dosage form was altered after three months storage at conditions of extreme temperature and 
humidity (40°C/ 87% RH), however the drug appeared to be chemically stable as there was no loss 
in potency of the drug when stored under the extreme conditions of temperature and humidity for 
three months. Further manipulation of this formulation, by the addition of a coating, was therefore 
recommended to improve the shelf life of the product. It is possible that a 1-2% coat may be 
beneficial in minimizing the effects of environmental conditions on long term storage, that alter 
drug release from this formulation, and to further prevent the ‘burst’ release observed over the first 
two hours of the dissolution test period. 
 
The matrix dosage forms exhibit the potential for further optimization and development. 
It was identified that Surelease® contributed towards controlling the release of MPTA from the 
formulation and therefore further investigation of this variable is suggested. It was found that 
increasing the amount of granulating fluid resulted in slower drug release rates. Consequently the 
scope for the use of ethylcellulose as the rate-controlling polymer in this formulation exists. 
Increasing the amount of granulating fluid, was precluded for this formulation as the use of HPMC 
within the granules resulted in an unworkable mass following granulation with a corresponding 
low yield of granules from the granulation process. The exclusion of HPMC and the possible 
inclusion of ethylcellulose into the granules may be more effective in achieving sustained release 
characteristics from highly water-soluble drugs such as MPTA, and these suggestions are included 
as topics for further investigation. 
 
It has been widely reported that the drug to polymer ratio significantly impacts on drug release 
behaviour from a matrix system, consequently it was found that even small increases in the amount 
of matrix forming polymer (HPMC K100M) resulted in a significant decrease of drug release rates. 
However, further characterization of this variable may allow for the determination of an optimal 
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drug: polymer ratio for sustaining the release of MPTA from this formulation. This approach may 
enable the development of a system from which drug release is controlled entirely by the 
hydrophilic polymer, HPMC.  
 
Process variables, including the impact of granule drying time and compression force on drug 
release were evaluated. Shorter drying times (6 hours) resulted in faster drug release possibly due 
to the creation of more pores within the matrix as a result if residual moisture. In this case faster 
diffusion through the tablet was suspected. A granule drying time of 17 hours did not exhibit 
significant differences in release rates from drying times of 12 hours when incorporated into the 
tablet. It is likely that drying times greater than those assessed may also impact on drug release 
profiles, and should be investigated further. Compression force was varied to achieve tablets of 
different hardness, however similarity and difference factor values obtained from comparison of 
these batches were within the limits for acceptance, indicating that there was no significant 
differences between the drug release profiles of these batches. The evaluation of process variables 
is particularly important in the scale-up stages of product development and would require further 
investigation.  
 
The multiparticulate combination dosage form of HCTZ and MPTA resembled a hybrid system, in 
which a combination of matrix and membrane technologies was used to achieve zero order release 
of MPTA. The immediate release HCTZ component was incorporated into the gelatin capsule as a 
loose powder blend. Compression of the matrix formulation into smaller tablets (3.5mm diameter) 
such that six tablets contained an equivalent drug loading to that of the larger 100mg tablets 
(11.5mm diameter), resulted in drug release rates that were significantly faster from the smaller 
tablets. The use of a hydrophobic coat was found to retard drug release from the mini-tablets and 
an increase in the coating level resulted in a corresponding decrease in the rate of drug release from 
the tablets. Six mini-tablets coated to the same percentage weight gain did not provide the required 
sustained release characteristics over the 22-hour period of testing. The use of combinations of 
coated tablets resulted drug delivery profiles that were more closely represented of zero order 
release kinetics. Combination C14, containing tablets coated to 4.83% weight gain (2 tablets) and 
6.97% weight gain (4 tablets) resulted in linear drug release over 22 hours and linear regression 
analysis resulted in a r2 = 0.9946. This is an indication that drug release from the dosage form 
 162 
followed zero order kinetics.  
 
No difference in release between HCTZ included as a powder in the capsule and a commercially 
available immediate release tablet were observed. Thus, the combination, which consisted of six 
coated matrix tablets consisting of MPTA and a HCTZ powder blend enclosed within a gelatin 
capsule, was considered feasible for use as a once-daily combination dosage form for the treatment 
of hypertension and subsequently requires in vivo evaluation. 
 
The feasibility of the combination dosage for large scale manufacture may be compromised by the 
inclusion of both powder and tablet components into the capsule. Consequently, compression of 
the powder into a mini-tablet may also be necessary to facilitate capsule filling on a large scale. 
 
Characterization of the film coats may also be beneficial in determining the optimal coating levels 
to achieve zero order release over the 22-hour period. For this formulation, the coating solution 
contained 10% w/w triethyl citrate as a plasticiser. Plasticisers are known to alter drug release, and 
assessment of altering the type and content of the plasticiser, may be useful and may aid in 
identifying a single coating level that would retard MPTA release over the test period. Similarly, 
the incorporation of a channeling agent such as HPC or HPMC into the coating solutions may also 
be beneficial in this respect. It was also thought that a more facile dosage form could be produced 
by the addition of a second enteric coat onto the mini-tablets coated to 4.83% weight gain, where 3 
tablets would be coated with the enteric polymer such that bimodal drug release may be achieved. 
This may also eliminate some of the difficulties experienced with the coating process and is under 
further investigation.  
 
Stability testing of the combination dosage form is also necessary to evaluate the effectiveness of 
the coat in minimizing the impact of adverse environmental factors on drug release and to identify 
possible instabilities of the powder blend on long term storage and to determine whether the 
possible interaction between MPTA and HCTZ identified by DSC, is valid.  
 
It is evident that the formulation composition of both dosage forms was capable of sustaining the 
release of MPTA over a 22-hour period and may be used as once daily dosage forms for the 
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sustained release of MPTA alone or in combination with other drugs. The inclusion of HCTZ as a 
powder blend in the combination dosage form resulted in rapid release of the drug and may be 
beneficial in achieving a rapid reduction of blood pressure to within normal limits. Several 
recommendations for optimization of the formulation may provide alternative means of sustaining 
drug release via simple and economic processes and are currently being considered. 
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APPENDIX I: BATCH DATA FOR MATRIX TABLETS 
 
 
BATCH: M0022005 
 
Date of Manufacture: 20/05/00 
Press: Manesty B3B (Tableted 21/05/00) 
 Batch Size: 250g 
 
Composition (%) 
    Metoprolol tartrate   15 
    Methocel® K4M   10 
    Emcompress®    40  
    Emcocel® 90 M   35 
   Surelease®    0.28 gram/gram of granules    
   Methocel® K100M   15 
   Emcocel® 90M   7 
   Emcompress®    10 
   Magnesium stearate   1 
 
   
       
 Physical Tests :  
 
 
 Mean ± SD % RSD 
Weight (mg) 487± 7.18 1.47 
             
 Friability   passed 
 Weight before (20 tablets) 16.24g  
 Weight after 100 drops 16.22g 
 Percent lost   0.12 
 
  
Dissolution Profile (USP Apparatus II) 
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BATCH: M011508 
 
Date of Manufacture: 15/08/00 
Press: Manesty B3B (Tableted 16/08/01) 
 Batch Size: 400g 
 
Composition (%) 
    Metoprolol tartrate   15 
    Methocel® K4M   10 
    Emcompress®    40  
    Emcocel® 90 M   35 
   Surelease®    0.36 gram/gram of granules    
   Methocel® K100M   15 
   Emcocel® 90M   7 
   Emcompress®    10 
   Magnesium stearate   1 
 
   
       
 Physical Tests :  
 
 
 Mean ± SD % RSD 
Weight (mg) 516 ± 16.57 3.79 
Hardness (kp) 5.89 ± 0.79 13.66 
             
 Friability   passed 
 Weight before (20 tablets) 10.30g  
 Weight after 100 drops 10.27g 
 Percent lost   0.29 
 
 Dissolution Profile (USP Apparatus III) 
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BATCH: M012208 
 
Date of Manufacture: 22/08/00 
Press: Manesty B3B (Tableted 23/08/00) 
 Batch Size: 287.5g 
 
Composition (%) 
    Metoprolol tartrate   26.00 
    Methocel® K4M   8.69 
    Emcompress®    34.78  
    Emcocel® 90 M   30.43 
   Surelease®    0.18 gram/gram of granules    
   Methocel® K100M   15 
   Emcocel® 90M   7 
   Emcompress®    10 
   Magnesium stearate   1 
 
   
       
 Physical Tests :  
 
 
 Mean ± SD % RSD 
Weight (mg) 507.44 ± 12.48 2.46 
Hardness (kp) 10.04 ± 0.52 5.18 
             
 Friability   passed 
 Weight before (20 tablets) 10.21g   
 Weight after 100 drops 10.21g 
 Percent lost    0.00% 
 
 Dissolution Profile (Apparatus II and III) 
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BATCH: M013009 
 
Date of Manufacture: 30/09/00  
Press: Manesty B3B (Tableted 02/10/00) 
 Batch Size: 250g 
 Comments: Granules dried for 17 hours 
 
Composition (%) 
    Metoprolol tartrate   26 
    Methocel® K4M   8.7 
    Emcompress®    35  
    Emcocel® 90 M   30.5 
   Surelease®    0.19 gram/gram of granules    
   Methocel® K100M   15 
   Emcocel® 90M   7 
   Emcompress®    10 
   Magnesium stearate   1 
 
   
       
 Physical Tests :  
 
 
 Mean ± SD % RSD 
Weight (mg) 543 ± 7.33 1.35 
Hardness (kp) 10.81 ± 0.70 6.51 
             
 Friability   passed 
 Weight before (20 tablets) 10.86 
 Weight after 100 drops 10.84 
 Percent lost    0.18 
 
 Dissolution Profile 
 
 
 
 
 
 
 
 
 
 
 
 
BATCH: M023009 
 
Date of Manufacture: 30/09/00 (tabletted 03/10/00) 
M013009
0
20
40
60
80
100
120
0 5 10 15 20 25
Time (hours)
%
 R
el
ea
se
d
 
 168 
 BATCH: M023009 
 Date of manufacture: 30/09/00 
Press: Manesty B3B (Tableted 03/10/00) 
Batch Size: 250g 
 
Composition (%) 
    Metoprolol tartrate   30 
    Methocel® K4M   8.2 
    Emcompress®    32.8  
    Emcocel® 90 M   29 
   Surelease®    0.20 gram/gram of granules    
   Methocel® K100M   20 
   Emcocel® 90M   9.33 
   Emcompress®    13.33 
   Magnesium stearate   1.00 
 
   
       
 Physical Tests :  
 
 
 Mean ± SD % RSD 
Weight (mg) 490.5 ± 7.59 1.55 
Hardness (kp) 7.95 ± 0.43 5.44 
             
 Friability   passed 
 Weight before (20 tablets) 9.89 
 Weight after 100 drops 9.88 
 Percent lost   0.10 
 
 Dissolution Profile 
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BATCH: M011210 
 
Date of Manufacture: 12/10/00 
Press: Manesty B3B (Tableted 13/10/00) 
 Batch Size: 250g 
 
Composition (%) 
    Metoprolol tartrate   20 
    Methocel® K4M   9.4 
    Emcompress®    37.65  
    Emcocel® 90 M   33 
   Surelease®    0.19 gram/gram of granules    
   Methocel® K100M   20 
   Emcocel® 90M   7 
   Emcompress®    10 
   Magnesium stearate   1 
 
   
      
 Physical Tests :  
 
 
 Mean ± SD % RSD 
Weight (mg) 689.5 ± 12.34 1.79 
Hardness (kp) 15.43 ± 1.94 12.55 
             
 Friability   passed 
 Weight before (20 tablets) 13.79  
 Weight after 100 drops 13.78 
 Percent lost    0.07 
 Content Uniformity (n=10) = 96.45mg 
 
 Dissolution Profile 
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BATCH: M010711 
 
Date of Manufacture: 07/11/00 
Press: Manesty B3B 
 Batch Size: 200g 
 Comments: Capping occurred, Granules dried for 6 hours 
 
Composition (%) 
    Metoprolol tartrate   23 
    Methocel® K4M   9.1 
    Emcompress®    36.24  
    Emcocel® 90 M   31.70 
   Surelease®    0.24 gram/gram of granules    
   Methocel®  K100M   18 
   Emcocel® 90M   7 
   Emcompress®    10 
   Magnesium stearate   1 
 
   
       
 Physical Tests :  
 
 
 Mean ± SD % RSD 
Weight (mg) 578.00 ± 7.68 1.33 
Hardness (kp) 12.47 ± 3.37 27.02 
             
 Friability   passed 
 Weight before (20 tablets) 12.06g  
 Weight after 100 drops 12.05g 
 Percent lost   0.08% 
 
 Dissolution Profile 
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BATCH: M011711 
 
Date of Manufacture: 17/11/00  
Press: Manesty B3B (Tableted 10/11/00) 
 Batch Size: 275g 
 
Composition (%) 
    Metoprolol tartrate   26 
    Methocel® K4M   8.7 
    Emcompress®    34.8  
    Emcocel® 90 M   30.5 
   Surelease®    0.18 gram/gram of granules    
   Methocel® K100M   15 
   Emcocel® 90M   7 
   Emcompress®    10 
   Magnesium stearate   1 
 
   
       
 Physical Tests :  
 
 
 Mean ± SD % RSD 
Weight (mg) 540.5 7.39 1.37 
Hardness (kp) 10.56 ± 0.49 4.65 
             
 Friability   passed 
 Weight before (20 tablets) 10.76g 
 Weight after 100 drops 10.75g 
 Percent lost   0.09% 
 
 Dissolution Profile 
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BATCH: M021711 
 
Date of Manufacture: 17/11/00 
Press: Manesty B3B (Tableted 19/11/00) 
 Batch Size: 275g 
 
Composition (%) 
    Metoprolol tartrate   20 
    Methocel® K4M   9.41 
    Emcompress®    37.65  
    Emcocel® 90 M   32.94 
   Surelease®    0.21 gram/gram of granules    
   Methocel® K100M   20 
   Emcocel® 90M   7 
   Emcompress®    10 
   Magnesium stearate   1 
 
   
       
 Physical Tests :  
 
 
 Mean ± SD % RSD 
Weight (mg) 667.17 ± 14.53 2.18 
Hardness (kp) 15.73 ± 1.55 9.87 
             
 Friability   passed 
 Weight before (20 tablets) 13.25g 
 Weight after 100 drops 13.25g 
 Percent lost   0.00% 
 
 Dissolution Profile 
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BATCH: M001080301 
 
Date of Manufacture: 08/03/01  
Press: Manesty B3B (Tableted 13/03/01) 
 Batch Size: 200g 
 
Composition (%) 
    Metoprolol tartrate   20 
    Methocel® K4M   9.41 
    Emcompress®    37.65 
    Emcocel® 90 M   33 
   Surelease®    0.16 gram/gram of granules    
   Methocel® K100M   20 
   Emcocel® 90M   7 
   Emcompress®    10 
   Magnesium stearate   1 
 
   
       
 Physical Tests :  
 
 
 Mean ± SD % RSD 
Weight (mg) 670.27 ± 41.92 6.25 
Hardness (kp) 15.11 ± 1.40 9.26 
             
 Friability   passed 
 Weight before (20 tablets) 13.41g 
 Weight after 100 drops 13.41g 
 Percent lost   0.00% 
 
 Dissolution Profile 
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BATCH: M001080302 
 
Date of Manufacture: 08/03/03  
Press: Manesty B3B (Tableted 13/10/01) 
 Batch Size: 300g 
 
Composition (%) 
    Metoprolol tartrate   40 
    Methocel® K4M   7.1 
    Emcompress®    28.34  
    Emcocel® 90 M   24.70 
   Surelease®    0.25 gram/gram of granules    
   Methocel® K100M   20 
   Emcocel® 90M   7 
   Emcompress®    10 
   Magnesium stearate   1 
 
   
       
 Physical Tests :  
 
 
 Mean ± SD % RSD 
Weight (mg) 695.99 ± 15.13 2.17 
Hardness (kp) 12.90 ± 1.71 13.28 
             
 Friability   passed 
 Weight before (20 tablets) 13.82g 
 Weight after 100 drops 13.81g 
 Percent lost   0.07% 
 
 Dissolution Profile 
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 M001270501 
 
 Date of Manufacture: 27/05/01 
Press: Manesty B3B (Tableted 28/05/01) 
 Batch Size: 250g 
 
Composition (%) 
    Metoprolol tartrate   40 
    Methocel® K4M   10 
    Emcompress®    30  
    Emcocel® 90 M   20 
   Surelease®    0.21 gram/gram of granules    
   Methocel® K100M   20 
   Emcocel® 90M   7 
   Emcompress®    10 
   Magnesium stearate   1 
   
       
 Physical Tests :  
 
 
 Mean ± SD % RSD 
Weight (mg) 681.16 ± 35.17 5.16 
Hardness (kp) 13.67 ± 1.48 10.79 
             
 Friability   passed 
 Weight before (20 tablets) 13.57g  
 Weight after 100 drops 13.54g 
 Percent lost   0.22% 
 
 Content Uniformity: 178.34 ±  6.56 mg (200mg tablets) 
 
 Dissolution Profile 
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BATCH: M001270502 
 
Date of Manufacture: 27/05/01 
Press: Manesty B3B (Tableted 29/05/01) 
 Batch Size: 500g 
 
Composition (%) 
    Metoprolol tartrate   15 
    Methocel® K4M   10 
    Emcompress®    40  
    Emcocel® 90 M   35 
   Surelease®    0.18 gram/gram of granules    
   Methocel®  K100M   20 
   Emcocel® 90M   7 
   Emcompress®    10 
   Magnesium stearate   1 
 
   
      
 Physical Tests :  
 
 
 Mean ± SD % RSD 
Weight (mg) 544.78 ± 10.67 1.96 
Hardness (kp) 7.22 1.02 13.18 
             
 Friability   passed 
 Weight before (20 tablets) 10.79g  
 Weight after 100 drops 10.76g 
 Percent lost   0.28% 
  
Content Uniformity: 55.43 ± 4.19 mg (50mg tablets) 
  
Dissolution Profile 
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BATCH: M001270503 
 
Date of Manufacture: 27/05/01 
Press: Manesty B3B (Tableted 29/05/01) 
 Batch Size: 250g 
 
Composition (%) 
    Metoprolol tartrate   20 
    Methocel® K4M   10 
    Emcompress®    30  
    Emcocel® 90 M   40 
   Surelease®    0.26 gram/gram of granules    
   Methocel® K100M   20 
   Emcocel® 90M   7 
   Emcompress®    10 
   Magnesium stearate   1 
 
   
      
 Physical Tests :  
 
 
 Mean ± SD % RSD 
Weight (mg) 646.31 ± 22.09 3.42 
Hardness (kp) 15.02 ± 2.03 13.49 
             
 Friability   passed 
 Weight before (20 tablets) 11.82g 
 Weight after 100 drops 11.81g 
 Percent lost   0.085% 
  
Content Uniformity: 85.96 ± 5.40mg 
  
Dissolution Profile 
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BATCH: M001270504 
 
Date of Manufacture: 27/05/01 
Press: Manesty B3B (Tableted 28/05/01) 
 Batch Size: 1000g 
 Comments: Compressed to varying hardness 
 
Composition (%) 
    Metoprolol tartrate   20 
    Methocel® K4M   10 
    Emcompress®    37.5  
    Emcocel® 90 M   32.5 
   Surelease®    0.39gram/gram of granules    
   Methocel® K100M   20 
   Emcocel® 90M   7 
   Emcompress®    10 
   Magnesium stearate   1 
   
       
 Physical Tests :   
 Mean ± SD % RSD 
Weight (mg) 675.60 ± 10.15 1.50 
Hardness (kp) 7.29 ± 0.87 
10.55 ± 0.83 
17.94 ± 2.93 
20.04 ± 0.76 
11.93 
7.95 
16.13 
3.77 
            
  
Friability   passed 
 Weight before (20 tablets) 13.57g  
 Weight after 100 drops 13.55g 
 Percent lost   0.15% 
 
 Dissolution Profile (for tablets with hardness of 18.02 ± 2.93kp) 
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BATCH: M00050601 
 
Date of Manufacture: 05/06/01 
Press: Manesty B3B (Tableted on 05/06/01) 
 Batch Size: 250g 
Comments: Both wet and dry granules screened through 20-mesh screen on oscillating 
granulator 
 
Composition (%) 
    Metoprolol tartrate   20 
    Methocel® K4M   10 
    Emcompress®    37.5  
    Emcocel® 90 M   32.5 
   Surelease®    0.19 gram/gram of granules    
   Methocel® K100M   20 
   Emcocel® 90M   7 
   Emcompress®    10 
   Magnesium stearate   1 
   
       
 Physical Tests :  
 
 
 Mean ± SD % RSD 
Weight (mg) 649.20 ± 6.37 0.98 
Hardness (kp) 12.51 ± 1.10 8.80 
             
 Friability   passed 
 Weight before 20 tablets) 12.89g 
 Weight after 100 drops 12.88g 
 Percent lost   0.08% 
 
 Dissolution Profile 
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APPENDIX II: BATCH DATA FOR MINI-TABLETS 
 
 
BATCH: M00050601M 
 
Date of Manufacture: 05/06/01 
Press: Manesty F3 (Tableted on 06/06/01) 
 Granules manufactured: 300g 
 
Composition (%) 
    Metoprolol tartrate   20 
    Methocel® K4M   10 
    Emcompress®    37.5  
    Emcocel® 90 M   32.5 
   Surelease®    0.19 gram/gram of granules    
   Methocel® K100M   20 
   Emcocel® 90M   7 
   Emcompress®    10 
   Magnesium stearate   1 
   
       
 Physical Tests :  
 
 
 Mean ± SD % RSD 
Weight (mg) 106.27 ± 6.56 6.17 
Hardness (kp) 7.12 ± 0.81 12.14 
             
 Friability   passed 
 Weight before (40 tablets) 4.22g  
 Weight after 100 drops 4.21g 
 Percent lost   0.078% 
 
 Dissolution Profile 
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BATCH: M00110601M 
 
Date of Manufacture: 11/06/01 
Press: Manesty F3  (Tableted on 12/06/01) 
 Granules manufactured: 650g 
 
Composition (%) 
    Metoprolol tartrate   20 
    Methocel® K4M   10 
    Emcompress®    37.5  
    Emcocel® 90 M   32.5 
   Surelease®    0.20 gram/gram of granules    
   Methocel® K100M   20 
   Emcocel® 90M   7 
   Emcompress®    10 
   Magnesium stearate   1 
 
   
      
 Physical Tests :  
 
 
 Mean ± SD % RSD 
Weight (mg) 108.42 ± 3.04 2.80 
Hardness (kp) 6.82 ± 0.75 11.05 
             
 Friability   passed 
 Weight before (20 tablets) 2.09g 
 Weight after 100 drops 2.08g 
 Percent lost   0.48% 
 
 Content Uniformity: 90.54mg 
 
 Dissolution Profile 
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BATCH: M00200910M 
 
Date of Manufacture: 02/09/01 
Press: Manesty F3  (Tableted on 04/09/01) 
 Granules manufactured: 1250g 
 
Composition (%) 
    Metoprolol tartrate   20 
    Methocel® K4M   10 
    Emcompress®    37.5  
    Emcocel® 90 M   32.5 
   Surelease®    0.20 gram/gram of granules    
   Methocel® K100M   20 
   Emcocel® 90M   7 
   Emcompress®    10 
   Magnesium stearate   1 
 
   
      
 Physical Tests :  
 
 
 Mean ± SD % RSD 
Weight (mg) 121.58 ± 1.29 1.06 
Hardness (kp) 6.80 ± 0.71 10.39 
             
 Friability   passed 
 Weight before (20 tablets) 2.42g 
 Weight after 100 drops 2.41g 
 Percent lost   0.41% 
 
Content Uniformity: 98.35 mg (100mg) 
 
 Dissolution Profile 
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APPENDIX TIl 
BATCH PRODUCTION RECORDS 
Only one coating record is included for this batch. The records for the other batches and other 
coating levels are available on request. 
PHARMACEUTICS DEPARTMENT 
Faculty of Pharmacy, Rhodes University 
Grahamstown, 6140 
BATCH PRODUCTION RECORD 
Product name: Metoprolol tartrate granules 
Batch #: f'f\ 00 0..0 Oq \0 N\ 
Page 1 of S 
Batch size: 1250g 
MANUF ACTURING APPROVALS 
Batch record issued bY: __ -+~-Ir+-=;""---/,,----
Master record issued by: ___ w-=-___ --t:.,r-----
Date: o~!o9/ol 
Date: ~ 
183 
.\T I" 
,I 
i l.\!, I', 
I" i,I 
I\i 
II 
I 
\1 
II 
PHARMACEUTICS DEPARTMENT 
Faculty of Pharmacy, Rhodes Univenity 
Graharnstown, 6140 
BATCH PRODUcrlON RECORD 
Product name: Metoprolol tartrate granules 
Batch #: MOO2Q 0 '\'0 ~ 
Page 2 of 'l> 
Batch size: 1250g 
Quantity 
(w/w) 
20 
10 
37.5 
32.5 
9· S 
Component Name RM # 
MASTER FORMULA AND BATCH FORMULA 
LotN Amount! 
Batch 
Amount 
Dispensed 
Metoprolol tartrate RM000052 
(MPTA) 
505242 25000g 
Methocel K4M 
Emcompress 
Emcocel90M 
Surelease 
M0539 
486.75g 
406.25g 
RMOOOOIO IN500647 
PHAR.MACEUTICS DEPARTMENT 
Faculty of Pharmacy, Rhodes Univenity 
Graharnstown. 6140 
BATCH PRODUcrlON RECORD 
Dispensed By 
Product name: Metoprolol tartrate granules 
Batch #: MOO2ooq 10 "" 
Page 3 of ~ 
Batch size: 1250g 
EQUIPMENT VERIFICATION 
DescriPtion Type Verified By Confirme.d by 
Sieves #20 mesh r.J-I .~ 'W_ 
Scale Precisa 4000 (J ,.£L/ ...,- W 
Blender Kenwood Major i/"-V 1- J.t'" 
Pump Masterflex V U- 11~1l 
.I\i~!.1.g Ma.~terflex LS 14 }tIl --rW 
Granulator Erweka Oscillating U '.:r 1JW 
Oven I I 
184 
Checked by 
PHARMACEUTICS DEPARTMENT 
Faculty ofPbarmacy, Rhodes University 
Grahamstown. 6140 
BATCH PRODUCTION RECORD 
Product name: Metoprolol tartrate granules 
Batch#:· k\oO.;u,OG \(0 tv" 
Step 
I 
2 
3 
MANUFACTURING DIRECTIONS 
Procedure Weight Time 
Separately screen the following materials through a 20 
mesh screen. cc.: $"\ 
Metoprolol tartrate '~>'''''!j 
Methocel K4M ,at;oOj "':'51 
Emcompress ~'I"'j (%.:50' 
Emcocel90M ~:S'.,. 
Place the following materials in the Kenwood bowl 
4O"J'J 
Metoprolol tartrate 
,as''''' j 0/0:00 Methocel K4M ''-c ,o':l do'· ,:1 
Emcompress """,c'\j c:t: S'r 
Emcocel90M 
Blend the materials in step 2 for 2 minutes at low speed. 
1IO'·3j e..:S'," 
Time started: 0,,": ,~ 
Time completed: o~: II+' 
Total blending time: .. ""ft'*c.a 
Speed setting: 
PHARMACEUTICS DEPARTMENT 
Faculty of Pharmacy, Rhodes University 
Grahamstown. 6140 
BATCH PRODUCTION RECORD 
Product name: Metoprolol tartrate granules r\ 
Batch #. il+.~ N\"O~l.OO<'\IO N 
'(i) 
Step 
4 
5 
6 
MANUFACTURING DIRECTIONS 
Procedure 
Place the Surelease in a tared beaker and insert pump 
tubing. 
With the blender on low speed, add the Surelease at a 
pump rate of8 - 9 for a total time of 10 minutes. 
Time .,tarte':\' 0 9- ~ ,:; 
Time completed: oo:r.: ~ ':} 
Total time taken: II\' ~ 
Blender speed: t 
Pump setting: " 
Amount of Sure lease added: .2."10 ·"It 
Transfer the granules to the granulator and screen as 
follows, using 20 mesh screen and 100 rpm motor 
speed. 
Speed: 
<D "f~I'''.l'''_!'\.J..,c:.l 
G 'br~4''.I,pj 
.!""lC - w"':j t<llt.h JJ"'-/ 
185 ~{ ~ 
Page 4 of ~ 
Batch size: 1250g 
Date Done by 
0;1.-0'1-01 t 
ol.-oq -01 ;-
Oi1.00C)"..ol r 
".:1,.- 0,,\-01 #= 
00l"¢'l-Q1 r D)·oq ... Ol 
.a-o,\ ~ol J;, ~~-oq-Ol 
7J 
~"C'\-o' jJ 
Page 5 of ~ 
Batch size: 1250g 
Date Done By 
Checked by 
~ 
-rw 
'1Je./ 
1JlJ 
~ 
-riJ.J 
'"'f¥IJ 
--rUJ 
Checked By 
PHARMACEUTICS DEPARTMENT 
Faculty orPhannaey, Rhodes University 
Grahamstown. 6140 
BATCH PRODUCTION RECORD 
Product name: Metoprolol tartrate granules 
Batch #: Moo~q,o M 
Step 
7 
8 
MANUFACI'URING DIRECTIONS 
Procedure Weight Time 
Place the granules on weighing paper and dry in the 
oven at 60 degrees for 12 hours 
Time started: 0 , ~ &0 
Time completed: .tf. oO 
Total drying time: ra·$k,o,~ 
Oven temperature: ~ ·c 
Remove the dried granules from ~e oven, and 
rescreen using the oscillating granidator (20 mesh, 
speed~. s:o 1'"' ® 
Speed: $01 .... 
PHARMACEUTICS DEPARTMENT 
Faculty orPhannaey, Rhodes University 
Grahamstown. 6140 
BATCH PRODUCTION RECORD 
Product name: Metoprolol tartrate granules 
Batch #: /VIooQcc::q to N\ 
Step 
9 
10 
11 
MANUFACTURING DIRECTIONS 
Procedure Time 
Record the weight of acceptable granules obtained. 
Gross weight: I a 83 . 1I;j 
Tare weight: '''' 1:.01 j 
Net weight: '2.0~. sij 
Work out the percent yield as follows. 
Weight acceptable granules (AG): 
Other weight accounted for (describe): 
lI-\:.ao 
186 
Page60f ~ 
Batch size: 1250g 
Date Done by 
~ 
Page 70f 7i~ ® 
Batch size: 
Date Done By 
Checked by 
-ow 
""Q.LJ 
Checked By 
• 
-00 
-...l 
Product name: Metoprolol tartrate granules 
Batch #: t<\ (!)O~ 0.' 10 f..t\ 
Full Name (print) Signature 
..,-. W,<..p 
PHARMACEUTICS DEPARTMENT 
Faculty ofPhannacy, Rhodes University 
Grahamstown, 6140 
BATCH PRODUCTION RECORD 
Page 8 of '6 
Batch size: 1250g 
SIGNATURE AND INITIAL REFERENCE 
Initials Date 
01... - "-=t -0 I 
PHARMACEtrrICS DEPARTMENT 
Faculty or Phal'lllacy, Rhodes University 
~a~town.6140 
BATCH PRODUCTION RECORD 
Product name: Metoprolol tartrate tablets 
Batch #:' (ll\oo;;J.OOcliO "" 
Page I of G. 
Quantity Component Name 
(w/w) 
62 Metoprolol tartrate 
granules 
20 Methocel KIOOM 
10 Emcom ress 
7 Emcocel90M 
I Magnesium 
stearate 
RM# 
MASTER FORMULA AND BATCH FORMULA 
Lot # 
M0020901G 
M0539 
24K 
Amount! 
Batch 
Amount 
Dispensed 
PHARMACEtrrICS DEPARTMENT 
Faculty or Pharmacy, Rhodes University 
~aharnstown. 6140 
BATCH PRODUCTION RECORD 
Batch size: I !!II?> j . 
Dispensed By 
Product name: Metoprolol tartrate tablets 
Batch #: Moo:.l..<:.oq \0 "" 
Page 2 of G 
Batch size: I ~ I ~ j 
EQUIPMENT VERIFICATION 
Description Type Verified By Confirmed by 
Sieves #20 mesh, #44 mesh If' -TJ.A.J 
Scale Precisa 4000 V()-
-r:v-I 
Blender Cube blender(Erweka) ~ "1'JA.J 
Tablet press Manesty F3 V i--
./.!JJ 
1/ 
188 
Checked by 
Product name: Metoprolol tartrate tablets 
Batch #: .v\ c.o ~oo<\ 10 N\ 
PHARMACEUfICS DEPARTMENT 
Faculty of Pharmacy, Rhodes University 
Grahamstown.6140 
BATCH PRODUCTION RECORD 
MANUFACTURING DIRECTIONS 
Page 3 of (, 
Batch size: 'a' !3 
Step Procedure Weight Time Date Done by 
I Screen the following materials through a #20 mesh, 
Methocel KIOOM 
Emcompress 
Emcocel90M 
2 Place the following in the cube blender, 
Metoprolol tartrate granules 
Methocel KI 00 M 
Emcompress 
Emcocel90M 
3 Blend the materials in step 2 for 20 minutes at speed 50, 
Time started: \ 1 " :3 I 
Time completed: , , " SI , 
Total blending time: U1MJN 
Speed: '1''1 ~ SI 1''''' 
1"O'3~ ,,',.to 
'IS'I~ "~u 
""~j I. :;1:. 
'Ic:I ' ':J It::lt 
1'\0,\1'1 ,,: ~.3 
'1~'I"j II! loS 
""t) II:as 
PHARMACEUTICS DEPARTMENT 
Faculty ofPhannacy, Rhodes University 
Grahamstown. 6140 
BATCH PRODUCTION RECORD 
• ",'"'C"\.o' ~4:l 
0'10-0'1-0 , 
o .. ·Oq -0' 
o ...... ~-()I 
tJ*-o~·OI 
0", -oq-OI 
0 .... -oq -01 
Product name: Metoprolol tartrate tablets 
Batch #:(Y'po· ... ooer \ 0 "" 
Page 4 of G. 
Batch size: I,!, 13  
~1ANUFACTURING DIRECTIONS 
~ 
~ 
1; 
J:...., 
U 
Checked by 
"1J.A,I 
~ 
~ 
~ 
""WI 
-rJ,W 
~ 
Step Procedure Weight 
"I, ~~ 
Time 
1\ ','i'"I 
Date Done by Checked by 
4 Screen the ma nesium stearate usin a #44 mesh, 
5 Add the magnesium stearate to the blender and blend for 3 minutes at 
50 rpm, 
6 
7 
Time started: /1', s.a. 
Tillie COlllplc:lcJ, " " b t 
Total blending time: 3''''';-
Speed: 11-'1- $:1. '1 ..... 
Calculate the percent accountability and yield, 
Gross weight (blend): l"c "" r':;" ~j 
Tare weight: I(".l.~j 
Net weight: 1311j 
Other weight (Describe): o..:./~ 
,,~-O'\-ol IJv 
,,"'-0' '01 
PHARMACEl/TICS DEPARTMENT 
Faculty orPhannacy, Rhodes Univenity 
Grahamstown, 6140 
BATCH PRODUcrION RECORD 
Product name: Metoprolol tartrate tablets 
Batch 1#: N'looQJ!lo<'\ 10M 
Step 
8 
9 
10 
II 
MANUFACTURING DIRECTIONS 
Sample 4 tablets every Vminutes and check hardness and weight. 
Enter results on the in- rocess results sheet. 
Perform physical tests of hardness, friability and weight uniformity on the 
fmal batch. 
PHARMACEtmCS DEPARTMENT 
Faculty orPhannacy, Rhodes Univenity 
Grahamstown, 6140 
. BATCH PRODUCTION RECORD 
Product name: Metoprolol tartrate tablets 
Batch 1#: N\co~or"l, 'ON\ 
Step 
12 
13 
MANUFACTURING DIRECTIONS 
Procedure Time 
Record the weight of acceptable tablets obtained. 
Gross weight: ' -::I. "I' ~. 'S 
. iJ~O"~ Tare weight: CD 
Net weight: ~ "I 't~ ·o~ 
Work out the percent yield as follows. 
Weight acceptable tablets (AT): "'I'I'~ o():t.s 
Other weight accounted for (describe): .3 \·0 S"3 
Total weight accounted for (TW): "~'Ij 
Percent accountability = (TWI \J I • j ) x 100% = ~ ....... ~ % 
Percent 'eld = AGI I:\I!. x 100% = 'TOI·IJ % 
190 
Page 5 of " 
Batch size: \3'~~ 
Date Done by 
Q~-O' ~ 
Page 6 of " 
Batch size: ,a' a 3 
Date Done By 
Checked by 
-rw 
Checked By 
PHARMACEUTICS DEPARTMENT 
Faculty of Pharmacy, Rhodes University 
Grahamstown, 6140 
BATCH PRODUCTION RECORD 
Product name: Metoprolol tartrate tablets 
Batch#:' f{)(X)~q 10M Batch size: t 3\ ~ 
IN-PROCESS TABLETING REPORT 
Date Time Hardness C-4) Weight <"~tt) 
0+-09 -0\ ,It:o , '" . 0\ I~a-G 
..... 
o~ -0"1- 0\ s·sl ,9-a· s; 
.. ,.:t~ \'clO '?, 
,-02- I lOt \. I 
l't', ao "S"~ ,,'\ • 4' 
~.~'t 1\'" " 
':l-' '\t \Cl.o·~ 
1'\ go \~. It-
• 'i-! 3'T "·€,I ,a\-3 
,+.\~ 1~'1f 
~.~'t lilt·" 
"S'IO /Q\'O 
IS~OO s·g-\ 11-.~· $ 
"01 , a.\.g 
-:f-·as Io.S"q 
S -9\ lQQ· 5' 
IS',~, ::J'~'t- l'aO' :3 
~' Ilf ,Q\' \ 
s;.'\~ 10l.4- ., 
b'O~ \~Q-s 
IS;: *'t 't-tq I~I'O 
~·\O I~Q-S 
,S·Gl 1\ 1\' 8' 
',0\ 1~4-· t· 
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-PHARMACE1lTICS DEPARTMENT 
Faculty orPharmaC)', Rhodes Ualvenlty 
Grahamstown, 6140 . 
BATCH PRODUcnON RECORD 
Product name: Metoprolol tartrate tablets . 
Batch #: N\oo~o cHoM 
Pagelof 4 
Quantity Component Name RMII 
100g Metoprolol tartrate 
tablets 
lS%soln Surelease 
lOOlaw/w TEC 
MASTER FORMULA AND BATCH FORMULA 
Lot II Amount! Amount 
Batch Dispensed 
MOO2090IM lOOg 
,00' 0'::) 
PHARMACEUTICS DEPARTMENT 
Faculty orPhannaC)', Rhodes Uaivenity 
Grahamstown, 6140 
BATCHPRODUcnONRECORD 
Batch sim: \CO 5· 
Dispensed By 
Product name: Metoprolol tartrate tablets 
Batch II: M 00 ~OOq 10 N\ 
Page 2 of 'I-
Batch size: lo::J 
EQUIPMENT VERIFICATION 
Description Type Verified By Confirmed by 
Fluid bed drier Aeromatic Strea-I 11 -rUJ 
Scale ~c4t\~ v~ 
.'""Tl4 
Mixer c...1I. A \u,..,uI K "T:1.JJ 
Peristaltic pump Masterflex. LS 13 tubinlt (j j-J 
--rv.I 
Checked by 
~is,~tal ~,ermometer __ ._~ut>'<>_I'I ___ ._. ____ , ___ . __ 3L ,L..... ___ .. __ , __ ,_._~ __ . ___ . __ ._ 
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Product name: Metoprolol tartrate tablets 
Batch #: tt\ 00 Qpo'\l'N\ 
PHARMACEUI'ICS DEPARTMENT 
Faculty of Pbanaacy, Rhodes Uaivenity 
Orahamstown. 6140 . 
BATCH PRODUCTION RECORD 
~A~GD~cnONS 
Page 3 of 
Batch size: 
Step . Procedure Weight Time Date 
1 Place the tablets in the product container l(JO'o'a "10:1. ''+/rt/Clo 
2 Start the f1uidising air at a rated temperature of 60 degrees and 
allow the tablets to circulate for S minutes untU a product bed 
, temperature of 40 desrees is reached. 
Time started: .. 10 $ 
Time completed: " I -" 
Total time: ... ....n 
3 Begin spraying by turning on the pump at a speed setting of 1.0 
and ~g on the atomising air to a pressure of 20 psi. 
Pump speed: L. 1-1) 
Atomising air pressure: IDr.si. '.' 
Actual s ra rate: " 't ...... 
4 Spray the product until a theoretICal weight gain of S%. ICthe 
product becomes tacky and no lO~ger fluidises effectively, tum 
off'the pump and allow the tablets to circulate freely for 2-3 
minutes before recommencing spraying. Record product bed 
tom rature wei ht of Sureleasee and time of a uses. 
Product name: Metoprolol tartrate tablets 
Batch #: N\ CO :;l.CX)C\ ,0 M 
PHARMACEUTICS DEPARTMENT 
Faculty of Pharmacy, Rhodes Uaivenity 
Grahamstown,6140 
BATCH PRODUCTION RECORD 
MANUFACTURING DIRECTIONS 
\I \ 10 Ic.a. 
II ~ Iol .... ,,: ,0 
Page 4 of 't' 
Batch size: 'COj 
Done by Checked by 
dY -rw 
ck W 
<... so'lolJ - so...c· CI:I~ ) 
c.. S;'2. ~.~,. - 'I'IO'OClJ) 
Step Procedure Time Date Done By Checked By 
S Record the following parameters at 5 minute intervals on the in 
process record sheet. 
Inlet air temperature 
Outlet air ~perature 
Product temperature 
,,,,-0'1-01 t:: i"W Atomisins air eressure 
6 Allow the tablets to fluidise for a drying time of 20 minutes onee 
sl!ra:r:ina has fmished. '''I -(;1'0\ /J ~M, 
7 Record the weight of coated tablets obtained. 
Gross weight: ~~.''1'j 
Tare weight: ~~II.02j 
'4 -0 ... ·01 Net wei ht: 10 ... ·11' ... 
8 Work out the pereent weight as follows. 
Weight coated tablets (CT): 10 't.,'1 ,j 
Other weight accounted for (describe): -
Total weight accounted for (TW): 10"" b~ 
'to 8'3)'. Pereent weight gain - (TW - 1".,11/ ICIO~)X 100%= 
% 
9 Store eroduct in an airtight container. 193 ''t~''·OI ~ -o".j 
I II 
" 
i 
" I, 
I 
I 
,ii 
PHARMACEUTICS DEPARTMENT 
Faculty of Pharmacy, Rhodes University 
Grahamstown. 6140 
BATCH PRODUCTION RECORD 
Product name: Metoprolol tartrate tablets 
Batch #: ""oO~oCl\ \b N\ Batch size: , ,313"-..) 
IN-PROCESS COATING REPORT 
Time Inlet Air Outlet Air Product Atomising Air 
Temperature Temperature Temperature 
" ',\0 !:'.l c:.>c.. 4.).. °C 4-,"'(. :10 t'$~ 
II ~15 ,S;;:;l. "'c 4-~"c.... 4- 'l t ... I"p~, 
1/ 'p.(;) S,3.. Clc. 'r;:). .. c 4- "l"<- ;)..Op:.' 
1\', g £ ~1!Jc. .~."c.. 'r-f> "c I~ p..s.~' 
II : ':30 ~~t'.oC '1-')... ·L 4-S"'C. ..z.OP$l 
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r 
f, 
i 
~ <' , 
I 
PHARMACEUTICS DEPARTMENT 
Faculty of Pharmacy, Rhodes University 
Grahamstown, 6140 
BATCH PRODUCfION RECORD 
Product name: Hydrochlorothiazide powder blend 
Batch #:H02 Batch size: 200g 
MASTER FORMULA AND BATCH FORMULA 
Quantity Component Name RM# Lot # Amount! Amount 
(w/w) Batch Dispensed 
12.5 Hydrochlorothiazide RMOOOO -l-O ~CC":.\'i·S 2Sg :;I~ (,;I.e, 
87.5 Emcocel90M 17Sl'I ,'l-S ·.iC\ 
0.5 Magnesium stearate hl: I '" n...J 
J 
EQUIPMENT VERlFlCATION 
Description Type Verified By 
Sieves #20 mesh, #44 mesh A/ 
Blender Cube blender j)t 
Scale Precisa 4000 U.l 
". () 
MANUFACTUruNGDrnECTIONS 
Step Procedure Weight Time Date 
I Separately screen the following materials through a 20 
mesh screen. 11',$1 c( (,,)<"\·C1 
Hydrochlorothiazide J. ~ "'j 
Emcocel90M l'll';ij It' S:.'~ cG 0'1-0\ 
2 Blend in cube blender at 50 rpm for 20 minutes. C. 5',,\'''-) 
Time started: " '. ,; ., 
Time completed: ,,/0..1" 
Total blendin time: ;tO~\M\\<':' 
3 Separately screen magnesium stearate through a 44 mesh 
Dispensed By 
,:tJ 
:; ·v 
YJ 
rr 
Confirmed bv 
--(JI..i 
'·n·lii 
?,r\v 
Done by 
cf 
ct: 
screen 
1 0 ") I) '".). " (\>-c·~ .,,, J 
4 Blend in a cube blender at 50 rpm for 3 minutes. 
Time started: 11"> 
Time completed: 1.l:iS' c6· " ... ", 
Total blendin time: .. ;M,\I\ ... 
:> Store prouuct ill a "irtight container 
" \; (;'1-";- tf 
195 
Checked by 
...., lIN 
~\,-j, 
-1 l'~ 
Checked by 
.-11vt 
'(jv~,J 
,(J\}/ 
(JI;{ 
·1f~Vi· 
..fpt{' 
,I 
I' 
I 
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